[
  {
    "id": "EP2007769B1",
    "text": "Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof AbstractThe present invention relates to novel dimers of specific artemisinin derivatives, to the preparation thereof, to compositions containing them, and to their use as a medicament, in particular as anticancer agents. (I). Claims (\n12\n)\n\n\n\n\n \n\n\nAnticancer product of formula (I):\n\n \n \n\nin which:\n\na) A is a divalent group chosen from -S-, -SO-, -SO\n2\n-, -NH-, -N (CH\n2\n-C(O) O-CH\n2\n-CH\n3\n) - or -N (CH\n2\n-COOH)-, epoxide, (C\n1\n-C\n6\n)alkylene, -NHCO- or 1,2,3-triazole;\n\n\nb) X\n1\n and X\n2\n are identical and are O;\n\n\nc) n\n1\n and n\n2\n are identical or different and have the value 1, 2, 3 or 4;\n\nin the form of a base or of an addition salt with an acid, and in the form of a hydrate or a solvate.\n\n\n\n\n \n \n\n\nProduct according to Claim 1, \ncharacterized in that\n n\n1\n and n\n2\n are identical and have the value 2, 3 or 4.\n\n\n\n\n \n \n\n\nProduct according to Claim 1, \ncharacterized in that\n A is chosen from -NH-, -N(CH\n2\n-C(O)O-CH\n2\n-CH\n3\n)- or -N(CH\n2\n-COOH)- and that n\n1\n and n\n2\n are identical and have the value 2.\n\n\n\n\n \n \n\n\nProduct according to Claim 1, \ncharacterized in that\n A is chosen from (C\n1\n-C\n6\n) alkenylene or epoxide and that n\n1\n and n\n2\n are identical and have the value 1.\n\n\n\n\n \n \n\n\nProduct according to Claim 1, \ncharacterized in that\n A is chosen from -NHCO- or -1,2,3-triazole and that n\n1\n and n\n2\n are different and independently have the value 1 or 2.\n\n\n\n\n \n \n\n\nProduct according to any one of Claims 1 to 5, \ncharacterized in that\n the product is\n\n• in nonchiral form, or\n\n\n• in racemic form, or\n\n\n• in a form enriched in one stereoisomer, or\n\n\n• in a form enriched in one enantiomer;\n\nand \nin that\n it is optionally salified.\n\n\n\n\n \n \n\n\nProduct according to Claim 1, chosen from the following list:\n\n- (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,8'aS,-9'R,10'R,12'R,12'aR)-10,10'-[thiobis(2,1-ethanediyloxy)]bis[decahydro-3,6,9-trimethyl-10-(trifluoromethyl)-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepine;\n\n\n- (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,-8'aS,9'R,10'R,12'R,12'aR)-10,10'-[sulfinylbis(2,1-ethanediyloxy)]bis[decahydro-3,6,9-trimethyl-10-(trifluoromethyl)-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepine;\n\n\n- (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,-8'aS,9'R,10'R,12'R,12'aR)-10,10'-[sulfonylbis(2,1-ethanediyloxy)]bis[decahydro-3,6,9-trimethyl-10-trifluoromethyl)-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepine;\n\n\n- (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,-8'aS,9'R,10'R,12'R,12'aR)-10,10'-[thiobis(3,1-propanediyloxy)]bis[decahydro-3,6,9-trimethyl-10-(trifluoromethyl)-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepine;\n\n\n- (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,-8'aS,9'R,10'R,12'R,12'aR)-10,10'-[sulfinylbis(3,1-propanediyloxy)]bis[decahydro-3,6,9-trimethyl-10-(trifluoromethyl)-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepine;\n\n\n- (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,-8'aS,9'R,10'R,12'R,12'aR)-10,10'-[sulfonylbis(3,1-propanediyloxy)]bis[decahydro-3,6,9-trimethyl-10-(trifluoromethyl)-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepine;\n\n\n- (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,-8'aS,9'R,10'R,12'R,12'aR)-10,10'-[thiobis(4,1-butanediyloxy)]bis[decahydro-3,6,9-trimethyl-10-(trifluoromethyl)-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepine;\n\n\n- 2-[[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-10-(trifluoromethyl)-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]-N-[2-[[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-10-(trifluoromethyl)-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]oxy]ethyl]-N-methylethanamine;\n\n\n- 2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}-N-(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}ethyl)ethanamine;\n\n\n- ethyl N,N-bis(2-{[(3S,5aS,6R,8aS,9R,10R,-12R,12aR)-3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}ethyl)glycinate;\n\n\n- N,N-bis(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}ethyl)glycine;\n\n\n- 2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}-N-(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}ethyl)acetamide;\n\n\n- (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,-8'aS,9'R,10'R,12'R,12'aR)-10,10'-[(2E)-but-2-ene-1,4-diylbis(oxy)]bis[3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene];\n\n\n- (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,-8'aS,9'R,10'R,12'R,12'aR)-10,10'-[(2Z)-but-2-ene-1,4-diylbis(oxy)]bis[3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene];\n\n\n- (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5'aS,6'R,-8'aS,9'R,10'R,12'R,12'aR)-10,10'-[(2R,3R)-oxirane-2,3-diylbis(methyleneoxy)]bis[3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene];\n\n\n- (1-(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}ethyl)-4-({[(3S,5aS,6R,8aS,9R,10R,-12R,12aR)-3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}methyl)-1H-1,2,3-triazole;\n\n\n- 1-(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}ethyl)-5-({[(3S,5aS,6R,8aS,9R,10R,-12R,12aR)-3,6,9-trimethyl-10-(trifluoromethyl)decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}ethyl)-1H-1,2,3-triazole.\n \n\n\n\n\n \n \n\n\nProduct according to Claim 1, chosen from the following list:\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n \n\n\n\n\n \n \n\n\nProduct according to Claim 8, \ncharacterized in that\n the product is\n\n• in nonchiral form, or\n\n\n• in racemic form, or\n\n\n• in a form enriched in one stereoisomer, or\n\n\n• in a form enriched in one enantiomer;\n\nand \nin that\n it is optionally salified.\n\n\n\n\n \n \n\n\nPharmaceutical composition comprising a product according to any one of Claims 1 to 9, or an addition salt of this product with a pharmaceutically acceptable acid, or a hydrate or a solvate of this product.\n\n\n\n\n \n \n\n\nMedicament comprising a product according to any one of Claims 1 to 9, or an addition salt of this product with a pharmaceutically acceptable acid, or a hydrtae or a solvate of this product.\n\n\n\n\n \n \n\n\nIntermediate product of formula (II):\n\n \n \n\nin which n has the value 1, 2, 3 or 4 and G represents a bromine atom or an -N3 group. Description\n\n\nTranslated from \nFrench\n\n\n\n\n\n\n \nLa présente invention se rapporte à des dimères de dérivés d'artémisinine, à leur préparation et à leur application en thérapeutique.\nThe present invention relates to dimers of artemisinin derivatives, their preparation and their therapeutic application.\n\n\n\n\n\n\n \nPlus particulièrement, l'invention se rapporte à des dimères de dérivés d'artémisinine présentant une activité anticancéreuse, et en particulier une activité inhibitrice de la prolifération cellulaire,\nMore particularly, the invention relates to dimers of artemisinin derivatives exhibiting anticancer activity, and in particular an inhibitory activity of cell proliferation,\n\n\n\n\n\n\n \nA ce jour, la plupart des composés commerciaux utilisés en chimiothérapie posent des problème importants d'effets secondaires, de tolérance par les patients ou encore de résistance. Ainsi, il y a un besoin important pour de nouvelles classes de composés susceptible d'agir en tant qu'agents anti-cancéreux.\nTo date, most commercial compounds used in chemotherapy pose significant problems of side effects, tolerance by patients or resistance. Thus, there is an important need for new classes of compounds that may act as anti-cancer agents.\n\n\n\n\n\n\n \nParmi les produits naturels, l'artémisinine est une endoperoxide sesquiterpene qui a été isolé en 1971 de la plante \nArtemisia annua\n et présente des propriétés antimalariques. Certains dérivés simples tels que la dihydroartémisinine ou l'artéméther ont été préparés et présentent également des propriétés anti-malariques. En plus de cette activité, il a été démontré que certains dérivés et dimères de l'artémisinine présentent des propriétés anti-cancéreuses (\n \nJ. Med. Chem. 2003, 46, 987-994\n \n , brevet \n \nUS 6,790,863\n \n).\nAmong natural products, artemisinin is an endoperoxide sesquiterpene that was isolated in 1971 from the plant \nArtemisia annua\n and has antimalarial properties. Certain simple derivatives such as dihydroartemisinin or artemether have been prepared and also have anti-malarial properties. In addition to this activity, it has been shown that certain artemisinin derivatives and dimer have anti-cancer properties ( \n \n J. Med. Chem. 2003, 46, 987-994 \n \n patent \n \n US 6,790,863 \n \n ).\n\n\n\n\n\n\n \nLe problème que se propose de résoudre la présente invention est d'obtenir de nouveaux produits sous forme de digères d'artémisinine présentant une activité anti-cancéreuse.\nThe problem to be solved by the present invention is to obtain new products in the form of artemisinin digests having anti-cancer activity.\n\n\n\n\n\n\n \nLa présente invention a pour objet les produits tels que définis à l'une des revendications 1 à 9.\nThe subject of the present invention is the products as defined in one of claims 1 to 9. \n\n\n\n\n\n\n\n\n \nArt antérieur\nPrior art\n\n\n\n\n\n\n\n\n \nAucun de ces digères de l'art antérieur (\n \nJ. Med. Chem. 2003, 46, 987-S94\n \n ; brevet \n \nUS 8,790,863\n \n) n'est substitué par un groupe B\n1\n ou B\n2\n tel que décrit ci-dessus selon la présente invention.\nNone of these digests of the prior art ( \n \n J. Med. Chem. 2003, 46, 987-S94 \n \n ; patent \n \n US 8,790,863 \n \n ) is substituted with a group B \n1\n or B \n2\n as described above according to the present invention.\n\n\n\n\n\n\n \n \n \nUS 6790863\n \n décrit des dimères d'artémisine ne comportant pas de substituant -CF\n3\n et présentant un motif A différent.\n \n \n US 6790863 \n \n discloses artemisinin dimers having no -CF \n3\n substituent and having a different A-motif.\n\n\n\n\n\n\n \nL'article \n \n« Trioxane dimers have potent antimalarial antiproliferative and antitumor activités in vitro» Bioorganic and medicinal chemistry, Vol.5, N°7, 1997. pages 1257-1265\n \n décrit des dimères ne comportant pas de substituant -CF\n3\n. Ce document est relatif de plus à un domaine technique différent, celui des composés anti-malaria.\nArticle \n \n \"Trioxane dimers have potent antimalarial antiproliferative and antitumor activities in vitro\" Bioorganic and medicinal chemistry, Vol.5, No. 7, 1997. pages 1257-1265 \n \n discloses dimers having no -CF \n3\n substituent. This document is moreover related to a different technical field, that of anti-malaria compounds.\n\n\n\n\n\n\n \n \n \nUS 2005/038024\n \n est relatif à un domaine technique différent, celui des composés anti-mataria. De plus, il ne décrit ni ne suggère de dimères.\n \n \n US 2005/038024 \n \n is relative to a different technical field, that of anti-mataria compounds. Moreover, he does not describe or suggest dimers.\n\n\n\n\n\n\n \nParmi ces produits, des produits préférés sont ceux pour lesquels A est -S-, -SO- ou encore -SO\n2\n- .\nAmong these products, preferred products are those for which A is -S-, -SO-  or else -SO \n2\n -.\n\n\n\n\n\n\n \nD'autres produits de formule générale (1) sont ceux pour lesquels A est -N(CH\n3\n)-.\nOther products of general formula (1) are those for which A is -N (CH \n3\n ) -.\n\n\n\n\n\n\n \nSelon la présente invention, n\n1\n et n\n2\n sont préférentiellement identiques et ont pour valeur 2, 3 ou 4.\nAccording to the present invention, n \n1\n and n \n2\n are preferably identical and are 2, 3 or 4.\n\n\n\n\n\n\n \nD'autres produits de formule générale (1) sont ceux pour lesquels A est choisi parmi -NH-, N(CH\n2\n-C(O)O-CH\n2\n-CH\n3\n)- ou -N(CH\n2\n-COOH)-, et éventuellement caractérisé en ce que n\n1\n et n\n2\n sont identiques et ont pour valeur 2.\nOther products of general formula (1) are those for which A is chosen from -NH-, N (CH \n2\n -C (O) O-CH \n2\n -CH \n3\n ) - or -N (CH \n2\n -COOH) - , and optionally characterized in that n \n1\n and n \n2\n are identical and have the value 2.\n\n\n\n\n\n\n \nD'autres produits de formule générale (1) sont ceux pour lesquels A est choisi parmi (C\n1\n-C\n6\n)alcénylène ou époxyde, et éventuellement caractérisé en ce que n\n1\n et n\n2\n sont identiques et ont pour valeur 1.\nOther products of general formula (1) are those for which A is chosen from (C \n1\n -C \n6\n ) alkenylene or epoxide, and optionally characterized in that n \n1\n and n \n2\n are identical and have a value of 1.\n\n\n\n\n\n\n \nD'autres produits de formule générale (1) sont ceux pour lesquels A est choisi parmi -NHCO- ou -1,2,3-triazole, et éventuellement caractérisé en ce que n\n1\n et n\n2\n sont différents et ont indépendamment pour valeur 1 ou 2.\nOther products of general formula (1) are those for which A is chosen from -NHCO- or -1,2,3-triazole, and optionally characterized in that n \n1\n and n \n2\n are different and are independently 1 or 2.\n\n\n\n\n\n\n \nLes produits de formule (1) peuvent comporter un ou plusieurs atomes de carbone asymétriques. Ils peuvent donc exister sous forme d'énantiomères ou de diastéréoisomères. Ces énantiomères, diastéreoisomères, ainsi que leurs mélanges, y compris les mélanges racémiques, font partie de l'invention.\nThe products of formula (1) can comprise one or more asymmetric carbon atoms. They can therefore exist as enantiomers or diastereoisomers. These enantiomers, diastereoisomers, as well as their mixtures, including racemic mixtures, form part of the invention.\n\n\n\n\n\n\n \nLes produits de formule (I) peuvent exister à l'état de bases ou de sels d'addition à des acides. De tels sels d'addition font partie de l'invention.\nThe products of formula (I) may exist in the form of bases or addition salts with acids. Such addition salts are part of the invention.\n\n\n\n\n\n\n \nCes sels peuvent être préparés avec des acides pharmaceutiquement acceptables, mais les sels d'autres acides utiles, par exemple, pour la purification ou l'isolément des produits de formule (1) font également partie de l'invention.\nThese salts may be prepared with pharmaceutically acceptable acids, but the salts of other acids useful, for example, for the purification or isolation of the products of formula (1) also form part of the invention.\n\n\n\n\n\n\n \nLes produits de formule (I) peuvent également exister sous forme d'hydrates ou de solvats, à savoir sous forme d'associations ou de combinaisons avec une ou plusieurs molécules d'eau ou avec un solvant. De tels hydrates et solvates font également partie de l'invention.\nThe products of formula (I) may also exist in the form of hydrates or solvates, namely in the form of associations or combinations with one or more water molecules or with a solvent. Such hydrates and solvates are also part of the invention.\n\n\n\n\n\n\n \nDans le cadre de la présente invention, on entend par :\n\n \nun atome d'halogène : un fluor, un chlore, un brome ou un iode ;\n \nun groupe alkyle : un groupe aliphatique saturé linéaire ou ramifié. A titre d'exemples, on peut citer les groupes méthyle, éthyle, propyle, isopropyle, butyle, isobutyle, tertbutyle, pentyle, etc ;\n \nun groupe cycloalkyle : un groupe alkyle cyclique. A titre d'exemples, on peut citer les groupes cyclopropyle, méthylcyclopropyle, cyclobutyle, cyclopentyle, cyclohexyle, etc ;\n \n\n\n \nun groupe fluoroalkyle : un groupe alkyle dont un ou plusieurs atomes d'hydrogène ont été substitués par un atome de fluor ;\n \nun groupe alcényle: un groupe aliphatique mono- ou poly-insaturé, linéaire ou ramifié, comprenant par exemple une ou deux insaturations éthyléniques;\n \nun groupe alcynyle: un groupe aliphatique mono- ou poly-insaturé, alinéaire ou ramifié, comprenant par exemple une ou deux insaturations acétyléniques.\n \n In the context of the present invention, the following terms mean: \n \n a halogen atom: a fluorine, a chlorine, a bromine or an iodine; \n \n an alkyl group: a linear or branched saturated aliphatic group. By way of examples, mention may be made of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, and the like; \n \n a cycloalkyl group: a cyclic alkyl group. By way of examples, mention may be made of cyclopropyl, methylcyclopropyl, cyclobutyl and cyclopentyl groups,  cyclohexyl, etc .; \n \n \n \n a fluoroalkyl group: an alkyl group of which one or more hydrogen atoms have been substituted by a fluorine atom; \n \n an alkenyl group: a linear or branched, mono- or poly-unsaturated aliphatic group, comprising, for example, one or two ethylenic unsaturations; \n \n an alkynyl group: a mono- or polyunsaturated, sub-branched or branched aliphatic group comprising, for example, one or two acetylenic unsaturations. \n \n\n\n\n\n\n\n \nIl est entendu que le groupe divalent A est susceptible d'être lié dans les deux sens possibles.\nIt is understood that the divalent group A is likely to be bound in both directions.\n\n\n\n\n\n\n \nConformément à la présente invention, les produits de formule générale (I) peuvent être préparés selon les méthodes conventionnelles de la chimie organique. Des exemples de synthèse sont illustrés dans les schémas 1 à 4 ci-dessous, dans lequel les produits de départ et les réactifs, quand leur mode de préparation n'est pas décrit, sont disponibles dans le commerce ou décrits dans la littérature, ou bien peuvent être préparés selon des méthodes qui y sont décrites ou qui sont connues de l'Homme du métier.\n\n \n \n\n\n \n \n\n\n \n \n\n\n \n \n \nAccording to the present invention, the products of general formula (I) can be prepared according to conventional methods of organic chemistry. Examples of synthesis are illustrated in Schemes 1 to 4 below, wherein starting materials and reagents, when their mode of preparation is not described, are commercially available or described in the literature, or can be prepared according to methods described therein or which are known to those skilled in the art. \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n\n \nUn objet de la présente invention concerne un procédé de préparation d'un produit de formule général (I) caractérisé en ce que le produit de formule générale (III) suivante:\n\n \n \n\ndans lequel B représente un substituant -CF\n3\n subit une substitution de l'atome de brome à l'aide d'un nucléophile tel qu'un bromo-alcool, pour donner un produit de formule générale (II) suivante\n\n \n \n\ndans lequel X représente O n représente n\n1\n ou n\n2\n, tel que défini précédemment, et dans lequel soit G représente un groupe partant tel qu'un atome de brome, puis ce produit de formule générale (II) subit une substitution nucléophile pour former un dimère de formule générale (I) ou un précurseur d'un produit de formule générale (I), soit G représente une fonction chimique F1, qui peut éventuellement être activé par une réaction de réduction ou d'oxydation, puis ce produit de formule générale (II) réagit avec un autre produit de formule (II) où G représente un groupe partant tel qu'un atome de brome ou une fonction chimique F2 susceptible de réagir avec F1, pour former un dimère de formule générale (I) ou un précurseur d'un produit de formule générale (I).\nAn object of the present invention relates to a process for preparing a product of general formula (I), characterized in that the product of general formula (III) below: \n \n \n wherein B represents a -CF \n3\n substituent undergoes a substitution of the bromine atom with a nucleophile such as a bromoalcohol, to give a product of the following general formula (II) \n \n \n wherein X represents O n represents n \n1\n or n \n2\n , as defined above, and wherein either G represents a leaving group such as a bromine atom, then this product of general formula (II) undergoes a nucleophilic substitution to form a dimer of general formula (I)  or a precursor of a product of general formula (I), ie G represents a chemical function F1, which can optionally be activated by a reduction or oxidation reaction, and then this product of general formula (II) reacts with another product of formula (II) wherein G represents a leaving group such as a bromine atom or a chemical function F2 capable of reacting with F1, to form a dimer of general formula (I) or a precursor of a product of general formula (I).\n\n\n\n\n\n\n \nUn objet de la présente invention concerne plus particulièrement les produits de formule générale (II) dans laquelle X est un atome d'oxygène, n a pour valeur 0,1, 2, 3 ou 4, B est un groupe trifluorométhyl*e et G représente un atome de brome, un groupe -N3, -NH2, acényle, alcynyle ou -COOH. Ces composés sont utiles en tant que produits intermédiaires pour la synthèse des produits de formule générale (I).\nAn object of the present invention relates more particularly to the products of general formula (II) in which X is an oxygen atom, n is 0.1, 2, 3 or 4, B is a trifluoromethyl group and G represents a bromine atom, a group -N3, -NH2, acenyl, alkynyl or -COOH. These compounds are useful as intermediates for the synthesis of the products of the general formula (I).\n\n\n\n\n\n\n \nOn entend par groupe partant, un groupe pouvant être facilement clivé d'une molécule par rupture d'une liaison hétérolytique, avec départ d'une paire électronique. Ce groupe peut ainsi être remplacé facilement par un autre groupe lors d'une réaction de substitution, par exemple. De tels groupes partants sont, par exemple, les halogènes ou un groupe hydroxy activé tel qu'un méthanesulfonate, benzènesulfonate, p-toluènesulfonate, triflate, acétate, etc, Des exemples de groupes partants ainsi que des références pour leur préparation sont donnés dans \n \n« Advances in Organic Chemistry », J. March, 3rd édition, Wiley Interscience, p. 310-316\n \n,\nThe term \"leaving group\" means a group that can be easily cleaved from a molecule by breaking a heterolytic link, with the departure of an electronic pair. This group can thus be easily replaced by another group during a substitution reaction, for example. Such leaving groups are, for example, halogens or an activated hydroxy group such as methanesulphonate, benzenesulphonate, p-toluenesulphonate, triflate, acetate, etc. Examples of leaving groups as well as references for their preparation are given in \n \n Advances in Organic Chemistry, J. March, 3rd Edition, Wiley Interscience, p. 310-316 \n \n ,\n\n\n\n\n\n\n \nLes exemples suivants décrivent la préparation de certains produits conformes à l'invention. Ces exemples ne sont pas limitatifs et ne font qu'illustrer la présente invention.\nThe following examples describe the preparation of certain products according to the invention. These examples are not limiting and only illustrate the present invention.\n\n\n\n\n\n\n\n\n \nAbréviations;\nAbbreviations;\n\n\n\n\n\n\n\n\n \n \n°C\n degré Celsius \nCCM\n chromatographie sur couche mince; δ déplacement chimique; \nd\n doublet; \ndd\n doublet de doublets ; \nDMSO-d\n6\n \n diméthylsulfoxyde deutéré ; \ndt\n doublet de triplets ; \neq.\n équivalent ; \nES+/-\n electrospray (modes positif / négatif) ; \ng\n gramme; \nh\n heure ; \nHz\n hertz ; \nIC\n50\n \n constante d'inhibition à 80% d'activité; \nJ\n constante de couplage ; \nm\n multiplet; \nmg\n miligramme: \nMHz\n mégahertz : \nmL\n millilitre ; \nµL\n microlitre ; \nmm\n millimètre ; \nµm\n micromètre \nmmol\n millimole ; \nppm\n parties par million; \nq\n quadruplet ; \nRf\n rapport frontal; \nRMN \n1\nH\n résonance magnétique nucléaire du proton ; \ns\n singulet ; \ns1\n singulet large \n;\n triplet ;; \nU.V.\n ultraviolet\n \n° C\n degree Celsius \nTLC\n thin layer chromatography; δ chemical shift; \nd\n doublet; \ndd\n doublet of doublets; \nDMSO-d \n6\n \n dimethylsulfoxide deuterated; \ndt\n doublet of triplets; \neq.\n equivalent; \nES +/-\n electrospray (positive / negative modes); \ng\n gram; \nh\n hour; \nHz\n hertz; \nIC \n50\n \n inhibition constant at 80% activity; \nJ\n coupling constant; \nm\n multiplet; \nmg\n milligram: \nMHz\n megahertz: \nmL\n milliliter; \nμL\n microliter; \nmm\n millimeter; \nμm\n micrometer \nmmol\n millimole; \nppm\n parts per million; \nq\n quadruplet; \nRf\n frontal report; \n \n1\n H NMR\n proton nuclear magnetic resonance; \ns\n singlet; \ns1\n large singlet \n;\n triplet; \nUV\n ultraviolet \n\n\n\n\n\n\n \n \nEX1\n: (3\nS\n,5a\nS\n.6\nR\n,8a\nS\n,9\nR\n,10\nR\n,12\nR\n,12a\nR\n,3'\nS\n,5'a\nS\n,6'\nR\n,8'a\nS\n,9'\nR\n, 10'\nR\n,12'\nR\n,12'a\nR\n)-10,10'-[thiobis(2,1-éthanediyloxy)]bis[décahydro-3,6,9-triméthyl-10-(trifiuorométhyl)-3,12-époxy-12\nH-\npyrano[4,3-\nj\n-],2-benzodioxépine\n \nEX 1\n : (3 \nS\n , 5a \nS\n .6 \nR\n , 8a \nS\n , 9 \nR\n , 10 \nR\n , 12 \nR\n , 12a \nR\n , 3 ' \nS\n , 5'a \nS\n , 6' \nR\n , 8'a \nS\n , 9 ' \nR\n , 10 \nR\n , 12 ' \nR\n , 12'a \nR\n ) -10,10' - [thiobis (2,1-ethanediyloxy)] bis [decahydro-3,6,9-trimethyl-10- (trifluoromethyl) -3,12- epoxy-12 \nH-\n pyrano \n[4,3-j\n -], 2-benzodioxepine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \na) Etape 1: Préparation de (3\nS\n,5a\nS\n,6\nR\n,8a\nS\n,9\nR\n,10\nR\n,12\nR\n,12a\nR\n,3'\nS\n,5'a\nS\n,6'\nR\n,8'a\nS\n,9'\nR\n,10'\nR\n,12'\nR\n,12'a\nR\n)- 10-(2-bromoéthoxy)decahydro-3,6,9-triméthyl-10-(trifluorométhyl)-3,12-époxy-12\nH-\npyrano[4,3\n-j\n]-1,2-benzodioxépine \n2\n \na) Step 1: Preparation of (3 \nS\n , 5a \nS\n , 6 \nR\n , 8a \nS\n , 9 \nR\n , 10 \nR\n , 12 \nR\n , 12a \nR\n , 3 ' \nS\n , 5'a \nS\n , 6' \nR\n , 8'a \nS\n , 9 ' \nR\n , 10' \nR\n , 12 ' \nR\n , 12'a \nR\n ) - 10- (2-bromoethoxy) decahydro-3,6,9-trimethyl-10- (trifluoromethyl) -3,12-epoxy- \n12H-\n [4,3 \nj]\n -1,2-benzodioxepin \n2\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 942 mg (2,27 mmol)de 3,12-epoxy-12\nH-\npyrano[4,3\n-j\n]-1,2-benzodioxepin, (3\nS\n,5a\nS\n,6\nR\n,8a\nS\n,9\nR\n,10\nS\n,12\nR\n,12a\nR\n)-10-(bromo)decahydro-3,6,9-trimethyl-10(trifluoromethyl)-3,12-époxy-12\nH-\npyrano[4,3\n-j\n]-1,2-benzodioxépine \n1\n (préparé selon \n \nOrg. Lett. 2002, 4, 757-759\n \n), dans 20 mL de dichlorométhane, sont ajoutés successivement à température ambiante 1,2 ml d'héxafluoropropanol (5 éq.), puis 1,6 mL de bromo-2-éthanol (10 éq.). Le mélange réactionnel est ensuite agité à température ambiante pendant 2 heures 15 minutes, puis 10 mL d'une solution saturée de bicarbonate de sodium sont ajoutés. La phase organique est séchée sur sulfate de magnésium, et évaporée à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable dans l'heptane, puis élué par un gradient linéaire de 0 à 100% du mélange B [(Heptane/Acétate d'éthyle), (90/10), (V/V)] dans A (Heptane). 217 mg (21%) du produit attendu \n2\n sont obtenus sous forme d'une huile,\nTo a solution of 942 mg (2.27 mmol) of 3,12-epoxy-12 \nH-\n pyrano [4,3 \nj]\n -1,2-benzodioxepin, (3 \nS,\n 5a \nS,\n 6 \nR,\n 8a \nS,\n 9 \nR,\n 10 \nS,\n 12 \nR,\n 12a \nR)\n -10- (bromo) decahydro-3,6,9-trimethyl-10 (trifluoromethyl) -3,12-epoxy-12 \nH-\n pyrano [4,3 \n-j]\n -1,2-benzodioxepin \n1\n (prepared according to \n \n Org. Lett. 2002, 4, 757-759 \n \n ) in 20 ml of dichloromethane are successively added at room temperature 1.2 ml of hexafluoropropanol (5 eq.), then 1.6 ml of bromo-2-ethanol (10 eq.). The reaction mixture is then stirred at room temperature for 2 hours 15 minutes, then 10 ml of saturated sodium bicarbonate solution are added. The organic phase is dried over magnesium sulphate and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned in heptane and then eluted with a linear gradient from 0 to 100% of the mixture B [(heptane / ethyl acetate), (90/10), (V). / V)] in A (Heptane). 217 mg (21%) of the  expected product \n2\n are obtained in the form of an oil,\n\n\n\n\n\n\n \nRf =0,45 dans le système (Heptane/Acétate d'éthyle), (90/10). (V/V)\nRf = 0.45 in the system (Heptane / ethyl acetate), (90/10). (V / V)\n\n\n\n\n\n\n \nES.m/z=481 (MNa*)\nES.m / z = 481 (MNa *)\n\n\n\n\n\n\n \nRMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K : 0,92 (m partiellement masqué, 1H) ; 0,96 (d, J = 6,5 Hz, 3H) ; 1,01 (d large, J = 7,5 Hz, 3H) ; de 1,21 à 1,58(m, 4H) ; 1,42 (s, 3H) ; de 1,65 à 2,08 (m,5H); 2,38 (m; 1H) ; 2,88 (m, 1H) ; de 3,45 à 3,57 (m, 2H) ; 4,02 (m, 1H) ; 4,17 (m, 1H); 5,57 (s, 1H).\nNMR 1H at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform solvent - d1 (CDCl3-d1) referenced at 7.27 at the temperature of 303K: 0.92 (m partially masked, 1H); 0.96 (d, J = 6.5 Hz, 3H); 1.01 (broad d, J = 7.5 Hz, 3H); from 1.21 to 1.58 (m, 4H); 1.42 (s, 3H); from 1.65 to 2.08 (m, 5H); 2.38 (m; 1H); 2.88 (m, 1H); from 3.45 to 3.57 (m, 2H); 4.02 (m, 1H); 4.17 (m, 1H); 5.57 (s, 1H).\n\n\n\n\n\n\n \nb) Etape 2: préparation l'\nEX1\n \nb) Step 2: preparing the \nEX1\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 215 mg (0,47 mmol) de \n2\n dans 16 mL d'éthanol anhydre, sous atmosphère inerte d'argon à une température voisine de 20°C, sont ajoutés après 10 minutes 18 mg (0,234 mmol) de sulfure de sodium. L'agitation est maintenue à cette température pendant environ 190 heures. 20 mL d'une solution saturée en chlorure de sodium sont ensuite ajoutés, Le mélange est extrait par 3 x 20 mL d'acétate d'éthyle. Les phases organiques sont regroupées, lavées avec 20mL d'une solution saturée en NaCl, séchées sur sulfate de magnésium et évaporées à sec sous pression réduite. Le résidu huileux obtenu est chromatographie sur gel de silice conditionné au préalable dans l'heptane, puis élué par un gradient linéaire de 0 à 100% du mélange B [(Heptane/Acétate d'éthyle), (85/15), (V/V)] dans A (heptane) 60 mg (33%) du produit attendu \nEX1\n sont obtenus sous forme de meringue.\nTo a solution of 215 mg (0.47 mmol) of \n2\n in 16 ml of anhydrous ethanol, under an argon inert atmosphere at a temperature in the region of 20 ° C., are added after 10 minutes 18 mg (0.234 mmol) of sulphide. sodium. Stirring is maintained at this temperature for about 190 hours. 20 ml of a saturated solution of sodium chloride are then added. The mixture is extracted with 3 × 20 ml of ethyl acetate. The organic phases are combined, washed with 20 ml of saturated NaCl solution, dried over magnesium sulphate and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned in heptane and then eluted with a linear gradient from 0 to 100% of the mixture B [(heptane / ethyl acetate), (85/15), (V). / V)] in A (heptane) 60 mg (33%) of the expected product \nEX1\n are obtained in the form of meringue.\n\n\n\n\n\n\n \nRf = 0,20 dans le système (Heptane/Acétate d'éthyte), (90/10), (V/V)\nRf = 0.20 in the system (Heptane / Ethyl acetate), (90/10), (V / V)\n\n\n\n\n\n\n \nES : m/z=835 (M + HCOOH - H)\nES: m / z = 835 (M + HCOOH-H)\n\n\n\n\n\n\n \nRMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant diméthylsulfoxide - d6 (DMSO-d6) référencé à 2,50 ppm à la température de 303K : 0,86 (m partiellement masqué, 2H); 0,90 (d, J = 6,5 Hz, 6H) ; 0,93 (d large, J = 7,5 Hz, 6H); 1,22 (m, 2H) ; de 1,27 à 1,60 (m, 8H) ; 1,31 (s, 6H) ; 1,66 (m, 2H); de 1,75 à 1,89 (m, 4H) ; 2,04 (m, 2H); 2,21 (m, 2H) : 2,67 (m, 2H); de 2,71 à 2,87 (m, 4H) ; 3,64 (m, 2H); 3,94 (m, 2H) ; 5,58 (s, 2H)\n1H NMR at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in dimethylsulfoxide-d6 solvent (DMSO-d6) referenced at 2.50 ppm at a temperature of 303K: 0.86 (m partially masked, 2H); 0.90 (d, J = 6.5 Hz, 6H); 0.93 (broad d, J = 7.5 Hz, 6H); 1.22 (m,  2H); from 1.27 to 1.60 (m, 8H); 1.31 (s, 6H); 1.66 (m, 2H); from 1.75 to 1.89 (m, 4H); 2.04 (m, 2H); 2.21 (m, 2H): 2.67 (m, 2H); from 2.71 to 2.87 (m, 4H); 3.64 (m, 2H); 3.94 (m, 2H); 5.58 (s, 2H)\n\n\n\n\n\n\n \n \nEX2\n :(3\nS\n,5a\nS\n,6\nR\n,8a\nS\n,9\nR\n,10\nR\n,12\nR\n,12a\nR\n,3'\nS\n,5'a\nS\n,6'\nR\n,8'a\nS\n,9'\nR\n,10'\nR\n,12'\nR\n;12'a\nR\n)-10,10'-[sulfinylbis(2,1-éthanediyloxy)]bis[décahydro-3,6,9-triméthyl-10-(trifluorométhyl)- 3,12-époxy-12\nH-\npyrano[4,3\n-j\n]-1,2-benzodioxépine et \nEX3\n : (3\nS\n,5a\nS\n,6\nR\n,8a\nS\n,9\nR\n,10\nR\n,12\nR\n,12a\nR\n,3'\nS\n,5'a\nS\n,6'\nR\n,8'a\nS\n,9'\nR\n,10'\nR\n,12'\nR\n,12'a\nR\n)-10,10'-[sulfonylbis(2,1-éthanediyloxy)]bis[décahydro-3,6,9-triméthyl-10-(trifluorométhyl)-3,12-époxy-12\nH-\npyrano[4,3\n-j\n]-1,2-benzodioxépine\n \nEX2\n : (3 \nS\n , 5a \nS\n , 6 \nR\n , 8a \nS\n , 9 \nR\n , 10 \nR\n , 12 \nR\n , 12a \nR\n , 3 ' \nS\n , 5'a \nS\n , 6' \nR\n , 8'a \nS\n , 9 ' \nR\n , 10 \nR\n , 12 '\nR\n;12'a \nR\n ) -10,10' - [sulfinylbis (2,1-ethanediyloxy)] bis [decahydro-3,6,9-trimethyl-10- (trifluoromethyl) - 3,12- epoxy-12 \nH-\n pyrano [4,3 \nj]\n -1,2-benzodioxepin and \nEX3:\n (3 \nS,\n 5a \nS,\n 6 \nR,\n 8a \nS,\n 9 \nR,\n 10 \nR,\n 12 \nR,\n 12a \nR,\n 3 \n'S\n , 5'a \nS,\n 6 \n'R,\n \nS\n 8'a, 9' \nR\n 10 \n'R,\n 12' \nR,\n 12'a \nR)\n -10,10 '- [sulfonylbis (2,1-éthanediyloxy)] bis [ decahydro-3,6,9-trimethyl-10- (trifluoromethyl) -3,12-epoxy-12 \nH-\n pyrano [4,3 \nj]\n -1,2-benzodioxepin\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 35 mg (0,044 mmol) de l'\nEX1\n dans 3 mL de dichlorométhane à une température voisine de 20°C, sont ajoutés lestement 16,4 mg (0,066 mmol) d'acide \nmeta\n-chloroperbenzoique, L'agitation est maintenue à cette température pendant environ 3 heures puis 3 mL d'une solution saturée en bicarbonate de sodium sont ajoutés. Le mélange est extrait par 3 x 10 mL d'acétate d'éthyle, Les phases organiques sont regroupées, lavées avec 2x 10 mL d'une solution aqueuse saturée en chlorure de sodium, séchées sur sulfate de magnésium, filtrées et évaporées à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable dans l'heptane, puis élué par un gradient linéaire de 0 à 100% d'acétate d'éthyle dans l'heptane. 14,5mg (40%) du produit \nEX3\n sont obtenus sous forme d'un solide blanc :\nTo a solution of 35 mg (0.044 mmol) of \nEX1\n in 3 ml of dichloromethane at a temperature in the region of 20 ° C., 16.4 mg (0.066 mmol) of \nmeta-\n chloroperbenzoic acid are added with vigorous stirring. maintained at this temperature for about 3 hours then 3 ml of a saturated solution of sodium bicarbonate are added. The mixture is extracted with 3 × 10 mL of ethyl acetate. The organic phases are combined, washed with 2 × 10 mL of saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and evaporated to dryness under water. reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned in heptane and then eluted with a linear gradient of 0 to 100% ethyl acetate in heptane. 14.5 mg (40%) of the product \nEX3\n are obtained in the form of a white solid:\n\n\n\n\n\n\n \nRf = 0,60 dans le système (Heptane/Acétate d'éthyle), (50/50) (V/V)\nRf = 0.60 in the system (Heptane / Ethyl acetate), (50/50) (V / V)\n\n\n\n\n\n\n \nEs m/z=867 (M + HCOOH - H)\n+\n \nEs m / z = 867 (M + HCOOH-H) \n+\n \n\n\n\n\n\n\n \nRMN 1H à 500 MHz sur spectromètre BRUKER AVANCE DRX-500 avec les déplacements chimiques (δ en ppm) - dans le solvant diméthylsulfoxide - d6 (DMSO-d6) référencé à 2,50 ppm à la température de 298K: 0,85 (m partiellement masqué, 2H); 0,89 (d, J = 6,5 Hz, 6H) 0,92 (d large, J = 7,5 Hz, 6H) ; 1,18 (m, 2H) ; 1.32 (si 6H) ; 1,36 (m, 2H) ; de 1,47 à 1.58 (m, 6H) ; 1,62 (m, 2H); 1,71 (m, 2H) ; 1,84 (m, 2H) : 2,04 (m, 2H) ; 2,21 (m, 2H) 2,68 (m, 2H) ; 3,48 (m, 2H) ; 3,59 (m, 2H) ; 3,83 (m, 2H); 4,19 (m, 2H) : 5,63 (s, 2H).\n1H NMR at 500 MHz on a BRUKER AVANCE DRX-500 spectrometer with chemical shifts (δ in ppm) - in dimethylsulfoxide-d6 solvent (DMSO-d6) referenced at 2.50 ppm at a temperature of 298K: 0.85 (m partially  masked, 2H); 0.89 (d, J = 6.5 Hz, 6H) 0.92 (broad d, J = 7.5 Hz, 6H); 1.18 (m, 2H); 1.32 (if 6H); 1.36 (m, 2H); from 1.47 to 1.58 (m, 6H); 1.62 (m, 2H); 1.71 (m, 2H); 1.84 (m, 2H): 2.04 (m, 2H); 2.21 (m, 2H) 2.68 (m, 2H); 3.48 (m, 2H); 3.59 (m, 2H); 3.83 (m, 2H); 4.19 (m, 2H): 5.63 (s, 2H).\n\n\n\n\n\n\n \nainsi que 12,4 mg (35%) du produit \nEX2\n sous forme de meringue blanche ;\nas well as 12.4 mg (35%) of the \nEX2\n product as a white meringue;\n\n\n\n\n\n\n \nRf = 0,22 dans le système (Heptane/Acétate d'éthyle), (50/50), (V/V)\nRf = 0.22 in the system (Heptane / ethyl acetate), (50/50), (V / V)\n\n\n\n\n\n\n \nES : m/z=851(M + HCOOH - H)\nES: m / z = 851 (M + HCOOH-H)\n\n\n\n\n\n\n \nRMN 1H à 500 MHz sur spectromètre BRUKER AVANCE DRX-500 avec les déplacements chimiques (δ en ppm) - dans le solvant diméthylsulfoxide - d6 (DMSO-d6) référencé à 2,50 ppm à la température de 298K (un mélange 50% ~50 % d'isomères) :0,85 (m partiellement masqué, 2H) ; 0,88 (d, J = 6,5 Hz, 3H) ; 0,90 . (d, J = 6,5 Hz, 3H) ; 0,93 (d large, J = 7.5 Hz, 6H) ; de 1,14 à 1,89 (m, 16H) ; 1,31 (s, 3H) ; 1,32 (s, 3H) ; 2,03 (m, 2H) ; 2,20 (m, 2H) ; 2,67 (m, 2H) ; 2,98 (m, 2H) ; 3,12 (m, 2H) ; 3,79 (m, 1H) 3,87 (m, 1H) de 4,11 à 4.20 (m, 2H) ; 5,58 (s, 1H) ; 5,61 (s, 1H).\n1H NMR at 500 MHz on BRUKER AVANCE DRX-500 spectrometer with chemical shifts (δ in ppm) - in dimethylsulfoxide-d6 solvent (DMSO-d6) referenced at 2.50 ppm at a temperature of 298K (a mixture of 50% ~ 50% isomers): 0.85 (partially masked m, 2H); 0.88 (d, J = 6.5 Hz, 3H); 0.90. (d, J = 6.5 Hz, 3H); 0.93 (broad d, J = 7.5 Hz, 6H); from 1.14 to 1.89 (m, 16H); 1.31 (s, 3H); 1.32 (s, 3H); 2.03 (m, 2H); 2.20 (m, 2H); 2.67 (m, 2H); 2.98 (m, 2H); 3.12 (m, 2H); 3.79 (m, 1H) 3.87 (m, 1H) from 4.11 to 4.20 (m, 2H); 5.58 (s, 1H); 5.61 (s, 1H).\n\n\n\n\n\n\n \n \nEX4\n : (3\nS\n,5a\nS\n;6\nR\n,8a\nS\n,9\nR\n,10\nR\n,12\nR\n,12a\nR\n,3'\nS\n,5'a\nS\n,6'\nR\n,8'a\nS\n,9'\nR\n,10'\nR\n,12'\nR\n,12'a\nR\n)-10,10'-[thiobis(3,1-propanediyloxy)]bis[décahydro-3,6,9-triméthyl-10-(trifluorométhyl)-3,12-époxy-12\nH-\npyrano[4,3\n-j\n]-1.2-benzodioxépine\n \nEX4\n : (3 \nS\n , 5a \nS\n ; 6 \nR\n , 8a \nS\n , 9 \nR\n , 10 \nR\n , 12 \nR\n , 12a \nR\n , 3 ' \nS\n , 5'a \nS\n , 6' \nR\n , 8'a \nS\n , 9 ' \nR\n , 10 \nR\n , 12 ' \nR\n , 12'a \nR\n ) -10,10' - [thiobis (3,1-propanediyloxy)] bis [decahydro-3,6,9-trimethyl-10- (trifluoromethyl) -3,12- epoxy-12 \nH-\n pyrano [4,3 \nj]\n -1,2-benzodioxepin\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \na) Etape 1: Preparation du (3\nS\n,5a\nS\n,6\nR\n,8a\nS\n,9\nR\n,10\nR\n,12\nR\n,12a\nR\n,3'\nS\n,5'a\nS\n,6'\nR\n,8'a\nS\n,9'\nR\n,10'\nR\n,12'\nR\n,12'a\nR\n)- 10-(3-bromopropoxy)decahydro-3,6,9-triméthyl-10-(trifluorométhyl)-3,12-époxy-12\nH-\n \npyrano[4,3\n-j\n]-1,2-bénzodioxépine 3\n \na) Step 1: Preparation of (3 \nS\n , 5a \nS\n , 6 \nR\n , 8a \nS\n , 9 \nR\n , 10 \nR\n , 12 \nR\n , 12a \nR\n , 3 ' \nS\n , 5'a \nS\n , 6' \nR\n , 8'a \nS\n , 9 ' \nR\n , 10' \nR\n , 12 ' \nR\n , 12'a \nR\n ) - 10- (3-bromopropoxy) decahydro-3,6,9-trimethyl-10- (trifluoromethyl) -3,12-epoxy- \n12H-\n \n[4,3 \nj]\n -1,2-benzodioxepin 3\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 471 mg (1,14 mmol) de \n \n1\n \n dans 7 mL de dichlorométhane, sont ajoutés successivement à température ambiante 0,607 ml d'héxafluoropropanol (5 éq.), puis 1,03 mL de bromo-3-propanol (10 éq.). Le mélange réactionnel est ensuite agité à température ambiante pendant 2 heures 30 minutes, puis 5 mL d'une solution saturée de bicarbonate de sodium sont ajoutés, la phase organique est séchée sur sulfate de magnésium, filtrée et évaporée à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionnée au préalable dans l'heptane, puis élué par un gradient linéaire de 0 à 100% du mélange B [(Heptane/Acétate d'éthyle), (90/10), (V/V)] dans A (Heptane). 229 mg (43%) du produit attendu \n \n3\n \n sont obtenus sous forme d'une huile,\nTo a solution of 471 mg (1.14 mmol) of \n \n1\n \n in 7 ml of dichloromethane, 0.607 ml of hexafluoropropanol (5 eq.) And then 1.03 ml of bromo-3-propanol (10 ml) are successively added at room temperature. eq.). The reaction mixture is then stirred at ambient temperature for 2 hours 30 minutes, then 5 ml of saturated sodium bicarbonate solution are added, the organic phase is dried over magnesium sulphate, filtered and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel conditioned beforehand in heptane and then eluted with a linear gradient from 0 to 100% of the mixture B [(Heptane / ethyl acetate), (90/10), (V). / V)] in A (Heptane). 229 mg (43%) of the expected product \n \n3\n \n are obtained in the form of an oil,\n\n\n\n\n\n\n \nRf = 0,38 dans le système (Heptane/Acétate d'éthyle), (90/10), (V/V)\nRf = 0.38 in the system (Heptane / ethyl acetate), (90/10), (V / V)\n\n\n\n\n\n\n \nIC m/z=490 (MNH\n4\n)\n+\n; m/x=354 (m/z=490 - BrCH\n2\nCH\n2\nCH\n2\nOH + 2H)*\nIC m / z = 490 (MNH \n4\n ) \n+\n ; m / x = 354 (m / z = 490 - BrCH \n2\n CH \n2\n CH \n2\n OH + 2H) *\n\n\n\n\n\n\n \nRMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme \"- d1 (CDCl\n3\n-d1) référencé à 7,27 ppm la température de 303K: 0,90 (m partiellement masqué, 1H) ; 0,97 (d, J = 6,5 Hz, 3H) ; 1,00 (d large, J = 7,5 Hz, 3H) ; de 1,22 à 1,54 (m, 4H) ; 1,44 (s, 3H) de 1,60 à 1,73 (m, 2H) : 1,82 (m, 1H) ; 1,91 (m, 1H) ; de 2,00 à 2,20 (m, 3H) ; 2,39 (m, 1H) : 2,87 (m, 1H) ; de 3,45 à 3,55 (m, 2H) ; 3,80 (m, 1H) 3,94 (m, 1H) ; 5,41 (s, 1H),\n1H NMR at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform solvent \"- d1 (CDCl \n3\n -d1) referenced at 7.27 ppm at 303K temperature: 0.90 ( m partially masked, 1H), 0.97 (d, J = 6.5 Hz, 3H), 1.00 (d wide, J = 7.5 Hz, 3H), 1.22 to 1.54 (m , 4H), 1.44 (s, 3H) from 1.60 to 1.73 (m, 2H): 1.82 (m, 1H), 1.91 (m, 1H), from 2.00 to 2; , (M, 3H), 2.39 (m, 1H): 2.87 (m, 1H), 3.45 to 3.55 (m, 2H), 3.80 (m, 1H) 3, 94 (m, 1H), 5.41 (s, 1H),\n\n\n\n\n\n\n \nb) Etape 2: préparation de l'\nEX4\n \nb) Step 2: preparation of the \nEX4\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 220 mg (0.46 mmol) du produit \n3\n dans 16 mL d'éthanol anhydre, sous atmosphère inerte d'argon à une température voisine de 20°C, sont ajoutés après 10 minutes 18,2 mg (0,23 mmol) de sulfure de sodium, l'agitation est maintenue à cette température pendant environ 80 heures puis 20 mL d'une solution saturée en chlorure de sodium sont ajoutés. Le mélange est extrait par 3 x 20 mL d'acétate d'éthyle. Les phases organiques sont regroupées, lavées avec 20mL d'une solution aqueuse saturée en chlorure de sodium, séchées sur sulfate de magnésium, filtrées et évaporées à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable dans l'heptane, puis élué par un gradient linéaire de 0 à 100% du mélange B [(Heptane/Acétate d'éthyle), (85/15), (V/V)] dans A (Heptane). 103 mg (54%) du produit attendu \nEX4\n sont obtenus sous forme d'un solide blanc.\nTo a solution of 220 mg (0.46 mmol) of product \n3\n in 16 mL of anhydrous ethanol,  under an inert atmosphere of argon at a temperature in the region of 20 ° C., 18.2 mg (0.23 mmol) of sodium sulphide are added after 10 minutes, the stirring is maintained at this temperature for about 80 hours and then 20 ml saturated sodium chloride solution are added. The mixture is extracted with 3 x 20 mL of ethyl acetate. The organic phases are combined, washed with 20 ml of a saturated aqueous sodium chloride solution, dried over magnesium sulphate, filtered and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned in heptane and then eluted with a linear gradient from 0 to 100% of the mixture B [(heptane / ethyl acetate), (85/15), (V). / V)] in A (Heptane). 103 mg (54%) of the expected product \nEX4\n are obtained in the form of a white solid.\n\n\n\n\n\n\n \nRf = 0,20 dans le système (Heptane/Acétate d'éthyle), (90/10). (V/V)\nRf = 0.20 in the system (Heptane / ethyl acetate), (90/10). (V / V)\n\n\n\n\n\n\n \nES : m/z=841 MNa\n+\n \nES: m / z = 841 MNa \n+\n \n\n\n\n\n\n\n \nRMN 1H 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl\n3\n-d1) référencé à 7,27 à la température de 303K 0,93 (m partiellement masqué, 2H) ; 0,97 (d, J = 6,5 Hz, 8H) : 1,00 (d large, J = 7,5 Hz, 6H) ; de 1,22 à 1,38 (m, 4H); 1,43 (s, 6H) : de 1,44 à 1,55 (m, 4H) ; de 1,63 à 1,74 (m, 12H) ; 2,04 (m, 2H) ; 2,38 (m, 2H) ; de 2,51 à 2,66 (m, 4H) : 2,85 (m, 2H) ; 3,71 (m, 2H) ; 3,91 (m, 2H) ; 5,37 (s, 2H).\nNMR 1H 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform solvent - d1 (CDCl \n3\n -d1) referenced at 7.27 at a temperature of 303K 0.93 (partially masked m , 2H); 0.97 (d, J = 6.5Hz, 8H): 1.00 (d, J = 7.5Hz, 6H); from 1.22 to 1.38 (m, 4H); 1.43 (s, 6H): 1.44 to 1.55 (m, 4H); from 1.63 to 1.74 (m, 12H); 2.04 (m, 2H); 2.38 (m, 2H); from 2.51 to 2.66 (m, 4H): 2.85 (m, 2H); 3.71 (m, 2H); 3.91 (m, 2H); 5.37 (s, 2H).\n\n\n\n\n\n\n \n \nEX5\n :(3\nS\n,5a\nS\n,6\nR\n,8a\nS\n,9\nR\n,12\nR\n,12\nR\n,12a\nR\n,3'\nS\n,5'a\nS\n,6'\nR\n,8'\nS\n,9'\nR\n,10'\nR\n,12'\nR\n,12'a\nR\n)-10,10'-[sulfinylbis(3,1-propanediyloxy)]bis[décahydro-3,6,9-triméthyl-10-(trifluorométhy!)- 3,12-èpoxy-12\nH-\npyrano[4,3\n-j\n]-1,2-benzodioxépine et \nEX6\n: (3\nS\n,5a\nS\n,6\nR\n,8a\nS\n,9\nR\n,10\nR\n,12\nR\n,12a\nR\n,3'\nS\n,5'a\nS\n,6'\nR\n,8'a\nS\n,9'\nR\n,10'\nR\n, 12'\nR\n,12'a\nR\n)- 10,10'-[sulfonylbis(3,1-propanediyloxy)]bis[décahydro-3,6,9-triméthyl-10-(trifluorométhyl)-3,12-èpoxy-12\nH-\npyrano[4,3\n-j\n].1,2-benzodioxépine\n \nEX5\n : (3 \nS\n , 5a \nS\n , 6 \nR\n , 8a \nS\n , 9 \nR\n , 12 \nR\n , 12 \nR\n , 12a \nR\n , 3 ' \nS\n , 5'a \nS\n , 6' \nR\n , 8 ' \nS\n , 9' \nR\n , 10 ' \nR,\n 12 \n'R,\n 12'a \nR)\n -10,10' - [sulfinylbis (3,1-propanediyloxy)] bis [3,6,9-trimethyl-decahydro-10- (trifluoromethyl) - 3,12- epoxy-12 \nH-\n pyrano [4,3 \nj]\n -1,2-benzodioxepin and \nEX6:\n (3 \nS,\n 5a \nS,\n 6 \nR,\n 8a \nS,\n 9 \nR,\n 10 \nR,\n 12 \nR,\n 12a \nR,\n 3 \n'S\n , 5'a \nS,\n 6 \n'R,\n \nS\n 8'a, 9' \nR\n 10 \n'R,\n 12' \nR,\n 12'a \nR)\n - 10,10 '- [sulfonylbis (3,1-propanediyloxy)] bis [ decahydro-3,6,9-trimethyl-10- (trifluoromethyl) -3,12-epoxy-12 \nH-\n pyrano [4,3 \n-j]\n .1,2-benzodioxepine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 21,4 mg (0,026 mmol) de \nl'EX4\n dans 2 mL de dichlorométhane à une température voisine de 20°C, sont ajoutés lentement 9,1 mg (0,036 mmol) d'acide \nmeta\n chloroperbenzoïque. L'agitation est maintenue à cette température pendant environ 3 heures puis 3 mL d'une solution saturée en bicarbonate de sodium sont ajoutés. Le mélange est extrait par 3 x 10 mL d'acétate d'éthyle. Les phases organiques sont regroupées, lavées avec 2 x 10 mL d'une solution aqueuse saturée en chlorure de sodium, séchées sur sulfate de magnésium, filtrées et évaporées à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable dans l'heptane, puis élué par un gradient linéaire de 0 à 100% d'acétate d'éthyle dans l'heptane. 7,7 mg (34%) du produit \nEX6\n sont obtenus sous forme d'un solide blanc.\nTo a solution of 21.4 mg (0.026 mmol) of \nEX4\n in 2 ml of dichloromethane at a temperature in the region of 20 ° C., 9.1 mg (0.036 mmol) of chloroperbenzoic \nmeta\n acid are added slowly. Stirring is maintained at this temperature for about 3 hours and then 3 mL of a saturated solution of sodium bicarbonate is added. The mixture is extracted with 3 x 10 mL of ethyl acetate. The organic phases are combined, washed with 2 × 10 ml of a saturated aqueous sodium chloride solution, dried over magnesium sulphate, filtered and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned in heptane and then eluted with a linear gradient of 0 to 100% ethyl acetate in heptane. 7.7 mg (34%) of \nEX6\n product are obtained as a white solid.\n\n\n\n\n\n\n \nRf = 0,68 dans le système (Heptane/Acétate d'éthyle), (50/50), (V/V)\nRf = 0.68 in the system (Heptane / ethyl acetate), (50/50), (V / V)\n\n\n\n\n\n\n \nES : m/z=873 MNa\n+\n \nES: m / z = 873 MNa \n+\n \n\n\n\n\n\n\n \nRMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K :0,92 (m partiellement masqué, 2H) ;;. 0,97 (d, J = 6,5 Hz, 6H) ; 1,00 (d large, J = 7,5 Hz, 6H) ; de 1,23 à 1,68 (m, 4H) ; 1,43 (s, 6H) ; de 1,44 à 1,72 (m, 8H) ; 1,83 (m, 2H) ; 1,92 (m, 2H) ; 2,05 (m, 2H) ; 2,12 (m, 4H) ; 2,38 (m, 2H) ; 2.87 (m, 2H) ; 3,00 (m, 2H) ; 3,13 (m, 2H) ; 3,75 (m, 2H) ; 3,97 (m, 2H) ; 5,34 (s, 2H).\nNMR 1H at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform solvent - d1 (CDCl3-d1) referenced at 7.27 at the temperature of 303K: 0.92 (m partially masked, 2H); 0.97 (d, J = 6.5 Hz, 6H); 1.00 (broad d, J = 7.5 Hz, 6H); from 1.23 to 1.68 (m, 4H); 1.43 (s, 6H); from 1.44 to 1.72 (m, 8H); 1.83 (m, 2H); 1.92 (m, 2H); 2.05 (m, 2H); 2.12 (m, 4H); 2.38 (m, 2H); 2.87 (m, 2H); 3.00 (m, 2H); 3.13 (m, 2H); 3.75 (m, 2H); 3.97 (m, 2H); 5.34 (s, 2H).\n\n\n\n\n\n\n \nainsi que 8,5 mg (39%) du produit \nEX5\n sous forme de meringue blanche.\nas well as 8.5 mg (39%) of the \nEX5\n product as a white meringue.\n\n\n\n\n\n\n \nRf = 0,20 dans le système (Heptane/Acétate d'éthyle), (50/50), (V/V)\nRf = 0.20 in the system (Heptane / ethyl acetate), (50/50), (V / V)\n\n\n\n\n\n\n \nES : m/z=857 MNa\n+\n \nES: m / z = 857 MNa \n+\n \n\n\n\n\n\n\n \nRMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K (un mélange 50%-50% d'isomères): 0,90 (m partiellement masqué, 2H) ; 0,97 (d, J = 6,5 Hz, 6H) ; 1,00 (d large, J = 7,5 Hz, 6H) ; de 1,24 à 1,36 (m, 4H) ; 1,43 (s, 6H) ; de 1,45 à 1,72 (m, 8H) ; 1,82 (m, 2H) ; 1,92 (m, 2H) ; de 2,00 à 2,11 (m, 6H) ; 2,38 (m, 2H) ; de 2,68 à 2,82 (m, 4H) ; 2,86 (m, 2H) ; 3,77 (m, 2H) ; 3,96 (m, 2H) ; 5,33 (s, 1H) ; 5,35 (s, 1H).\n1H NMR at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in solvent chloroform - d1 (CDCl3-d1)  referenced at 7.27 at the temperature of 303K (a mixture of 50% -50% isomers): 0.90 (partially masked m, 2H); 0.97 (d, J = 6.5 Hz, 6H); 1.00 (broad d, J = 7.5 Hz, 6H); from 1.24 to 1.36 (m, 4H); 1.43 (s, 6H); from 1.45 to 1.72 (m, 8H); 1.82 (m, 2H); 1.92 (m, 2H); from 2.00 to 2.11 (m, 6H); 2.38 (m, 2H); from 2.68 to 2.82 (m, 4H); 2.86 (m, 2H); 3.77 (m, 2H); 3.96 (m, 2H); 5.33 (s, 1H); 5.35 (s, 1H).\n\n\n\n\n\n\n \n \nEX7\n: \n(\n3\nS,\n5\naS,\n6\nR,\n8\naS,\n9\nR,\n10\nR,\n12\nR,\n12\naR,\n3\n'S,\n5\n'aS,\n6\n'R,\n8\n'aS,\n9\n'R,\n1\n0'R,\n12\n'R,\n12\n'aR)-\n10,10'-[thiobis(4,1-butanediyloxy)]bis[décahydro-3,6,9-triméthyl-10-(trifluorométhyl)-3,12-époxy-12\nH\n-pyrano[4,3-\nj\n]-1,2-benzodioxépine\n \nEX7\n : \n(\n 3 \nS,\n 5 \naS,\n 6 \nR,\n 8 \naS,\n 9 \nR,\n 10 \nR,\n 12 \nR,\n 12 a \nR,\n 3 \n'S,\n 5 \n' aS,\n 6 \n'R,\n 8 \n' aS,\n 9 \n'R,\n \n10'; R,\n 12 \n'R,\n 12 \n' aR) -10,10\n '- [thiobis (4,1-butanediyloxy)] bis [decahydro-3,6,9-trimethyl-10- (trifluoromethyl) -3,12-epoxy- 12 \nH\n -pyrano [4,3- \nd\n ] -1,2-benzodioxepin\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \na) Etape 1: preparation du \n(\n3\nS,\n5\naS,\n6\nR,\n8\naS,\n9\nR,\n10\nR,\n12\nR,\n12\naR,\n3\n'S,\n5\n'aS,\n6\n'R,\n8\n'aS,\n9\n'R,\n10\n'R,\n12\n'R,\n12\n'aR)-\n 10-(4-bromobutoxy)decahydro-3,6,9-triméthyl-10-(trifluorométhyl)-3,12-époxy-12\nH-\npyrano[4,3-\nj\n]-1,2-benzodioxépine, \n \n4\n \n \na) Step 1: Preparation of \n(\n 3 \nS,\n 5 \naS,\n 6 \nR,\n 8 \naS,\n 9 \nR,\n 10 \nR,\n 12 \nR,\n 12 \naR,\n 3 \n'S,\n 5 \n' aS,\n 6 \n'R,\n 8 \n' aS,\n 9 \n' R,\n 10 \n'R,\n \n12' R,\n 12 \n'aR) -\n 10- (4-bromobutoxy) decahydro-3,6,9-trimethyl-10- (trifluoromethyl) -3,12-epoxy-12 \nH-\n pyrano [4 , \n3-j]\n -1,2-benzodioxepin, \n \n4\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 1,07 g (2,58 mmol) de \n1\n dans 15 mL de dichlorométhane, sont ajoutés successivement à température ambiante 1,36 ml d'héxafluoropropanol (5 éq.), puis 2,5 g de bromo-4-butanol (6,3 éq.). Le mélange réactionnel est ensuite agité à température ambiante pendant 3 heures, puis 6 mL d'une solution saturée de bicarbonate de sodium sont ajoutés. La phase organique est séchée sur sulfate de magnésium, filtrée et évaporée à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable dans l'heptane, puis élué par un gradient linéaire de 0 à 100% du mélange B [(Heptane/Acétate d'éthyle), (90/10), (V/V)] dans A (Heptane). 90 mg (7%) du produit attendu \n \n4\n \n sont obtenus sous forme d'une huile.\nTo a solution of 1.07 g (2.58 mmol) of \n1\n in 15 ml of dichloromethane is added successively at room temperature 1.36 ml of hexafluoropropanol (5 eq.), Then 2.5 g of bromo-4 butanol (6.3 eq.). The reaction mixture is then stirred at room temperature for 3 hours and then 6 ml of saturated sodium bicarbonate solution are added. The organic phase is dried over magnesium sulphate, filtered and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned in heptane and then eluted with a linear gradient from 0 to 100% of the mixture B [(heptane / ethyl acetate), (90/10), (V). / V)] in A (Heptane). 90 mg (7%) of the expected product \n \n4\n \n are obtained in the form of an oil. \n\n\n\n\n\n\n \nRf = 0,40 dans le système (Heptane/Acétate d'éthyle), (9/1), (V/V)\nRf = 0.40 in the system (Heptane / ethyl acetate), (9/1), (V / V)\n\n\n\n\n\n\n \nIC : m/z=504 MNH\n4\n \n+\n \nIC: m / z = 504 MNH \n4\n \n+\n \n\n\n\n\n\n\n \nRMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant diméthylsulfoxide - d6 (DMSO-d6) référencé à 2,50 ppm à la température de 298K : 0,92 (m partiellement masqué, 1H) ; 0,97 (d,J = 6,0 Hz, 3H) ; 1,00 (d large, J = 7,5 Hz, 3H) ; de 1,05 à 1,62 (m partiellement masqué, 6H) ; 1,43 (s, 3H) ; de 1,65 à 2,10 (m, 7H) ; de 2,33 à 2,45 (m, 1H) ; 2,84 (m, 1H) ; de 3,40 à 3,51 (m, 2H) ; 3,63 (m, 1H) ; 3,88 (m, 1H) ; 5,32 (s, 1H).\n1H NMR at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in dimethylsulfoxide-d6 solvent (DMSO-d6) referenced at 2.50 ppm at a temperature of 298K: 0.92 (m partially masked, 1H); 0.97 (d, J = 6.0 Hz, 3H); 1.00 (d wide, J = 7.5 Hz, 3H); from 1.05 to 1.62 (partially masked m, 6H); 1.43 (s, 3H); from 1.65 to 2.10 (m, 7H); from 2.33 to 2.45 (m, 1H); 2.84 (m, 1H); from 3.40 to 3.51 (m, 2H); 3.63 (m, 1H); 3.88 (m, 1H); 5.32 (s, 1H).\n\n\n\n\n\n\n \nb) Etape 2: préparation de \nl'EX7\n \nb) Step 2: preparation of \nthe EX7\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 90 mg (0,19 mmol) de \n4\n dans 5 mL d'éthanol anhydre, sous atmosphère inerte d'argon à une température voisine de 20°C, sont ajoutés après 10 minutes 5,7 mg (0,073 mmol) de sulfure de sodium. L'agitation est maintenue à cette température pendant environ 42 heures puis 5 mL d'une solution saturée en chlorure de sodium sont ajoutés. Le mélange est extrait par 3 x 5 mL d'acétate d'éthyle. Les phases organiques sont regroupées, lavées avec 5 mL d'une solution aqueuse saturée en chlorure de sodium, séchées sur sulfate de magnésium, filtrées et évaporées à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable dans l'heptane, puis élué par un gradient linéaire de 0 à 20% d'acétate d'éthyle dans l'heptane 33 mg (50%) du produit attendu \nEX7\n sont obtenus sous forme d'une meringue.\nTo a solution of 90 mg (0.19 mmol) of \n4\n in 5 ml of anhydrous ethanol, under an inert atmosphere of argon at a temperature in the region of 20 ° C., 5.7 mg (0.073 mmol) are added after 10 minutes. sodium sulphide. Stirring is maintained at this temperature for about 42 hours and then 5 ml of a saturated solution of sodium chloride are added. The mixture is extracted with 3 x 5 mL of ethyl acetate. The organic phases are combined, washed with 5 ml of a saturated aqueous sodium chloride solution, dried over magnesium sulphate, filtered and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned in heptane and then eluted with a linear gradient of 0 to 20% of ethyl acetate in heptane. 33 mg (50%) of the expected product \nEX7\n are obtained in the form of a meringue.\n\n\n\n\n\n\n \nRf = 0,20 dans le système (Heptane/Acétate d'éthyle), (9/1), (V/V)\nRf = 0.20 in the system (Heptane / ethyl acetate), (9/1), (V / V)\n\n\n\n\n\n\n \nES ; m/z=891 (M + HCOOH - H)\n-\n \nES; m / z = 891 (M + HCOOH-H) \n-\n \n\n\n\n\n\n\n \nRMN 1H à 400 MHz sur spectromètre, BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant diméthylsulfoxide - d6 (DMSO-d6) référencé à 2,50 ppm à la température de 298K : 0,93 (m partiellement masqué, 2H) ; 0,97 (d, J = 6,0 Hz, 6H) ; 1,00 (d large, J = 7,5 Hz, 6H) ; de 1,22 à 1,37 (m, 4H) ; 1,43 (s, 6H) ; 1.50 (m, 4H) ; de 1,62 à 1,86 (m, 14H) ; 1,91 (m, 2H) : 2,04 (m, 2H) ; 2,36 (m, 2H) ; 2.54 (m, 4H) ; 2,84 (m, 2H) ; 3,62 (m, 2H) 3,85 (m, 2H) ; 5,33 (s, 2H).\nNMR 1H at 400 MHz on spectrometer, BRUKER AVANCE DRX-400 with chemical shifts (δ in ppm) - in solvent dimethylsulfoxide - d6 (DMSO-d6) referenced at 2.50 ppm at a temperature of 298K: 0.93 ( partially masked, 2H); 0.97 (d, J = 6.0 Hz, 6H); 1.00 (broad d, J = 7.5 Hz, 6H); from 1.22 to 1.37 (m, 4H); 1.43 (s, 6H); 1.50 (m, 4H); from 1.62 to 1.86 (m, 14H); 1.91 (m, 2H):  2.04 (m, 2H); 2.36 (m, 2H); 2.54 (m, 4H); 2.84 (m, 2H); 3.62 (m, 2H) 3.85 (m, 2H); 5.33 (s, 2H).\n\n\n\n\n\n\n \n \nEX8\n: 2-[[(3\nR\n,5a\nS\n,6\nR\n,8a\nS\n,9\nR\n,10\nR\n,12\nR\n,12a\nR\n)-decahydro-3,6,9-triméthyl-10-(trifluorométhyl)-3,12-époxy-12H-pyrano[4,3-\nj\n]-1,2-benzodioxépin-10-yl]oxy]-N-[2-[[(3\nR\n,5a\nS\n,6\nR\n,8a\nS\n,9\nR\n,10\nR\n,12\nR\n,12a\nR\n)-decahydro-3,6,9-triméthyl-10-(trifluorométhyl)-3,12-epoxy-12\nH\n-pyrano[4,3-\nj\n]-1,2-benzodioxépin-10-yl]oxy]éthyl]-\nN-\nméthyl- éthanamine\n \nEX8\n : 2 - [[(3 \nR\n , 5a \nS\n , 6 \nR\n , 8a \nS\n , 9 \nR\n , 10 \nR\n , 12 \nR\n , 12a \nR\n ) -decahydro-3,6,9-trimethyl-10- (trifluoromethyl) -3, 12-epoxy-12H-pyrano [4,3- \nd\n ] -1,2-benzodioxepin-10-yl] oxy] -N- [2 - [[(3 \nR\n , 5a \nS\n , 6 \nR\n , 8a \nS\n , 9 \nR)\n , 10 \nR,\n 12 \nR,\n 12a \nR)\n -decahydro-3,6,9-trimethyl-10- (trifluoromethyl) -3,12-epoxy-12 \nH\n -pyrano \n[4,3-j]\n -1,2-benzodioxepin -10-yl] oxy] ethyl] - \nN-methyl-\n ethanamine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 100 mg (0,218 mmol) du composé \n \n2\n \n dans 0,6 ml de tétrahydrofurane, sous atmosphère inerte d'argon à une température voisine de 20°C, sont ajoutés successivement 33 mg (0,218 mmol) d'iodure de sodium et 0,545 ml (1.09 mmol) d'une solution de méthylamine 2M dans le tétrahydrofurane. L'agitation est maintenue à 40°C pendant environ 20 heures. Le mélange réactionnel est repris par 3ml d'une solution aqueuse saturée en bicarbonate de sodium, puis extrait par 3x3 ml de dichlorométhane. Les phases organiques sont regroupées puis séchées sur sulfate de magnésium, filtrées et évaporées à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable dans l'heptane, puis élué par un gradient de 0 à 30% d'acétate d'éthyle dans l'heptane. 15 mg (18%) du produit attendu EX8 sont obtenus sous forme d'un solide blanc.\nTo a solution of 100 mg (0.218 mmol) of compound \n \n2\n \n in 0.6 ml of tetrahydrofuran under an inert atmosphere of argon at a temperature in the region of 20 ° C., 33 mg (0.218 mmol) of sodium iodide are successively added. and 0.545 ml (1.09 mmol) of a solution of 2M methylamine in tetrahydrofuran. Stirring is maintained at 40 ° C for about 20 hours. The reaction mixture is taken up in 3 ml of a saturated aqueous solution of sodium bicarbonate and then extracted with 3x3 ml of dichloromethane. The organic phases are combined and then dried over magnesium sulfate, filtered and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned in heptane and then eluted with a gradient of 0 to 30% ethyl acetate in heptane. 15 mg (18%) of the expected product EX8 are obtained in the form of a white solid.\n\n\n\n\n\n\n \nRf = 0,25 dans le système (Heptane/Acétate d'éthyle), (7/3), (V/V)\nRf = 0.25 in the system (Heptane / ethyl acetate), (7/3), (V / V)\n\n\n\n\n\n\n \nES : m/z=788 MH\n+\n \nES: m / z = 788 MH \n+\n \n\n\n\n\n\n\n \nRMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K après addition d'une goutte d'acide acétique-d4-(CD3OD-d4) : 0,91 (m partiellement masqué, 2H) ; 0,95 (d, J = 6,5 Hz, 6H) ; 0,98 (d large, J = 7,0 Hz, 6H) ; 1,28 (m, 2H) ; de 1,33 à 1,63 (m, 8H) ; 1.39 (s, 6H) ; 1,69 (m, 2H) ; 1,78 (m, 2H) ; 1,89 (m, 2H) ; 2,02 (m partiellement masqué, 2H) ; 2,36 (m, 2H) ; 2,86 (m partiellement masqué, 2H) ; 2,89 (s, 3H) ; 3,38 (m, 4H) ; 4,19 (m, 4H) ; 5,38 (s, 2H).\n1H NMR at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform-d1 solvent (CDCl3-d1) referenced at 7.27 at the temperature of 303K after addition of a drop of d d4- (CD3OD-d4) acetic acid: 0.91 (partially masked m, 2H); 0.95 (d, J = 6.5 Hz, 6H); 0.98 (broad d, J = 7.0 Hz, 6H); 1.28 (m, 2H); from 1.33 to 1.63 (m, 8H); 1.39 (s,  6H); 1.69 (m, 2H); 1.78 (m, 2H); 1.89 (m, 2H); 2.02 (partially masked m, 2H); 2.36 (m, 2H); 2.86 (partially masked m, 2H); 2.89 (s, 3H); 3.38 (m, 4H); 4.19 (m, 4H); 5.38 (s, 2H).\n\n\n\n\n\n\n \n \nEX 9\n: 2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromén-10-yl]oxy}-N-(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromén-10-yl]oxy}éthyl)éthanamine\n \nEX 9\n : 2 - {[(3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [1,2] dioxepino [4,3-i] isochromén-10-yl] oxy} -N- (2 - {[(3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl 10- (trifluoromethyl) decahydro-3,12-epoxy [1,2] dioxepino [4,3-i] isochromén-10-yl] oxy} ethyl) ethanamine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \na) étape 1 : préparation du (3R,5aS,6R,8aS,9R,10R,12R,12aR)-10-(2-azidoéthoxy)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromène, \n \n5\n \n \na) step 1: preparation of (3R, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -10- (2-azidoethoxy) -3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3, 12-epoxy [1,2] dioxepino [4,3-i] isochromene, \n \n5\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 574 mg (1,25 mmol) du composé \n \n2\n \n dans 20 mL de diméthylformamide, sous atmosphère inerte d'argon à une température voisine de 20°C\n,\n sont ajoutés 162,5 mg (2,5 mmol) d'azoture de sodium. L'agitation est maintenue à une température voisine de 20°C pendant 3 heures. Le mélange réactionnel est repris par 60 mL d'eau distillée puis extrait par 2 x 100 mL d'acétate d'éthyle. La phase organique est lavée par 2 x 80 mL d'une solution aqueuse saturée en chlorure de sodium, séchée sur sulfate de magnésium, filtrée et évaporée à sec sous pression réduite. 527 mg (Rendement quantitatif) du produit attendu 6 sont obtenus sous forme d'une huile jaune.\nTo a solution of 574 mg (1.25 mmol) of compound \n \n2\n \n in 20 ml of dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20 ° C. \n,\n are added 162.5 mg (2.5 mmol) of sodium azide. Stirring is maintained at a temperature of 20 ° C for 3 hours. The reaction mixture is taken up in 60 ml of distilled water and then extracted with 2 × 100 ml of ethyl acetate. The organic phase is washed with 2 × 80 ml of a saturated aqueous sodium chloride solution, dried over magnesium sulphate, filtered and evaporated to dryness under reduced pressure. 527 mg (quantitative yield) of the expected product 6 are obtained in the form of a yellow oil. \n\n\n\n\n\n\n \nRf = 0,43 dans le système (Heptane/Acétate d'éthyle), (8/2), (V/V)\nRf = 0.43 in the system (Heptane / ethyl acetate), (8/2), (V / V)\n\n\n\n\n\n\n \nRMN \n1\nH (CDCl\n3\n, 400MHz) δ\nppm\n : 5.48 (s, 1H) ; 3.97 (m, 1H) ; 3.78 (m, 1H) ; 3.48 (m, 2H) ; 2.88 (qu, 1H) ; 2,39 (td, 1H); 2.05 (dt, 1H) ; 197-1.88 (m, 1H) ; 1.87-1.77 (m, 2H) ; 1.76-1.68 (m, 1H); 1.53 (m, 1H) ; 1.50 (m, 1H) ; 1,43 (s, 3H) ; 1.39-1.25 (m, 2H) ; 1,03 (d, 3H) ; 1.01-0.89 (m, 1H) ; 0.98 (d, 3H).\n \n1\n H NMR (CDCl \n3\n , 400MHz) δ \nppm\n : 5.48 (s, 1H); 3.97 (m, 1H); 3.78 (m, 1H); 3.48 (m, 2H); 2.88 (qu, 1H); 2.39 (td, 1H); 2.05 (dt, 1H); 197-1.88 (m, 1H); 1.87-1.77 (m, 2H); 1.76-1.68 (m, 1H); 1.53 (m, 1H); 1.50 (m, 1H); 1.43 (s, 3H); 1.39-1.25 (m, 2H); 1.03 (d, 3H); 1.01-0.89 (m, 1H); 0.98 (d, 3H).\n\n\n\n\n\n\n \nb) étape 2 : préparation du 2-([(3R,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromén-10-yl]oxy}éthanamine, \n \n6\n \n \nb) Step 2: Preparation of 2 - ([(3R, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [ 1,2] dioxepino [4,3-i] isochron-10-yl] oxy} ethanamine, \n \n6\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 527 mg (1,25 mmol) du composé \n \n5\n \n dans 7 mL de tétrahydrofurane, sous atmosphère inerte d'argon à une température voisine de 20°C, sont ajoutés 328 mg (1,25 mmol) de triphénylphosphine. L'agitation est maintenue à une température voisine de 20°C pendant environ 24 heures. Le mélange réactionnel est repris par 1 mL d'eau distillée puis on poursuit l'agitation pendant environ 24 heures à la même température. Le mélange réactionnel est concentré sous vide et le résidu ainsi obtenu est repris par 5 mL de dichlorométhane, lavé par 2 mL d'une solution aqueuse saturée en bicarbonate de sodium, séchées sur sulfate de magnésium, filtrée et évaporée à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable dans la dichlorométhane, puis élué par un gradient linéaire de 0 à 100% du mélange B [(Dichlorométhane/Méthanol), (90/10), (V/V)] dans A (Diclorométhane). 344 mg (70%) du produit attendu \n \n6\n \n sont obtenus sous forme d'une poudre blanche.\nTo a solution of 527 mg (1.25 mmol) of compound \n \n5\n \n in 7 mL of tetrahydrofuran, under an inert atmosphere of argon at a temperature of 20 ° C, are added 328 mg (1.25 mmol) of triphenylphosphine. Stirring is maintained at a temperature of 20 ° C for about 24 hours. The reaction mixture is taken up in 1 ml of distilled water and stirring is continued for about 24 hours at the same temperature. The reaction mixture is concentrated in vacuo and the residue thus obtained is taken up in 5 ml of dichloromethane, washed with 2 ml of saturated aqueous sodium bicarbonate solution, dried over magnesium sulphate, filtered and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned in dichloromethane and then eluted with a linear gradient from 0 to 100% of the mixture B [(dichloromethane / methanol), (90/10), (V / V)] in A (Dichloromethane). 344 mg (70%) of the expected product \n \n6\n \n are obtained in the form of a white powder.\n\n\n\n\n\n\n \nMS: ES\n+\n: [M+H]\n+\n = 396.\nMS: ES \n+\n : [M + H] \n+\n = 396.\n\n\n\n\n\n\n \nSpectre RMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K : 0,94 (m partiellement masqué, 1H) ; 0,97 (d, J = 6,5 Hz, 3H) ; 1,03 (d large, J = 7.0 Hz, 3H) ; 1,30 (m, 2H) ; de 1,40 à 1,56 (m, 2H) ; 1,42 (s, 3H) ; de 1,63 à 1,95 (m, 4H) ; 2,04 (m, 1H) ; 2,38 (m, \n1\nH) ; 2,45 (m étalé, 2H) ; 2,87 (m, 1H) ; 2,94 (m, 2H) ; 3,75 (m, 1H) ; 3,85 (m, 1H) ; 5,42 (s, 1H).\n1H NMR spectrum at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform-d1 solvent (CDCl3-d1) referenced at 7.27 at 303K temperature: 0.94 (m partially masked, 1H); 0.97 (d, J = 6.5 Hz, 3H); 1.03 (broad, J = 7.0 Hz, 3H); 1.30 (m, 2H); from 1.40 to 1.56 (m, 2H); 1.42 (s, 3H); from 1.63 to 1.95 (m,  4H); 2.04 (m, 1H); 2.38 (m, \n1H);\n 2.45 (m spread, 2H); 2.87 (m, 1H); 2.94 (m, 2H); 3.75 (m, 1H); 3.85 (m, 1H); 5.42 (s, 1H).\n\n\n\n\n\n\n\n\n \nc) étape 3 : préparation de EX9\nc) Step 3: Preparation of EX9\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 282 mg (0,534 mmol) du composé \n \n2\n \n dans 7 mL de diméthylformamide, sous atmosphère inerte d'argon à une température voisine de 20°C, sont ajoutés successivement 98 mg (0,593 mmol) d'iodure de potassium, 164 mg (1,19 mmol) de carbonate de potassium et 232 mg (0,587 mmol) du composé \n \n6\n \n. L'agitation est maintenue à 70°C pendant environ 7 heures. Le mélange réactionnel est concentré à sec sous pression réduire. Le résidu obtenu est repris par 10 mL de dichlorométhane, puis lavé par 6 mL d'eau distillée, la phase aqueuse est à nouveau extraite par 10 mL de dichlorométhane. Les phases organiques réunies sont lavées par 6 mL d'une solution aqueuse saturée en bicarbonate de sodium, puis séchées sur sulfate de magnésium, filtrées et évaporées à sec sous pression réduite. Le résidu obtenu est chromatographie sur gel de silice conditionné au préalable dans le mélange (Heptane/Acétate d'éthyle), (9/1), (V/V) puis élué par un gradient de 10 à 60% d'acétate d'éthyle dans l'heptane, 116 mg (28%) du produit attendu EX9 sont obtenus sous forme d'un solide jaune pâle.\nTo a solution of 282 mg (0.534 mmol) of compound \n \n2\n \n in 7 ml of dimethylformamide under an inert atmosphere of argon at a temperature in the region of 20 ° C., 98 mg (0.593 mmol) of potassium iodide, mg (1.19 mmol) of potassium carbonate and 232 mg (0.587 mmol) of compound \n \n6\n \n . Stirring is maintained at 70 ° C for about 7 hours. The reaction mixture is concentrated to dryness under reduced pressure. The residue obtained is taken up in 10 ml of dichloromethane and then washed with 6 ml of distilled water, the aqueous phase is again extracted with 10 ml of dichloromethane. The combined organic phases are washed with 6 ml of saturated aqueous sodium bicarbonate solution, then dried over magnesium sulfate, filtered and evaporated to dryness under reduced pressure. The residue obtained is chromatographed on silica gel pre-conditioned in the mixture (Heptane / ethyl acetate), (9/1), (V / V) and then eluted with a gradient of 10 to 60% of acetate. ethyl in heptane, 116 mg (28%) of the expected product EX9 are obtained as a pale yellow solid.\n\n\n\n\n\n\n \nRf = 0,16 dans le système (Heptane/Acétate d'éthyle), (8/2), (V/V)\nRf = 0.16 in the system (Heptane / ethyl acetate), (8/2), (V / V)\n\n\n\n\n\n\n \nMS : ES\n+\n: [M+H]\n+\n = 774.\n\nES\n-\n : [M+HCOOH+H]\n+\n = 818.\nMS: ES \n+\n : [M + H] \n+\n = 774. \n ES \n-\n : [M + HCOOH + H] \n+\n = 818.\n\n\n\n\n\n\n \nSpectre RMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K : 0,92 (m partiellement masqué, 2H) ; 0,98 (d, J = 6,5 Hz, 6H) ; 1,00 (d large, J = 7,0 Hz, 6H) ; de 1,20 à 1,39 (m, 4H) ; 1,42 (s, 6H) ; de 1,40 à 1,83 (m, 11H) ; 1,90 (m, 2H) ; 2,03 (m, 2H) ; 2,38 (m, 2H) ; de 2,73 à 2,91 (m, 6H) ; 3,75 (m, 2H) ; 3,91 (m, 2H) ; 5,47 (s, 2H).\n400 MHz 1H NMR spectrum on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform-d1 solvent (CDCl3-d1) referenced at 7.27 at 303K temperature: 0.92 (m partially masked, 2H); 0.98 (d, J = 6.5 Hz, 6H); 1.00 (broad d, J = 7.0 Hz, 6H); from 1.20 to 1.39 (m, 4H); 1.42 (s, 6H); from 1.40 to 1.83 (m, 11H); 1.90 (m, 2H); 2.03 (m, 2H); 2.38 (m, 2H); from 2.73 to 2.91 (m, 6H); 3.75 (m, 2H); 3.91 (m, 2H); 5.47 (s, 2H). \n\n\n\n\n\n\n \n \nEX 10\n : N,N-bis(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromén-10-yl]oxy}éthyl)glycinate d'éthyle\n \nEX 10\n : N, N-bis (2 - {[(3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12- ethyl epoxy [1,2] dioxepino [4,3-i] isochromen-10-yl] oxy} ethyl) glycinate\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 37 mg (0,047 mmol) du composé \n \nEX9\n \n dans 1 mL de diméthylformamide, sous atmosphère inerte d'argon à une température voisine de 20°C, sont ajoutés successivement 15 µL (0,133 mmol) de l'ester éthylique de l'acide bromoacétique, 8 mg (0,047 mmol) d'iodure de potassium, 10 mg ( 0,071 mmol) de carbonate de potassium. L'agitation est maintenue à 50°C pendant 1 heure. Le mélange réactionnel est concentré à sec sous pression réduite. Le résidu obtenu est repris par 5 mL d'acétate d'éthyle, puis lavé par 3 mL d'eau distillée la phase aqueuse est à nouveau extraite par 2x5 mL d'acétate d'éthyle. Les phases organiques réunies sont lavées par 2×5 mL d'une solution aqueuse saturée en chlorure de sodium, puis séchées sur sulfate de magnésium, filtrées et évaporées à sec sous pression réduite. Le résidu obtenu est chromatographié sur gel de silice conditionné au préalable puis élué dans le mélange(Heptane/Acétate d'éthyle), (80/20), (V/V), 30mg (74%) du produit attendu \nEX10\n sont obtenus sous forme d'une pâte incolore.\nTo a solution of 37 mg (0.047 mmol) of the compound \n \nEX9\n \n in 1 ml of dimethylformamide, under an inert atmosphere of argon at a temperature in the region of 20 ° C., 15 μl (0.133 mmol) of the ethyl ester of the bromoacetic acid, 8 mg (0.047 mmol) of potassium iodide, 10 mg (0.071 mmol) of potassium carbonate. Stirring is maintained at 50 ° C for 1 hour. The reaction mixture is concentrated to dryness under reduced pressure. The residue obtained is taken up in 5 ml of ethyl acetate and then washed with 3 ml of distilled water, the aqueous phase is again extracted with 2x5 ml of ethyl acetate. The combined organic phases are washed with 2 × 5 mL of saturated aqueous sodium chloride solution, then dried over magnesium sulfate, filtered and evaporated to dryness under reduced pressure. The residue obtained is chromatographed on silica gel pre-conditioned and then eluted in the mixture (heptane / ethyl acetate), (80/20), (V / V), 30 mg (74%) of the expected product \nEX10\n are obtained under form of a colorless paste.\n\n\n\n\n\n\n \nCCM Rf = 0,49 dans le système (Heptane/Acétate d'éthyle), (7/3), (V/V)\nTLC Rf = 0.49 in the system (Heptane / ethyl acetate), (7/3), (V / V)\n\n\n\n\n\n\n \nMS : ES\n+\n: [M+H]\n+\n = 860.\n\nES\n-\n : [M+HCOOH+H]\n+\n = 904.\nMS: ES \n+\n : [M + H] \n+\n = 860. \n ES \n-\n : [M + HCOOH + H] \n+\n = 904.\n\n\n\n\n\n\n \nSpectre RMN 1N à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K: De 0,80 à 1,00 (m, 14H) ; de 1.19 à 1,38 (m partiellement masqué, 4H) ; 1,28 (t, J = 7,0 Hz, 3H) ; 1,40 (s, 6H) ; de 1,44 à 1,58 (m partiellement masqué, 4H) ; de 1,61 à 1,82 (m, 6H) ; 1,89 (m, 2H) ; 2,02 (m, 2H) ; 2,36 (m, 2H) ; de 2,70 à 2,90 (m, 4H) ; 3,02 (m, 2H) ; 3,40 (d, J = 17,5 Hz, 1H) ; 3,61 (m, 2H) ; 3,67 (d, J = 17,5 Hz, 1H) ; 3,98 (m, 2H) ; de 4,06 à 4,22 (m, 2H) ; 5,40 (s, 2H).\n1N NMR spectrum at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform solvent - d1 (CDCl3-d1) referenced at 7.27 at the temperature of 303K: From 0.80 to 1.00 (m, 14H); from 1.19 to 1.38 (partially masked m, 4H); 1.28 (t, J = 7.0 Hz, 3H); 1.40 (s, 6H); from 1.44 to 1.58 (partially masked m, 4H); from 1.61 to 1.82 (m, 6H); 1.89 (m, 2H); 2.02 (m, 2H); 2.36 (m, 2H); from 2.70 to 2.90 (m, 4H); 3.02 (m, 2H); 3.40 (d, J = 17.5 Hz, 1H); 3.61 (m, 2H); 3.67 (d, J = 17.5 Hz, 1H); 3.98 (m, 2H); from 4.06 to 4.22 (m, 2H); 5.40 (s, 2H). \n\n\n\n\n\n\n \n \nEX 11\n : N,N-bis(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-1]isochromén-10-yl]oxy}éthyl)glycine\n \nEX 11\n : N, N-bis (2 - {[(3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12- epoxy [1,2] dioxepino [4.3 to 1] isochromén-10-yl] oxy} ethyl) glycine\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 10 mg (0,011 mmol) du composé \n \nEX10\n \n dans 0,5 mL de méthanol, à une température voisine de 20°C, sont ajoutés 59 µL (0,059 mmol) d'une solution aqueuse de soude 1N. L'agitation est maintenue à la même température pendant environ 6,5 heures. Le mélange réactionnel est concentré à sec sous pression réduite. Le résidu obtenu est repris par 3 mL d'acétate d'éthyle, puis lavé par 1 mL d'une solution aqueuse saturée en chlorure de sodium. La phase aqueuse est à nouveau extraite par 3 mL d'acétate d'éthyle. Les phases organiques réunies séchées sur sulfate de magnésium, filtrées et évaporées à sec sous; pression réduite. Le résidu obtenu est chromatographié sur gel de silice conditionné au préalable puis élué dans le mélange (dichlorométhane/méthanol), (95/05), (V/V) 8 mg (81%) du produit attendu EX11 sont obtenus sous forme d'un solide incolore. MS : ES\n+\n : [M+H]\n+\n = 832.\n\nES\n-\n: [M-H]\n-\n = 830.\nTo a solution of 10 mg (0.011 mmol) of compound \n \nEX10\n \n in 0.5 ml of methanol at a temperature in the region of 20 ° C., 59 μl (0.059 mmol) of a 1N aqueous sodium hydroxide solution are added. Stirring is maintained at the same temperature for about 6.5 hours. The reaction mixture is concentrated to dryness under reduced pressure. The residue obtained is taken up in 3 ml of ethyl acetate and then washed with 1 ml of a saturated aqueous sodium chloride solution. The aqueous phase is again extracted with 3 mL of ethyl acetate. The combined organic phases are dried over magnesium sulfate, filtered and evaporated to dryness under water; reduced pressure. The residue obtained is chromatographed on silica gel preloaded and then eluted in the mixture (dichloromethane / methanol), (95/05), (V / V) 8 mg (81%) of the expected product EX11 are obtained in the form of a colorless solid. MS: ES \n+\n : [M + H] \n+\n = 832. \n ES \n-\n : [MH] \n-\n = 830.\n\n\n\n\n\n\n \nSpectre RMN 1H à 300 MHz sur spectromètre BRUKER AVANCE DPX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K : 0,92 (m partiellement masqué, 2H) ; 0,97 (d, J = 6,5 Hz, 6H) ; 1,01 (d large, J = 7,0 Hz, 6H) ; de 1,20 à 1,38 (m partiellement masqué, 4H) ; 1,42 (s, 6H) ; de 1,44 à 1,75 (m, 8H) ; de 1,80 à 2,10 (m, 6H) ; 2,39 (m, 2H) ; de 2,80 à 3,02 (m, 6H) ; 3,38 (d, J = 17,5 Hz, 1H) ; 3,55 (d, J = 17,5 Hz, 1H) ; de 3,77 à 3,98 (m, 4H) ; 5,32 (s, 2H).\n300 MHz 1H NMR spectrum on BRUKER AVANCE DPX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform-d1 solvent (CDCl3-d1) referenced at 7.27 at 303K temperature: 0.92 (m partially masked, 2H); 0.97 (d, J = 6.5 Hz, 6H); 1.01 (broad d, J = 7.0 Hz, 6H); from 1.20 to 1.38 (partially masked m, 4H); 1.42 (s, 6H); from 1.44 to 1.75 (m, 8H); from 1.80 to 2.10 (m, 6H); 2.39 (m, 2H); from 2.80 to 3.02 (m, 6H); 3.38 (d, J = 17.5 Hz, 1H); 3.55 (d, J = 17.5 Hz, 1H); from 3.77 to 3.98 (m, 4H); 5.32 (s, 2H).\n\n\n\n\n\n\n \n \nEX 12\n : 2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromén-10-yl]oxy}-N-(2-{[(35,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromén-10-yl]oxy}éthyl)acétamide\n \nEX 12\n : 2 - {[(3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [1,2] dioxepino [4,3-i] isochromén-10-yl] oxy} -N- (2 - {[(35,5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl 10- (trifluoromethyl) decahydro-3,12-epoxy [1,2] dioxepino [4,3-i] isochromén-10-yl] oxy} ethyl) acetamide\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \na) étape 1 : préparation de acide {[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromén-10-yl]oxy}acétique, \n \n8\n \n \na) Step 1: Preparation of {[(3R, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [1] acid , 2] dioxepino [4,3-i] isochromen-10-yl] oxy} acetic acid, \n \n8\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 100 mg (0,255 mmol) de \n \n7\n \n (prépare selon \n \nWO2003035651\n \n), dans 2 mL d'acétone sont ajoutés successivement à température ambiante 117 mg (0,742 mmol) de permanganate de potassium puis 11 mg (0,127 mmol) de bicarbonate de sodium, Le mélange réactionnel est ensuite agité à température ambiante pendant 3 heures, puis 1 eq. d'une solution aqueuse 1 N d'acide chlorhydrique sont ajoutés. L'agitation est poursuivie à température ambiante pendant environ 18 heures. Le milieux réactionnel est filtré puis évaporé à sec sous pression réduite, le résidu obtenu est repris par 10 mL d'acétate d'éthyle. La phase organique est lavée par 3 mL d'eau distillée, la phase aqueuse est acidifiée par 2 mL d'une solution aqueuse 1 N d'acide chlorhydrique puis extraite par 10 mL d'acétate d'éthyle. La phase organique est séchée sur sulfate de magnésium, filtrée puis évaporé à sec sous pression réduite. 27mg (26%) du produit attendu \n \n8\n \n sont obtenus sous forme d'un solide blanc.\nTo a solution of 100 mg (0.255 mmol) of \n \n7\n \n (prepares according to \n \n WO2003035651 \n \n ) in 2 ml of acetone are added successively at ambient temperature 117 mg (0.742 mmol) of potassium permanganate and then 11 mg (0.127 mmol) of sodium bicarbonate. The reaction mixture is then stirred at room temperature for 3 hours, then 1 eq. 1 N aqueous solution of hydrochloric acid are added. Stirring is continued at room temperature for about 18 hours. The reaction medium is filtered and then evaporated to dryness under reduced pressure, the residue obtained is taken up in 10 ml of ethyl acetate. The organic phase is washed with 3 ml of distilled water, the aqueous phase is acidified with 2 ml of a 1 N aqueous solution of hydrochloric acid and then extracted with 10 ml of ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then evaporated to dryness under reduced pressure. 27 mg (26%) of the expected product \n \n8\n \n are obtained in the form of a white solid.\n\n\n\n\n\n\n \nRMN \n1\nH (CDCl\n3\n, 300MHz) δ\nppm\n : 5.47 (s, 1H) ; 4.67 (d, 1H) ; 4.26 (d, 1H,) ; 2.91 (qu, 1H) ; 238 (td, 1H) ; 2.19 (dq, 1H) ; 2.04 (dt, 1H) ; 1.90 (m, 1H) ; 1.77 (m, 2H) ; 1.70 (m, 1H) ; 1.59-1.48 (m, 1H) ; 1.48-1.45 (m, 1H) ; 1,42 (s, 3H); 1.40-1.24 (m, 2H) ; 1.05 (d, 3H) ; 0.98-0.87 (m, 1H) ; 0.96 (d, 3H).\n \n1\n H NMR (CDCl \n3,\n 300MHz) δ \nppm:\n 5.47 (s, 1H); 4.67 (d, 1H); 4.26 (d, 1H,); 2.91 (qu, 1H); 238 (td, 1H); 2.19 (dq, 1H); 2.04 (dt, 1H); 1.90 (m, 1H); 1.77 (m, 2H); 1.70 (m, 1H); 1.59-1.48 (m, 1H); 1.48-1.45 (m, 1H); 1.42 (s, 3H); 1.40-1.24 (m, 2H); 1.05 (d, 3H); 0.98-0.87 (m, 1H); 0.96 (d, 3H).\n\n\n\n\n\n\n \nb) étape 2 : préparation de l'\nEX12\n \nb) Step 2: Preparation of the \nEX12\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 37 mg (0,09 mmol) du composé \n \n8\n \n dans 3 mL de dichlorométhane, sous atmosphère inerte d'argon à une température voisine de 20°C, sont ajoutés successivement 36 mg (0.27 mol) hydroxybenzotriaxol et 52 mg (0,27 mmol) de chlorhydrate de 1-(3-diméthylaminopropyl)-3-éthylcarbodiimide. L'agitation est maintenue à une température voisine de 20°C pendant environ 30 minutes, puis sont ajoutés 39 mg (0,099 mmol) du composé \n \n6\n \n. L'agitation est poursuivie à cette température pendant 1 heure. Le mélange réactionnel est repris par 5 mL d'eau distillée puis extrait par 3 x 20 mL d'acétate d'éthyle. La phase organique est lavés par 2 x 10 mL d'une solution aqueuse saturée en chlorure de sodium, séchées sur sulfate de magnésium, filtrée et évaporée à sec sous pression réduite. Le résidu obtenu est chromatographie sur gel de silice conditionné au préalable dans le mélange (Heptane/Acétate d'éthyle), (90/10), (V/V) puis élué par un gradient de 10 à 20% d'acétate d'éthyle dans l'heptane. 40 mg (56%) du produit attendu EX12 sont obtenus sous forme de gomme visqueuse.\nTo a solution of 37 mg (0.09 mmol) of compound \n \n8\n \n in 3 ml of dichloromethane, under an inert atmosphere of argon at a temperature in the region of 20 ° C., 36 mg (0.27 mol) of hydroxybenzotriaxol and 52 mg ( 0.27 mmol) of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride. Stirring is maintained at a temperature of 20 ° C for about 30 minutes, and then 39 mg (0.099 mmol) of compound \n \n6\n \n are added. Stirring is continued at this temperature for 1 hour. The reaction mixture is taken up in 5 ml of distilled water and then extracted with 3 × 20 ml of ethyl acetate. The organic phase is washed with 2 × 10 ml of a saturated aqueous sodium chloride solution, dried over magnesium sulphate, filtered and evaporated to dryness under reduced pressure. The residue obtained is chromatographed on silica gel preloaded in the mixture (heptane / ethyl acetate) (90/10) (V / V) and then eluted with a gradient of 10 to 20% of acetate. ethyl in heptane. 40 mg (56%) of the expected product EX12 are obtained in the form of a viscous gum.\n\n\n\n\n\n\n \nMS : ES\n+\n: [M+H]\n+\n = 788 ; [M+Na]\n+\n = 810.\n\nES : [M-H]\n-\n = 786 : [M+HCOOH+H]\n+\n = 832.\nMS: ES \n+\n : [M + H] \n+\n = 788; [M + Na] \n+\n = 810. \n ES: [MH] \n-\n = 786: [M + HCOOH + H] \n+\n = 832.\n\n\n\n\n\n\n \nSpectre RMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K : De 0,87 à 1.03 (m, 11H) ; 1,08 (d large, 3H) ; de 1,21 à 1,40 (m, 4H) ; 1,43 (s, 6H) ; de 1,45 à 1,65 (m partiellement masqué, 6H) ; 1,69 (m, 2H) ; de 1,78 à 1,97 (m, 4H) ; 2,05 (m, 2H) ; de 2,32 à 2,43 (m partiellment masqué, 2H) ; de 2,82 à 2,98 (m, 2H) ; 3,37 (m, 1H) ; de 3,65 à 3,81 (m, 2H) ; 3,95 (m, 1H) ; 4,14 (d, J = 16,0 Hz, 1H) ; 4,43 (d, J = 16,0 Hz, 1H) ; 5,33 (s, 1H) ; 5,36 (s, 1H) ; 6,52 (m, 1H).\n1H NMR spectrum at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform-d1 solvent (CDCl3-d1) referenced at 7.27 at 303K temperature: From 0.87 to 1.03 (m, 11H); 1.08 (bd, 3H); from 1.21 to 1.40 (m, 4H); 1.43 (s, 6H); from 1.45 to 1.65 (partially masked m, 6H); 1.69 (m, 2H); from 1.78 to 1.97 (m, 4H); 2.05 (m, 2H); from 2.32 to 2.43 (partially masked m, 2H); from 2.82 to 2.98 (m, 2H); 3.37 (m, 1H); from 3.65 to 3.81 (m, 2H); 3.95 (m, 1H); 4.14 (d, J = 16.0 Hz, 1H); 4.43 (d, J = 16.0 Hz, 1H); 5.33 (s, 1H); 5.36 (s, 1H); 6.52 (m, 1H).\n\n\n\n\n\n\n \n \nEX 13\n: (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5aS,6'R,8a'S,9'R,10'R,12'R,12a'R)-10,10'-[(2E)-but-2-ène-1,4-diylbis(oxy)]bis[3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromène] et \nEX14\n. (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5a'S,6'R,8a'S,9'R,10'R,12'R,12a'R)-10,10'-[(2Z)-but-2-ène-1,4-diylbis(oxy)]bis[3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-1]isochromène]\n \nEX 13\n : (3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR, 3'S, 5aS, 6'R, 8a'S, 9'R, 10'R, 12'R, 12a'R) -10,10 '- [(2E) -but-2-ene-1,4-diylbis (oxy)] bis [3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [1,2] dioxepino [4,3-i] isochromene] and \nEX14\n . (3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR, 3'S, 5a'S, 6'R, 8a'S, 9'R, 10'R, 12'R, 12a'R) -10,10 '- [ (2Z) -but-2-ene-1,4-diylbis (oxy)] bis [3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [1,2] dioxepino [4, 3-1] isochromene]\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nUne suspension de 200 mg (0,51 mmol) du composé \n \n7\n \n et 43 mg (0,051 mmol) de benzylidène-bis(tricyclohexylphosphine)dichlororuthénium dans 1,3 mL de dichlorométhane est agitée pendant environ 7 heures à une température voisine de 20°C. On ajoute une solution contenant 633 mg (5,10 mmol) de trishydroxyméthylphosphine et 1,43 mL (10,2 mmol) de triéthylamine, dans 3 mL de dichlorométhane. Une agitation énergique est maintenue à une température voisine de 20°C pendant environ 10 minutes, puis 6 mL d'eau sont ajoutés, l'agitation est poursuivie pendant 1 heure. La phase organique est lavée par 3 mL d'eau distillée, séchée sur sulfate de magnésium, filtrée et évaporé à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable puis élué dans le mélange (Heptane/Acétate d'éthyle), (95/5), (V/V). 57,5 mg (38%) de l'isomère E \nEX13\n sont obtenus sous forme de cristaux blanc. 20 mg (10%) de l'isomère \nZ EX14\n sont obtenus sous forme de cristaux blanc.\nA suspension of 200 mg (0.51 mmol) of compound \n \n7\n \n and 43 mg (0.051 mmol) of benzylidene-bis (tricyclohexylphosphine) dichlororuthenium in 1.3 mL of dichloromethane is stirred for about 7 hours at a temperature in the region of 20 ° C. . A solution containing 633 mg (5.10 mmol) of trishydroxymethylphosphine and 1.43 mL (10.2 mmol) of triethylamine is added in 3 mL of dichloromethane. Stirring is maintained at a temperature of 20 ° C for about 10 minutes, then 6 mL of water are added, stirring is continued for 1 hour. The organic phase is washed with 3 ml of distilled water, dried over magnesium sulphate, filtered and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel preloaded and then eluted in the mixture (heptane / ethyl acetate), (95/5), (V / V). 57.5 mg (38%) of the E \nEX13\n isomer are obtained in the form of white crystals. 20 mg (10%) of the \nZ EX\n isomer are obtained as white crystals.\n\n\n\n\n\n\n\n\n \nEX13 :\nEX13:\n\n\n\n\n\n\n\n\n \nRf = 0,41 dans le système (Heptane/Acétate d'éthyle), (8/2), (V/V)\nRf = 0.41 in the system (Heptane / ethyl acetate), (8/2), (V / V)\n\n\n\n\n\n\n \nIR: 983 cm\n-1\n (bande caractéristique CH=CH trans).\nIR: 983 cm \n-1\n (characteristic band CH = CH trans).\n\n\n\n\n\n\n \nMS : ES\n+\n: [M+Na]\n+\n= 779.\n\n    ES\n-\n: [M+HCOOH+H]\n+\n = 801.\nMS: ES \n+\n : [M + Na] \n+\n = 779. \n ES \n-\n : [M + HCOOH + H] \n+\n = 801.\n\n\n\n\n\n\n \nRMN \n1\nH (CDCl\n3\n, 300MHz) δ\nppm\n : 5.79 (t, 2H) ; 5.32 (s, 2H) ; 4.37 (dd, 2H) ; 4.19 (dd, 2H) ; 2.87 (qu, 2H) ; 2.39 (td, 2H) ; 2.04 (dt, 2H) ; 1.97.1.87 (m, 2H); 1.85-1.75 (m, 2H); 1.75-1.62 (m, 4H); 1.57.1.49 (m, 2H) ; 1.47 (m, 2H) ; 1.43 (s, 6H) ; 1.37-1.20 (m, 4H) ; 1.02 (d, 6H) ; 1.00-0.84 (m, 2H) ; 0.97 (d, 6H).\n \n1\n H NMR (CDCl \n3\n , 300MHz) δ \nppm\n : 5.79 (t, 2H); 5.32 (s, 2H); 4.37 (dd, 2H); 4.19 (dd, 2H); 2.87 (qu, 2H); 2.39 (td, 2H); 2.04 (dt, 2H); 1.97.1.87 (m, 2H); 1.85-1.75 (m, 2H); 1.75-1.62 (m, 4H); 1.57.1.49 (m, 2H); 1.47 (m, 2H); 1.43 (s, 6H); 1.37-1.20 (m, 4H); 1.02 (d, 6H); 1.00-0.84 (m, 2H); 0.97 (d, 6H).\n\n\n\n\n\n\n\n\n \nEX14:\nEX14:\n\n\n\n\n\n\n\n\n \nRf = 0,47 dans le système (Heptane/Acétate d'éthyle), (8/2), (V/V)\nRf = 0.47 in the system (Heptane / ethyl acetate), (8/2), (V / V)\n\n\n\n\n\n\n \nMS: ES\n+\n: [M+NH\n4\n]\n+\n =774.\nMS: ES \n+\n : [M + NH \n4\n ] \n+\n = 774.\n\n\n\n\n\n\n \nRMN \n1\nH (CDCl\n3\n, 300MHz) δ\nppm\n : 5.67 (t, 2H) ; 5.31 (s, 2H) ; 4.42 (dd, 2H) ; 4.25 (dd, 2H) ; 2.85 (qu, 2H) ; 2.38 (td, 2H) ; 2.04 (dt, 2H) ; 1.96-1.84 (m, 2H) ;; 1.84-1.74 (m, 2H) ; 1.74-1.61 (m, 4H) ; 1.57-1.49 (m, 2H) ; 1.47 (m, 2H) ; 1.43 (s, 6H) ; 1.37-1.20 (m, 4H) ; 1.01 (d, 6H) ; 1.00-0.87 (m, 2H) ; 0.97 (d, 6H).\n \n1\n H NMR (CDCl \n3\n , 300MHz) δ \nppm\n : 5.67 (t, 2H); 5.31 (s, 2H); 4.42 (dd, 2H); 4.25  (dd, 2H); 2.85 (qu, 2H); 2.38 (td, 2H); 2.04 (dt, 2H); 1.96-1.84 (m, 2H); 1.84-1.74 (m, 2H); 1.74-1.61 (m, 4H); 1.57-1.49 (m, 2H); 1.47 (m, 2H); 1.43 (s, 6H); 1.37-1.20 (m, 4H); 1.01 (d, 6H); 1.00-0.87 (m, 2H); 0.97 (d, 6H).\n\n\n\n\n\n\n \n \nEX15\n: (3S,5aS,6R,8aS,9R,10R,12R,12aR,3'S,5a'S,6'R,8a'S,9'R,10'R,12'R,12a'R)-10,10'[(2R,3R)-oxirane-2,3-diylbis(méthylèneoxy)]bis[3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromènel\n \nEX15\n : (3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR, 3'S, 5a'S, 6'R, 8a'S, 9'R, 10'R, 12'R, 12a'R) -10,10 ' [(2R, 3R) oxirane-2,3-diylbis (methyleneoxy)] bis [3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [1,2] dioxepino [4,3 -i] isochromènel\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 158 mg (0,209 mmol) du composé \n \nEX13\n \n dans 2,75 mL de dichlorométhane, à une température voisine de 20°C, sont ajoutés 103 mg (0,417 mmol) d'acide \nmeta\n-chloroperbenzoïque, L'agitation est maintenue à cette température pendant environ 8 heures. Le mélange réactionnel est lavé successivement par 3x5 mL d'une solution aqueuse saturée en bicarbonate de sodium et par 13 mL d'une solution aqueuse saturée en chlorure de sodium. La phase organique est séchée sur sulfate de magnésium, filtrée et évaporée à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable puis élué dans le mélange (Heptane/Acétate d'éthyle), (95/5), (V/V), 70 mg (43%) de l'un des deux l'isomères trans \nEX15\n sont obtenus sous forme de cristaux blanc.\nTo a solution of 158 mg (0.209 mmol) of compound \n \nEX13\n \n in 2.75 ml of dichloromethane at a temperature in the region of 20 ° C. is added 103 mg (0.417 mmol) of \nmeta-\n chloroperbenzoic acid. Stirring is maintained. at this temperature for about 8 hours. The reaction mixture is washed successively with 3 × 5 mL of saturated aqueous sodium bicarbonate solution and with 13 mL of a saturated aqueous sodium chloride solution. The organic phase is dried over magnesium sulphate, filtered and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned and then eluted in the mixture (heptane / ethyl acetate), (95/5), (V / V), 70 mg (43%) of one of the both \nEX15\n trans isomers are obtained as white crystals.\n\n\n\n\n\n\n \nMS: ES\n+\n ; [M+Na]\n+\n = 795.\nMS: ES \n+\n ; [M + Na] \n+\n = 795.\n\n\n\n\n\n\n \nSpectre RMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K ; De 0,86 à 0,98 (m, 14H) ; de 1.20 à 1.39 (m, 4H) ; 1,42 (s, 6H) ; de 1,44 à 1,55 (m, 4H) ; de 1,62 à 1,77 (m, 6H) ; 1,89 (m, 2H) ; 2,04 (m, 2H) ; 2,37 (m, 2H) ; 2.85 (m, 2H) 3,11 (s large, 2H) ; 3,69 (d large, J = 12,5 Hz, 2H) ; 4,31 (d, J = 12,5 Hz, 2H) ; 5,39: (s, 2H).\n400 MHz 1H NMR spectrum on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform-d1 (CDCl3-d1) solvent referenced at 7.27 at the temperature of 303K; 0.86 to 0.98 (m, 14H); from 1.20 to 1.39 (m, 4H); 1.42 (s, 6H); from 1.44 to 1.55 (m, 4H); from 1.62 to 1.77 (m, 6H); 1.89 (m, 2H); 2.04 (m, 2H); 2.37 (m, 2H); 2.85 (m, 2H); 3.11 (bs, 2H); 3.69 (broad d, J = 12.5 Hz, 2H); 4.31 (d, J = 12.5 Hz, 2H); 5.39: (s, 2H).\n\n\n\n\n\n\n \n \nEX 16:\n (1-(2-{[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromén-10-yl]oxy}éthyl)4-({[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromén-10. yl]oxy}methyl}-1H-1,2,3-triazole et \nEX17\n: 1-(2-([(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,31]isochromén-10-yl]oxy}éthyl)-5-({[(3S,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(trifluorométhyl)décahydro-3,12-époxy[1,2]dioxépino[4,3-i]isochromén-10-yl]oxy}éthyl)-1H-1,2,3-triazole\n \nEX 16:\n (1- (2 - {[(3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [ 1,2] dioxepino [4,3-i] isochromén-10-yl] oxy} ethyl) 4 - ({[(3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9 -trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [1,2] dioxepino [4,3-i] isochromén-10.  yl] oxy} methyl} -1H-1,2,3-triazole and \nEX17\n : 1- (2 - ([(3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9- trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [1,2] dioxepino [4.31] isochromén-10-yl] oxy} ethyl) -5 - ({[(3S, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl-10- (trifluoromethyl) decahydro-3,12-epoxy [1,2] dioxepino [4,3-i] isochromén-10-yl] oxy} ethyl) -1H-1,2,3-triazole\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \na) étape 1 : préparation de (3R,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-triméthyl-10-(prop-2-yn-1-yloxy)-10-(trifluoromethyl)décahydro-3, 12-époxy[1,2]dioxépino[4,3-i]isochromène, \n \n9\n \n \na) Step 1: Preparation of (3R, 5aS, 6R, 8aS, 9R, 10R, 12R, 12aR) -3,6,9-trimethyl-10- (prop-2-yn-1-yloxy) -10- ( trifluoromethyl) decahydro-3, 12-epoxy [1,2] dioxepino [4,3-i] isochromene, \n \n9\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 0,206 g (0,5 mmol) de 3,12-epoxy-12\nH\n-pyrano[4,3-\nj\n]-1,2-benzodioxepin, (3S,5a\nS\n,6\nR\n,8a\nS\n,9\nR\n,10\nS\n,12\nR\n,12a\nR\n)-10-(bromo)decahydro-3,6,9-trimethyl-10-(trifluoromethyl)- 3,12-époxy-12\nH\n-pyrano[4,3-\nj\n]-1,2-benzodioxépine \n \n1\n \n (préparé selon \n \nOrg. Lett. 2002, 4, 757-759\n \n), dans 5 mL de dichlorométhane, sont ajoutés successivement à température ambiante 0,266 mL d'héxafluoropropanol (5 éq.), puis 0,289 mL d'alcool propargylique (10 éq.). Le mélange réactionnel est ensuite agité à température ambiante pendant 1 heure 15 minutes, puis 5 mL d'une solution saturée de bicarbonate de sodium sont ajoutés La phase organique est séchée sur sulfate de magnésium et évaporée à sec sous pression réduite. Le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable dans l'heptane, puis élué par un gradient linéaire de 0 à 50% d'acétate d'éthyle dans l'héptane. 0,064 g (34%) du produit attendu \n \n9\n \n sont obtenus sous forme d'une huile.\nTo a solution of 0.206 g (0.5 mmol) of 3,12-epoxy-12 \nH\n -pyrano [4,3- \nd\n ] -1,2-benzodioxepin, (3S, 5a \nS\n , 6 \nR\n , 8a \nS\n , 9 \nR,\n 10 \nS,\n 12 \nR,\n 12a \nR)\n -10- (bromo) decahydro-3,6,9-trimethyl-10- (trifluoromethyl) - 3,12-epoxy-12 \nH\n -pyrano \n[4,3-j]\n -1,2-benzodioxepin \n \n1\n \n (prepared according to \n \n Org. Lett. 2002, 4, 757-759 \n \n ), in 5 ml of dichloromethane, 0.266 ml of hexafluoropropanol (5 eq) and then 0.289 ml of propargyl alcohol (10 eq) are successively added at ambient temperature. The reaction mixture is then stirred at ambient temperature for 1 hour 15 minutes, then 5 ml of saturated sodium bicarbonate solution are added. The organic phase is dried over magnesium sulphate and evaporated to dryness under reduced pressure. The oily residue obtained is chromatographed on silica gel pre-conditioned in heptane and then eluted with a linear gradient of 0 to 50% of ethyl acetate in heptane. 0.064 g (34%) of the expected product \n \n9\n \n are obtained in the form of an oil.\n\n\n\n\n\n\n \nRf = 0,40 dans le système (Heptane/Acétate d'éthyle), (85/15), (V/V)\n\n \n \n \n \n \n \n \n \n \n \nES\n \nm/z=391\n \nMH\n+\n \n \n \n \n \n \nm/x=335\n \nMH\n+\n - C\n3\nH\n4\nO\n \n \n \n \n \nRf = 0.40 in the system (Heptane / Ethyl acetate), (85/15), (V / V) \n \n \n \n \n \n \n \n \n \n \n ES \n \n m / z = 391 \n \n MH \n+\n \n \n \n \n \n \n m / x = 335 \n \n MH \n+\n - C \n3\n H \n4\n O \n \n \n \n \n \n\n\n\n\n\n\n \nSpectre RMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant diméthylsulfoxide - d6 (DMSO-d6) référencé à 2,50 ppm à la température de 303K : 0.88 (m partiellement masqué, 1H) ; 0,91 (d, J = 6,5 Hz, 3H) ; 0,95 (d large, J = 7,5 Hz, 3H) ; 1,23 (m, 1H) ; de 1,28 à 1,43 (m, 2H) ; 1,32 (s, 3H) ; de 1,50 à 1,63 (m, 2H) ; de 1,73 à 1,90 (m, 3H) ; 2,03 (m, 1H) ; 2,21 (m, 1H) ; 2,68 (m, 1H) ; 3,52 (t, J = 2,5 Hz, 1H) ; 4,30 (dd, J =2,5 et 16,0 Hz, 1H) ; 4,51 (dd, J = 2,5 et 16,0 Hz, 1H) ; 5,57 (s, 1H).\n1H NMR spectrum at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in dimethylsulfoxide-d6 solvent (DMSO-d6) referenced to 2.50 ppm at 303K temperature: 0.88 (m partially masked, 1H); 0.91 (d, J = 6.5 Hz, 3H); 0.95 (d wide, J = 7.5 Hz, 3H); 1.23 (m, 1H); from 1.28 to 1.43 (m, 2H); 1.32 (s, 3H); from 1.50 to 1.63 (m, 2H); from 1.73 to 1.90 (m, 3H); 2.03 (m, 1H); 2.21 (m, 1H); 2.68 (m, 1H); 3.52 (t, J = 2.5 Hz, 1H); 4.30 (dd, J = 2.5 and 16.0 Hz, 1H); 4.51 (dd, J = 2.5 and 16.0 Hz, 1H); 5.57 (s, 1H).\n\n\n\n\n\n\n \nb) étape 2: préparation de \nl'EX16 et de l'EX17\n \nb) Step 2: Preparation of \nEX16 and EX17\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nA une solution de 119 mg (0,305 mmol) du composé \n \n9\n \n dans 2,5 mL d'éthanol. à une température voisine de 20°C, sont ajoutés 257 mg (0,610 mmol) du composé 5. L'agitation est maintenue au reflux pendant environ 48 heures. Le mélange réactionnel est évaporé à sec au rotavapor et le résidu huileux obtenu est chromatographié sur gel de silice conditionné au préalable dans le dichlorométhane puis élué par un gradient linéaire de 0 à 100% du mélange B [(dichlorométhane/acétate d'éthyle), (96/4), (V/V)] dans A (dichlotométhane), 43mg (18%) du produit attendu \nEX16\n sont obtenus sous forme d'un solide blanc et 17mg (7%) du produit attendu \nEX17\n sont obtenus sous forme d'un solide blanc.\nTo a solution of 119 mg (0.305 mmol) of compound \n \n9\n \n in 2.5 mL of ethanol. at a temperature in the region of 20 ° C., 257 mg (0.610 mmol) of compound 5 are added. The stirring is maintained at reflux for approximately 48 hours. The reaction mixture is evaporated to dryness with a rotavapor and the oily residue obtained is chromatographed on silica gel pre-conditioned in dichloromethane and then eluted with a linear gradient from 0 to 100% of the mixture B [(dichloromethane / ethyl acetate), (96/4), (V / V)] in A (dichlomethane), 43 mg (18%) of the expected product \nEX16\n are obtained as a white solid and 17 mg (7%) of the expected product \nEX17\n are obtained in the form of of a white solid.\n\n\n\n\n\n\n\n\n \nEX16:\nEX16:\n\n\n\n\n\n\n\n\n \nRf = 0,26 dans le système (dichlorométhane/acétate d'éthyle), (96/4), (V/V).\n\n \n \n \n \n \n \n \n \n \n \nES\n \nm/z=834\n \nMNa\n+\n \n \n \n \n \n \nm/z=812\n \nMH\n+\n \n \n \n \n \n \nRf = 0.26 in the system (dichloromethane / ethyl acetate), (96/4), (V / V). \n \n \n \n \n \n \n \n \n \n \n ES \n \n m / z = 834 \n \n MNa \n+\n \n \n \n \n \n \n m / z = 812 \n \n MH \n+\n \n \n \n \n \n \n\n\n\n\n\n\n \nSpectre RMN 1H à 400 MHz sur spectromètre BRUKER AVANCE DRX-400 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K : De 0,75 à 1,70 (m partiellement masqué, 16H) ; 0,92 (d large, J = 7,0 Hz, 9H) ; 0,98 (d large, J = 7,0 Hz, 3H) ; 1,41 (s, 3H) ; 1,43 (s, 3H) ; 1,89 (m, 2H) ; 2,03 (m, 2H) ; 2,37 (m, 2H) ; 2,84 (m, 2H); 4,11 (m, 1H) ; 4,32 (m, 1H) ; de 4,40 à 4,80 (m, 2H) ; 4,71 (d, J = 12,5 Hz, 1H) ; 5,04 (d, J = 12, 5 Hz, 1H) ; 5,20 (s, 1H) 5,70 (s, 1H) ; 7,53 (s, 1H).\n1H NMR spectrum at 400 MHz on BRUKER AVANCE DRX-400 spectrometer with chemical shifts (δ in ppm) - in chloroform-d1 solvent (CDCl3-d1) referenced at 7.27 at 303K temperature: From 0.75 to 1.70 (partially masked m, 16H); 0.92 (d, J = 7.0 Hz, 9H); 0.98 (d wide, J = 7.0  Hz, 3H); 1.41 (s, 3H); 1.43 (s, 3H); 1.89 (m, 2H); 2.03 (m, 2H); 2.37 (m, 2H); 2.84 (m, 2H); 4.11 (m, 1H); 4.32 (m, 1H); from 4.40 to 4.80 (m, 2H); 4.71 (d, J = 12.5 Hz, 1H); 5.04 (d, J = 12.5 Hz, 1H); 5.20 (s, 1H) 5.70 (s, 1H); 7.53 (s, 1H).\n\n\n\n\n\n\n\n\n \nEX17:\nEX17:\n\n\n\n\n\n\n\n\n \nCCM Rf = 0,32 dans le système (dichlorométhane/acétate d'éthyle), (96/4), (V/V)\n\n \n \n \n \n \n \n \n \n \n \nES\n \nm/z=834\n \nMNa\n+\n \n \n \n \n \n \nm/z=812\n \nMH\n+\n \n \n \n \n \n \nTLC Rf = 0.32 in the system (dichloromethane / ethyl acetate), (96/4), (V / V) \n \n \n \n \n \n \n \n \n \n \n ES \n \n m / z = 834 \n \n MNa \n+\n \n \n \n \n \n \n m / z = 812 \n \n MH \n+\n \n \n \n \n \n \n\n\n\n\n\n\n \nSpectre RMN 1H à 500 MHz sur spectromètre BRUKER AVANCE DRX-500 avec les déplacements chimiques (δ en ppm) - dans le solvant chloroforme - d1 (CDCl3-d1) référencé à 7,27 à la température de 303K: De 0,55 à 1,70 (m partiellement masqué, 16H) ; 0,90 (d large, J = 7,0 Hz, 9H) ; 1,01 (d large, J = 7,0 Hz, 3H) ; 1,39 (s, 3H) ; 1,44 (s, 3H) ; de 2,30 à 2,43 (m, 2H) ; de 1.97 à 2.09 (m, 2H) ; de 2,28 à 2,42 (m, 2H) ; 2,80 (m, 1H) ; 2,90 (m, 1H) ; 4,11 (m, 1H) ; de 4,42 à 4,63 (m, 3H) ; 4,40 (d, J = 13,0 Hz, 1H) ; 5,04 (d, J = 13,0 Hz, 1H) ; 5,11 (s, 1H) ; 5,24 (s, 1H) ; 7,61 (s, 1H).\n1H NMR spectrum at 500 MHz on BRUKER AVANCE DRX-500 spectrometer with chemical shifts (δ in ppm) - in chloroform solvent - d1 (CDCl3-d1) referenced at 7.27 at the temperature of 303K: From 0.55 to 1.70 (partially masked m, 16H); 0.90 (d, J = 7.0 Hz, 9H); 1.01 (broad d, J = 7.0 Hz, 3H); 1.39 (s, 3H); 1.44 (s, 3H); from 2.30 to 2.43 (m, 2H); from 1.97 to 2.09 (m, 2H); from 2.28 to 2.42 (m, 2H); 2.80 (m, 1H); 2.90 (m, 1H); 4.11 (m, 1H); from 4.42 to 4.63 (m, 3H); 4.40 (d, J = 13.0 Hz, 1H); 5.04 (d, J = 13.0 Hz, 1H); 5.11 (s, 1H); 5.24 (s, 1H); 7.61 (s, 1H).\n\n\n\n\n\n\n\n\n\n\n \nActivité antiproliférative des produits préparés:\nAntiproliferative activity of prepared products:\n\n\n\n\n\n\n\n\n\n\n \nLes produits selon l'invention ont fait l'objet d'essais pharmacologiques permettant de déterminer leur activité antiproliférative. Elle a été déterminée par mesure de l'inhibition de la prolifération cellulaire de cellules HCT116. Les cellules sont ensemencées dans un milieu de culture cellulaire à une concentration de 10 000 cellules par puits, dans 0.17 mL de milieu, et 20 µL de produit à tester, à différentes concentrations, et 10 µL de Thymidine [methyl-14C] (100 µCi/ml - activité spécifique 47,90 mCi/mmol; NEN Technologies référence NEC568 batch 3550-001) sont ajoutés, puis les cellules sont incubées à 37°C et 5% de CO\n2\n.\nThe products according to the invention have been the subject of pharmacological tests for determining their antiproliferative activity. It was determined by measuring the inhibition of cell proliferation of HCT116 cells. The cells are seeded in a cell culture medium at a concentration of 10,000 cells per well, in 0.17 ml of medium, and 20 μl of product to be tested, at different concentrations, and 10 μl of Thymidine [methyl-14C] (100 μl). μCi / ml - specific activity 47.90 mCi / mmol, NEN Technologies reference NEC568 batch 3550-001) are added, and the cells are then incubated at 37 ° C. and 5% CO \n2\n .\n\n\n\n\n\n\n \nMilieu utilisé pour la culture de cellules HCT116 : milieu DMEM 2 mM L-glutamine, 200 Ul/ml pénicilline, 200µg/ml streptomycine and 10% (V/V) Sérum de veau foetal (Life Technologies).\nMedium used for the culture of HCT116 cells: DMEM medium 2 mM L-glutamine, 200 IU / ml penicillin, 200 μg / ml streptomycin and 10% (V / V) Fetal calf serum (Life Technologies).\n\n\n\n\n\n\n \nAprès 96 heures, l'incorporation de \n14\nC-thymidine est comptée dans un compteur à scintillation liquide 1450 Microbeta Wallac Trilux. Les résultats R sont exprimés en cpm (coups par minute) et convertis en pourcentage d'inhibition de croissance Gl% en faisant premièrement la soustraction de la moyenne du nombre de cpm des puits sans cellules B et en divisant ensuite par le nombre de cpm des puits des cellules non traitées C comprenant 20µL de milieu de dilution du produit contentant 1% d'éthanol. (GI % = (R - B) x 100/ C %).\nAfter 96 hours, \n14\n C-thymidine incorporation is counted in a 1450 Microbeta Wallac Trilux liquid scintillation counter. The R results are expressed in cpm (counts per minute) and converted to percent growth inhibition Gl% by first subtracting the average of the number of cpm from the wells without B cells and then dividing by the number of cpm of the  well of untreated cells C comprising 20μL of dilution medium of the product containing 1% ethanol. (GI% = (R - B) x 100 / C%).\n\n\n\n\n\n\n \nLes valeurs d'IC50 sont calculées à l'aide de l'équation 205 du logiciel XLFit (IDBS company, UK) par analyse de régression non linéaire utilisant l'algorithme Marquardt (\n \nDonald W. MARQUARDT, J.Soc.industry.appl, vol 11, No. 2, June, 1963\n \n).\nIC50 values are calculated using equation 205 of the XLFit software (IDBS company, UK) using nonlinear regression analysis using the Marquardt algorithm ( \n \n Donald W. MARQUARDT, J.Soc.industry.appl, vol 11, No. 2, June, 1963 \n \n ).\n\n\n\n\n\n\n \nLes produits présentent une IC50 sur les cellules HCT116 généralement Inférieure à 10µM et de préférence inférieure à 100nM.\n\n \n \n \n \n \n \n \n \n \nExemples\n \nIC50 (nM) /HCT116\n \n \n \n \n \nEX1\n \n \n47\n \n \n \n \nEX2\n \n \n23\n \n \n \n \nEX3\n \n \n21\n \n \n \n \nEX8\n \n \n30\n \n \n \n \n \nThe products have an IC50 on HCT116 cells generally less than 10 .mu.M and preferably less than 100 nM. \n \n \n \n \n \n \n \n \n \n Examples \n \n IC50 (nM) / HCT116 \n \n \n \n \n \nEX1\n \n \n 47 \n \n \n \n \nEX2\n \n \n 23 \n \n \n \n \nEX3\n \n \n 21 \n \n \n \n \nEX8\n \n \n 30 \n \n \n \n \n \n\n\n\n\n\n\n \nLes produits selon l'invention peuvent donc être utilisés pour la préparation de médicaments.\nThe products according to the invention can therefore be used for the preparation of medicaments.\n\n\n\n\n\n\n \nAinsi, selon un autre de ses aspects, l'invention a pour objet des médicaments qui comprennent un produit de formule (I) ou un sel d'addition de ce dernier à un acide pharmaceutiquement acceptable, ou encore un hydrate ou un solvant.\nThus, according to another of its aspects, the subject of the invention is medicaments which comprise a product of formula (I) or an addition salt thereof to a pharmaceutically acceptable acid, or a hydrate or a solvent.\n\n\n\n\n\n\n \nCes médicaments trouvent leur emploi en thérapeutique, notamment dans le traitement du cancer.\nThese drugs find their use in therapy, especially in the treatment of cancer.\n\n\n\n\n\n\n \nLa présente invention concerne donc l'utilisation d'un produit de formule (I) pour la fabrication d'un médicament utile pour traiter un état pathologique et plus particulièrement l'utilisation d'un produit de formule (I) pour la fabrication d'un médicament utile pour traiter le cancer.\nThe present invention thus relates to the use of a product of formula (I) for the manufacture of a medicament useful for treating a pathological state and more particularly the use of a product of formula (I) for the manufacture of a drug useful for treating cancer.\n\n\n\n\n\n\n \nLa présente invention concerne également l'utilisation d'un produit de formule (I) pour la fabrication d'un médicament utile pour traiter les pathologies où une néovascularisation ou angiogénèse se fait de façon inappropriée c'est-à-dire dans les cancers en général mais aussi dans des cancers particuliers tels que le sarcome de Kaposi ou l'hémoangiome infantile, et aussi dans l'arthrite rhumatoïde, l'osthéoarthrite et/ou ses douleurs associée, les maladies inflammatoires de l'intestin telle que la recto-colite hémorragique ou la maladie de Crohn's, les pathologies de l'oeil telle que la dégénérescence maculaire liée à l'âge, les rétinopathies diabétiques, l'inflammation chronique, le psoriasis.\nThe present invention also relates to the use of a product of formula (I) for the manufacture of a medicament useful for treating pathologies where neovascularization or angiogenesis is done inappropriately, that is to say in cancers in which general but also in particular cancers such as Kaposi's sarcoma or infantile hemoangioma, and also in rheumatoid arthritis, osteoarthritis and / or its associated pain, inflammatory bowel diseases such as rectocolitis hemorrhagic or Crohn's disease, eye pathologies such as age-related macular degeneration, diabetic retinopathies, chronic inflammation, psoriasis. \n\n\n\n\n\n\n \nL'angiogenèse est un processus de génération de nouveaux vaisseaux capillaires à partir des vaisseaux pré-existants. L'angiogenèse tumorale (formation de néovaisseaux sanguins), indispensable à la croissance tumorale, est également un des facteurs essentiels de la dissémination métastatique (\n \nOncogene, 2003 May 19;22(20):3172-9\n \n; \n \nNat Med. 1995 Jan;1(1):27-31\n \n.).\nAngiogenesis is a process of generating new capillaries from preexisting vessels. Tumor angiogenesis (formation of blood neovessels), essential for tumor growth, is also one of the essential factors of metastatic spread ( \n \n Oncogene, 2003 May 19; 22 (20): 3172-9 \n \n ; \n \n Nat Med. 1995 Jan; 1 (1): 27-31 \n \n .).\n\n\n\n\n\n\n \nSelon un autre de ses aspects, la présente invention concerne des compositions pharmaceutiques comprenant, en tant que principe actif, un produit selon l'invention. Ces compositions pharmaceutiques contiennent une dose efficace d'au moins un produit selon l'invention ou un sel pharmaceutiquement acceptable, un hydrate ou solvant dudit produit, ainsi qu'au moins un excipient pharmaceutiquement acceptable\nAccording to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active principle, a product according to the invention. These pharmaceutical compositions contain an effective dose of at least one product according to the invention or a pharmaceutically acceptable salt, a hydrate or solvent of said product, as well as at least one pharmaceutically acceptable excipient.\n\n\n\n\n\n\n \nLesdits excipients sont choisis selon la forme pharmaceutique et le mode d'administration souhaité, parmi les excipients habituels qui sont connus de l'Homme du métier.\nSaid excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.\n\n\n\n\n\n\n \nDans les compositions pharmaceutiques de la présente invention pour l'administration orale, sublinguale, sous-cutanée, intramusculaire, intra-veineuse, topique, locale, intra-trachéale, intra-nasale, transdermique ou rectale, le principe actif de formule (I) ci-dessus, ou son sel, solvat ou hydrate, peut être administré sous forme unitaire d'administration, en mélange avec des excipients pharmaceutiques classiques, aux animaux et aux êtres humains pour la prophylaxie ou le traitement des troubles ou des maladies ci-dessus.\nIn the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of formula (I) above, or its salt, solvate or hydrate, may be administered in unit dosage form, in admixture with conventional pharmaceutical excipients, to animals and humans for the prophylaxis or treatment of the above disorders or diseases. .\n\n\n\n\n\n\n \nLes formes unitaires d'administration appropriées comprennent les formes par voie orale telles que les comprimés, les gélules molles ou dures, les poudres, les granules et les solutions ou suspensions orales, les formes d'administration sublinguale, buccale, intra-trachéale, intraoculaire, intra-nasale, par inhalation, les formes d'administration topique, transdermique, sous-cutanée, intramusculaire ou intraveineuse, les formes d'administration rectale et les implants, Pour l'application topique, on peut utiliser les produits selon invention dans des crèmes, gels, pommades ou lotions.\nSuitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular forms of administration. , intranasal, by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants, For topical application, the products according to the invention can be used in creams, gels, ointments or lotions.\n\n\n\n\n\n\n \nA titre d'exemple, une forme unitaire d'administration d'un produit selon l'invention sous forme de comprimé peut comprendre les composants suivants :\n\n \n \n \n \n \n \n \n \nProduit selon l'invention\n \n50,0 mg\n \n \n \nMannitol\n \n223,75 mg\n \n \n \nCroscaramellose sodique\n \n6,0 mg\n \n \n \nAmidon de maïs\n \n15,0 mg\n \n \n \nHydroxypropyl-méthylcellulose\n \n2,25 mg\n \n \n \nStéarate de magnésium\n \n3,0 mg\n \n \n \n \n \nBy way of example, a unitary form of administration of a product according to the invention in tablet form may comprise the following components: \n \n \n \n \n \n \n \n \n Product according to the invention \n \n 50.0 mg \n \n \n \n mannitol \n \n 223.75 mg \n \n \n \n Croscaramellose sodium \n \n 6.0 mg \n \n \n \n Corn starch \n \n 15.0 mg \n \n \n \n Hydroxypropylmethylcellulose \n \n 2.25 mg \n \n \n \n Magnesium stearate \n \n 3.0 mg \n \n \n \n \n \n\n\n\n\n\n\n \nIl peut y avoir des cas particuliers où des dosages plus élevés ou plus faibles: sont appropriés : de tels dosages ne sortent pas du cadre de l'invention. Selon la pratique habituelle, le dosage approprié à chaque patient est déterminé par le médecin selon le mode d'administration, le poids et la réponse dudit patient.\nThere may be particular cases where higher or lower dosages are appropriate: such dosages are within the scope of the invention. According to the usual practice, the dosage appropriate to each patient is determined by the physician according to the mode of administration, the weight and the response of said patient.\n\n\n\n\n\n\n \nLes produits de la présente invention peuvent être administrés seuls ou en mélange avec d'autres anticancéreux. Parmi les associations possibles on peut citer:\n\n \nles agents alkylants et notamment le cyclophosphamide, le melphalan, l'ifosfamide, le chlorambucil, le busulfan, le thiotepa, la prednimustine, la carmustine, la lomustine, la semustine, la steptozotocine, la decarbazine, la témozolomide, la procarbazine et l'hexaméthylmétamine\n \nles dérivés du platine comme notamment la cisplatine, le carboplatine ou l'oxaliplatine\n \nles agents antibiotiques comme notamment la bléomycine, la mitomycine, la dactinomycine\n \nles agents antimicrotubules comme notamment la vinblastine, la vincristine, la vindésine, la vinorelbine, les taxoïdes (paclitaxel et docétaxel)\n \nles anthracyclines comme notamment la doxorubicine, la daunorubicine, l'idarubicine, l'épirubicine, la mitoxantrone, la losoxantrone\n \nles inhibiteurs de topoisomérases des groupes I et II telles que l'étoposide, le teniposide, l'amsacrine, l'irinotecan, le topotecan et le tomudex\n \nles fluoropyrimidines telles que la 5-fluorouracile, l'UFT, la floxuridine\n \nles analogues de cytidine telles que la 5-azacytidine, la cytarabine, la gemcitabine, la 6-mercaptomurine, la 6-thioguanine\n \nles analogues d'adénosine tels que la pentostatine, la cytarabine ou le phosphate de fludarabine\n \nle méthotrexate et l'acide folinique\n \nles enzymes et produits divers tels que la L-asparaginase, l'hydroxyurée, l'acide trans-rétinoique, la suramine, la dexrazoxane, l'amifostine, l'herceptine ainsi que les hormones oestrogéniques, androgéniques\n \nles agents antivasculaires tels que les dérivés de la combretastatine par exemple la CA4P, des chalcones ou de la colchicine, par exemple le ZD6126, et leurs prodrogues.\n \nLes inhibiteurs de kinases tels que l'ertonilib ou l'imatinib\n \nLes agents biothérapeutiques comme les anticorps tels que le rituximab, le bevacizumab, le cetuximab; le trastuzumab ou l'alemtuzumab\n \nLes inhibiteurs du protéasome tel que le bortesomib\n \n The products of the present invention may be administered alone or in admixture with other anticancer agents. Among the possible associations we can mention: \n \n alkylating agents and especially cyclophosphamide, melphalan, ifosfamide, chlorambucil, busulfan, thiotepa, prednimustine, carmustine, lomustine, semustine, steptozotocine, decarbazine, temozolomide, procarbazine and hexaméthylmétamine \n \n platinum derivatives such as cisplatin, carboplatin or oxaliplatin \n \n antibiotic agents such as bleomycin, mitomycin, dactinomycin \n \n antimicrotubule agents such as vinblastine, vincristine, vindesine, vinorelbine, taxoids (paclitaxel and docetaxel) \n \n anthracyclines such as doxorubicin, daunorubicin, idarubicin, epirubicin, mitoxantrone, losoxantrone \n \n Group I and II topoisomerase inhibitors such as etoposide, teniposide, amsacrine, irinotecan, topotecan and tomudex \n \n fluoropyrimidines such as 5-fluorouracil, UFT, floxuridine \n \n cytidine analogs such as 5-azacytidine, cytarabine, gemcitabine, 6-mercaptomurine, 6-thioguanine \n \n adenosine analogs such as pentostatin, cytarabine or fludarabine phosphate \n \n methotrexate and folinic acid \n \n enzymes and various products such as L-asparaginase, hydroxyurea, trans-retinoic acid, suramin, dexrazoxane, amifostine, herceptin as well as estrogenic, androgenic hormones \n \n antivascular agents such as derivatives of combretastatin, for example CA4P, chalcones or colchicine, for example ZD6126, and their prodrugs. \n \n Kinase inhibitors such as ertonilib or imatinib \n \n Biotherapeutic agents such as antibodies such as rituximab, bevacizumab, cetuximab; trastuzumab or alemtuzumab \n \n Proteasome inhibitors such as bortesomib \n \n\n\n\n\n\n\n \nIl est également possible d'associer aux produits de la présente invention un traitement par des radiations. Ces traitements peuvent être administrés simultanément, séparément, séquentiellement. Le traitement sera adapté par le praticien en fonction du malade à traiter.\nIt is also possible to associate the products of the present invention with a radiation treatment. These treatments can be administered simultaneously, separately, sequentially. The treatment will be adapted by the practitioner according to the patient to be treated."
  },
  {
    "id": "EP1619185B1",
    "text": "4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof AbstractA novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and/or diabetes insipidus, is provided. Claims (\n8\n)\n\n\n\n\n \n\n\nA 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative represented by a formula (I) or a pharmaceutically acceptable salt thereof\n\n \n \n\n[signs in the formula mean as follows,\n\nR\n1\n: a group represented by a formula (II),\n\n \n \n\nwherein,\n\nZ\n1\n: single bond, lower alkylene or -lower alkylene-C(=O)-,\n\nR\n11\n: lower alkyl which may be substituted with one or more groups selected from the group consisting of -OH, -O-lower alkyl, -CO\n2\nH, -CO\n2\n-lower alkyl and carbamoyl which may be substituted with one or two lower alkyls, or -H,\n\nR\n12\n: (1) when Z\n1\n represents single bond or lower alkylene, -H, -OH, -O-lower alkyl, -CO\n2\nH, -CO\n2\n-lower alkyl, carbamoyl which may be substituted with one or two lower alkyls, aryl which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h), cycloalkyl which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h), aromatic hetero ring which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h) or non-aromatic hetero ring which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h),\n\n(2) when Z\n1\n represents -lower alkylene-C(=O)-,\n\na group represented by the formula (III) or a formula (IV),\n\n \n \n\nwherein,\n\nZ\n2\n: single bond or lower alkylene,\n\nR\n15\n: -H, -OH, -O-lower alkyl, -CO\n2\nH, -CO\n2\n-lower alkyl, carbamoyl which may be substituted with one or two lower alkyls, aryl which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h), cycloalkyl which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h), aromatic hetero ring which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h) or non-aromatic hetero ring which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h),\n\nR\n13\n, R\n14\n: together with the adjacent nitrogen atom, non-aromatic cyclic amino group which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h),\n\nR\n2\n: CF\n3\n or halogen,\n\nR\n3\n: H or halogen,\n\na: a single bond,\n\nb: a double bond,\n\n-X-: -CH=CH-,\n\n-Y-: -CH-,\n\n-A-: -O- -S-, -NH- or -N(lower alkyl),\n\nB: lower alkyl, lower alkenyl, or lower alkynyl, each of which is optionally substituted with one or more groups selected from the substitutent groups shown in the following (a) to (g); or cycloalkyl or aryl, each of which is optionally substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h),\n\nwherein substituents (a) to (h) are as follows:\n\n(a) halogen,\n\n\n(b) -OH, -O-R\nz\n, -O-aryl, -OCO-R\nz\n , oxo (=O),\n\n\n(c) -SH, -S-R\nz\n, -S-aryl, -SO-R\nz\n,-SO-aryl, -SO\n2\n-R\nz\n, -SO\n2\n-aryl, sulfamoyl which may be substituted with 1 or 2 R\nz\n,\n\n\n(d) amino which may be substituted with 1 or 2 R\nz\n, -NHCO-R\nz\n, -NHCO-aryl, -NHSO\n2\n-R\nz\n, -NHSO\n2\n-aryl, nitro,\n\n\n(e) -CHO, -CO-R\nz\n, -CO\n2\nH, -CO\n2\n-R\nz\n, carbamoyl which may be substituted with I or 2 R\nz\n, cyano,\n\n\n(f) aryl or cycloalkyl which may be respectively substituted with one or more groups selected from the class consisting of -OH, -O-lower alkyl, amino which may be substituted with 1 or 2 lower alkyl, carbamoyl which may be substituted with 1 or 2 lower alkyl, aryl, aromatic hetero ring, halogen and R\nz\n,\n\n\n(g) aromatic hetero ring or non-aromatic hetero ring which may be respectively substituted with one or more groups selected from the class consisting of -OH, -O-lower alkyl, amino which may be substituted with 1 or 2 lower alkyl, carbamoyl which may be substituted with 1 or 2 lower alkyl, aryl, aromatic hetero ring, halogen and R\nz\n,\n\n\n(h) lower alkyl or lower alkenyl which may be respectively substituted with one or more groups selected from the substituent groups shown in the aforementioned (a) to (g), and\n\nR\nz\n: lower alkyl which may be substituted with one or more groups selected from the class consisting of -OH, -O-lower alkyl, amino which may be substituted with 1 or 2 lower alkyl, carbamoyl which may be substituted with 1 or 2 lower alkyl, aryl, aromatic hetero ring and halogen,\n\nand wherein\n\nthe term \"lower alkyl\" means a monovalent group of straight or branched C\n1-6\n carbon chain,\n\nthe term \"lower alkylene\" means a divalent group of straight or branched C\n1-6\n carbon chain,\n\nthe term \"lower alkenyl\" means a monovalent group of straight or branched C\n2-6\n carbon chain having at least one double bond,\n\nthe term \"lower alkynyl\" means a monovalent group of straight or branched C\n2-6\n carbon chain having at least one triple bond,\n\nthe term \"cycloalkyl\" means a monovalent group of C\n3-8\n non-aromatic hydrocarbon ring which may partially have a unsaturated bond,\n\nthe term \"aryl\" means a monovalent group of monocyclic to tricyclic C\n6-14\n aromatic hydrocarbon ring,\n\nthe term \"aromatic hetero ring\" means a monovalent group of monocyclic to tricyclic aromatic ring having hetero atom(s),\n\nthe term \"non-aromatic hetero ring\" means a monovalent group of 5- to 7-membered ring having hetero atom(s), which may partially have an unsaturated bond and may be condensed with aryl or aromatic hetero ring, and\n\nthe term \"non-aromatic cyclic amino group\" means a monovalent group of 3- to 10-membered non-aromatic cyclic amine, optionally having nitrogen, oxygen or sulfur, which may partially have an unsaturated bond].\n\n\n\n\n \n \n\n\nThe compound described in claim 1, wherein -A- is -O-.\n\n\n\n\n \n \n\n\nThe compound described in claim 2, wherein -B is lower alkyl which may be substituted with one or more groups selected from the substitutent groups shown in the (a) to (g) mentioned in claim 1.\n\n\n\n\n \n \n\n\nThe compound described in claim 3, wherein R\n2\n is trifluoromethyl, and R\n3\n is -H or -F.\n\n\n\n\n \n \n\n\nThe compound described in claim 1, which is\n\n(2Z)-N-(2-amino-2-oxoethyl)-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifl uoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene} acetamide,\n\n(2Z)-N-(2-hydroxyethyl)-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoro methyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n\n(2Z)-N-(2-hydroxyethyl)-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoro methyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n\n(2Z)-2- {4,4-difluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3, 4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,\n\n3-[((2Z)-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl] -1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetyl)amino]propanamide,\n\n(2Z)-N-[(2R)-2,3-dihydroxypropyl]-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n\n(2Z)-N-(2-amino-2-oxoethyl)-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifl uoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n\n(2Z)-2-{1-[4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetr ahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,\n\n(2Z)-2-{4,4-difluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3, 4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,\n\n(2Z)-2-{4,4-difluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3, 4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,\n\n(2Z)-2-{1-[4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoyl]-4,4,7-trifluoro-1,2,3,4-te trahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,\n\n(2Z)-N-[(2R)-2,3-dihydroxypropyl]-2-{4,4,7-trifluoro-1-[4-propoxy-2-(trifluoromethyl)b enzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n\n(2Z)-2-{4,4-difluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3, 4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,\n\n(2Z)-2-{4,4-difluoro-1-[4- [(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3, 4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2R)-2,3-dihydroxypropyl]acetamide,\n\n3-[((2Z)-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetyl)amino]propanamide,\n\n(2Z)-N-[(2R)-2,3-dihydroxypropyl]-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropylloxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n\n3-[((2Z)-2-{1-[4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoyl]-4,4,7-trifluoro-1,2,3, 4-tetrahydro-5H-1-benzazepin-5-ylidene}acetyl)amino]propanamide,\n\n(2Z)-2-{4,4-difluoro-1-[4-propoxy-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2R)-2,3-dihydroxypropyl]acetamide, or\n\n(2Z)-2-{4,4-difluoro-1-[4-propoxy-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,\n\nor a pharmaceutically acceptable salt thereof.\n\n\n\n\n \n \n\n\nA pharmaceutical composition which comprises the compound described in claim 1 as an active ingredient.\n\n\n\n\n \n \n\n\nThe compound according to any one of claim 1 to 5 or the pharmaceutical composition according to claim 6 for use in a method for treating urinary frequency, urinary incontinence, enuresis, central diabetes insipidus, nocturia and nocturnal enuresis.\n\n\n\n\n \n \n\n\nUse of the compound described in claim 1 for the manufacture of a pharmaceutical composition for treating urinary frequency, urinary incontinence, enuresis, central diabetes insipidus, nocturia and nocturnal enuresis. Description\n\n\n\n\nTechnical Field\n\n\n \n \n \nThis invention relates to a medicament, particularly a novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a salt thereof useful as a therapeutic agent for central diabetes insipidus and nocturia, and a medicament which uses said compound as the active ingredient.\n\n\n \nBackground of the Invention\n\n\n \n \n \nArginine vasopressin (AVP) is a peptide consisting of 9 amino acids which is biosynthesized and secreted in the hypothalamo-pituitary system. The receptor of AVP is classified into three subtypes V\n1a\n, V\n1b\n and V\n2\n, and a V\n1a\n receptor-mediated constriction action and a V\n2\n receptor-mediated antidiuretic action are known as the main pharmacological actions of AVP in the peripheral system. As a V\n2\n receptor-selective agonist, a peptide desmopressin (prepared by deleting amino group of the 1-position cysteine of AVP, and converting the 8-position arginine into \nd\n form) has been synthesized and used for the treatment of central diabetes insipidus (Non-patent Reference 1). However, since bioavailability of oral preparations of desmopressin is considerably low, a high dose is necessary for obtaining its effect. Thus, the desmopressin preparations are expensive, and generation of side effects based on the variation of absorption among individuals is observed in some cases. Accordingly, concern has been directed toward the development of a non-peptide antidiuretic agent which selectively stimulates V\n2\n receptor and has high bioavailability.\n\n\n \n \n \n \nOn the other hand, accompanied by the diversification of medical treatment and advance of age, single use of a drug became rather rare, and in many cases, two or more drugs are administered simultaneously or intermittently. This is the same in the field of AVP receptor agonists. Drugs are inactivated and converted into metabolites by undergoing the action of drug metabolizing enzymes, and the most important among these drug metabolizing enzymes is cytochrome P450 (CYP). A large number of molecular species exists in CYP, and when two or more drugs which are metabolized by CYP of the same molecular species compete on the metabolizing enzyme, it is considered that they undergo a certain metabolic inhibition, though it varies depending on the affinity of the drugs for CYP. As a result, increase of blood concentration, prolongation of blood half-life and the like drug interactions are expressed.\n\n\n \n \n \n \nSuch drug interactions are undesirable actions except for the case in which they are used aiming at the additive action or synergistic action, because they sometimes cause unexpected side effects. Thus, concern has been directed toward the creation of a medicament which has a low affinity for CYP and a small possibility of causing drug interactions.\n\n\n \n \n \n \nUp to now, tricyclic compounds represented by a general formula (A),a general formula (B) and a general formula (C) are known as non-peptide compounds which are V\n2\n receptor-selective agonists and show antidiuretic action (Patent Reference 1, Patent Reference 2, Patent Reference 3).\n\n \n \n\n(See said patent references for signs in the formulae.)\n\n\n \n \n \n \nAlso, a condensed azepine derivative represented by a general formula (D) is known as a V\n2\n receptor-selective agonist (Patent Reference 4).\n\n \n \n\n(See said patent reference for signs in the formula.)\n\n\n \n \n \n \nIn addition, benzazepine derivatives represented by a general formula (E) (Patent Reference 5, Patent Reference 6) and benzo-hetero ring compounds represented by a general formula (F) or a general formula (G) (Patent Reference 7, Patent Reference 8, Patent Reference 9) are known as V\n2\n receptor-selective agonists.\n\n \n \n\n(See said patent references for signs in the formulae.)\n\n\n \n \n \n \nHowever, there is no description in any of these patent references regarding the 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative of the invention.\n\n\n \n \n \n \nAlso, though 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative having antagonism for the AVP receptor or oxytocin receptor are known, nothing is known about their relation to V\n2\n receptor agonistic action, central diabetes insipidus and nocturia (Patent Reference 10, Patent Reference 11, Patent Reference 12). In this connection, Patent Reference 10 and Patent Reference 12 does not disclose the 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative of the invention in which CF\n3\n or halogen is substituted to the 2-position benzoyl substituting on the 1-position of benzazepine. In addition, Patent Reference 11 discloses only a compound in which an aromatic ring is directly bonded to a heteroaryl group bonding to the carbonyl substituting on the 1-position of benzazepine, but does not disclose the 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative of the invention in which the ring bonding to the carbonyl substituting on the 1-position of benzazepine has -O-, -S-, -NH- or a substituent group containing -N(lower alkyl)-.\n\n\n \n \n \n \nUnder such a situation, great concern has been directed toward the development of a non-peptide antidiuretic agent having high bioavailability, for the purpose of treating central diabetes insipidus and/or nocturia.\n\n \n \n \n[Non-patent Reference 1] \nJournal of Japan Endocrine Society, 54, 676 - 691, 1978\n \n \n[Patent Reference 1] International Publication No. \n \n99/06409\n \n \n \n[Patent Reference 2] International Publication No. \n \n99/06403\n \n \n \n[Patent Reference 3] International Publication No. \n \n00/46224\n \n \n \n[Patent Reference 4] International Publication No. \n \n01/49682\n \n \n \n[Patent Reference 5] International Publication No. \n \n97/22591\n \n \n \n[Patent Reference 6] Japanese Patent No. \n \n2926335\n \n \n \n[Patent Reference 7] Japanese Patent No. \n \n3215910\n \n \n \n[Patent Reference 8] Japanese Patent publication \n \nJP-A-11-349570\n \n \n \n[Patent Reference 9] Japanese Patent publication \n \nJP-A-2000-351768\n \n \n \n[Patent Reference 10] International Publication No. \n \n95/06035\n \n \n \n[Patent Reference 11] International Publication No. \n \n98/39325\n \n \n \n[Patent Reference 12] Japanese Patent publication \n \nJP-A-9-221475\n \n \n \n\n\nDisclosure of the Invention\n\n\n \n \n \nThe present inventors have conducted intensive studies on a compound having V\n2\n receptor agonistic action, from which effectiveness for central diabetes insipidus and/or nocturia can be expected, and found that a novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative has excellent said effect, thereby accomplishing the invention. In addition, it was found that the compound of the invention has markedly low inhibitory activity upon drug metabolizing enzymes CYP3A4 and CYP2C9 in comparison with conventionally known benzazepine derivatives having V\n2\n receptor agonistic action.\n\n\n \n \n \n \nThat is, according to the invention, there are provided a novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof which is useful as a therapeutic agent for central diabetes insipidus and/or nocturia; and a medicament which uses any one of these compounds as an active ingredient; particularly the aforementioned medicament which is an arginine vasopressin V\n2\n receptor agonist; and the aforementioned medicament which is a nocturia treating agent or a central diabetes insipidus treating agent.\n\n \n \n\nR\n1\n: a group represented by a formula (II),\n\n \n \n\nwherein,\n\nZ\n1\n: single bond, lower alkylene or -lower alkylene-C(=O)-,\n\nR\n11\n: lower alkyl which may be substituted with one or more groups selected from the group consisting of -OH, -O-lower alkyl, -CO\n2\nH, -CO\n2\n-lower alkyl and carbamoyl which may be substituted with one or two lower alkyls, or -H,\n\nR\n12\n:(1) when Z\n1\n represents single bond or lower alkylene, -H, -OH, -O-lower alkyl, -CO\n2\nH, -CO\n2\n-lower alkyl, carbamoyl which may be substituted with one or two lower alkyls, aryl which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h), cycloalkyl which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h), aromatic hetero ring which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h) or non-aromatic hetero ring which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h),\n\n \n \n \n(2) when Z\n1\n represents -lower alkylene-C(=O)-,\n\na group represented by the formula (III) or a formula (IV),\n\n \n \n \n \n\nwherein,\n\nZ\n2\n: single bond or lower alkylene,\n\nR\n15\n: -H, -OH, -O-lower alkyl, -CO\n2\nH, -CO\n2\n-lower alkyl, carbamoyl which may be substituted with one or two lower alkyls, aryl which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h), cycloalkyl which may be substituted with one or more groups selected from the substitutent groups shown in the following\n\n \n(a) to (h), aromatic hetero ring which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h) or non-aromatic hetero ring which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h),\n\nR\n13\n, R\n14\n:together with the adjacent nitrogen atom, non-aromatic cyclic amino group which may be substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h),\n\nR\n2\n: CF\n3\n or halogen,\n\nR\n3\n: H or halogen,\n\na: a single bond,\n\nb: a double bond,\n\n-X-: -CH=CH-,\n\n-Y-: -CH-,\n\n-A-: -O-, -S-, -NH- or -N(lower alkyl),\n\nB: lower alkyl, lower alkenyl, or lower alkynyl, each of which is optionally substituted with one or more groups selected from the substitutent groups shown in the following (a) to (g); or cycloalkyl or aryl, each of which is optionally substituted with one or more groups selected from the substitutent groups shown in the following (a) to (h),\n\nwherein substituents (a) to (h) are as follows:\n\n \n(a) halogen,\n \n(b) -OH, -O-R\nZ\n, -O-aryl, -OCO-R\nZ\n, oxo (=O),\n \n(c) -SH, -S-R\nZ\n, -S-aryl, -SO-R\nZ\n,-SO-aryl, -S4\n2\n-R\nZ\n, -SO\n2\n-aryl, sulfamoyl which may be substituted with 1 or 2 R\nZ\n,\n \n(d) amino which may be substituted with 1 or 2 R\nZ\n, -NHCO-R\nZ\n, -NHCO-aryl, -NHSO\n2\n-R\nZ\n, -NHSO\n2\n-aryl, nitro,\n \n(e)-CHO, -CO-R\nZ\n, -CO\n2\nH, -CO\n2\n-R\nZ\n, carbamoyl which may be substituted with 1 or 2 R\nZ\n, cyano,\n \n(f) aryl or cycloalkyl which may be respectively substituted with one or more groups selected from the class consisting of -OH, -O-lower alkyl, amino which may be substituted with 1or 2 lower alkyl, carbamoyl which may be substituted with 1 or 2 lower alkyl, aryl aromatic hetero ring, halogen and R\nZ\n,\n \n(g) aromatic hetero ring or non-aromatic hetero ring which may be respectively substituted with one or more groups selected from the class consisting of -OH, -O-lower alkyl, amino which may be substituted with 1 or 2 lower alkyl, carbamoyl which may be substituted with 1or 2 lower alkyl, aryl, aromatic hetero ring, halogen and R\nZ\n,\n \n(h) lower alkyl or lower alkenyl which may be respectively substituted with one or more groups selected from the substituent groups shown in the aforementioned (a) to (g), and\n \n\nR\nZ\n: lower alkyl which may be substituted with one or more groups selected from the class consisting of -OH, -O-lower alkyl, amino which may be substituted with 1 or 2 lower alkyl, carbamoyl which may be substituted with 1 or 2 lower alkyl, aryl, aromatic hetero ring and halogen.\n \n\n\n \n \n \nThe compound of the invention has a chemical structural characteristic in which it has difluoro group on the ring carbon atom adjacent to the benzazepine ring carbon atom where a substituted methylidene group is substituted, which is completely different from the structures of conventionally known V\n2\n receptor-selective agonists. In this connection, since the compound of the invention has difluoro group, the double bond conjugated to carbonyl group is not isomerized, so that it has sufficient Stability within an organism.\n\n\n \n \n \n \nParticularly desirable is a novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative represented by the aforementioned general formula (I), wherein -A- is -O-, or a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nMost desirable is a novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative represented by the aforementioned general formula (I), wherein, -A- is -0-: and -B is lower alkyl which may be substituted with one or more groups shown in the (a) to (g) mentioned above, or a pharmaceutically acceptable salt thereof.\n\n\n \n \n \n \nAmong them, a novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative wherein R\n2\n is trifluoromethyl; and R\n3\n is -H or -F, or a pharmaceutically acceptable salt thereof, is particularly desirable.\n\n\n \n \n \n \nParticularly desirable compounds among these compounds are compounds selected from the group consisting of a compound group P and a compound group Q, or pharmaceutically acceptable salts thereof, and preferred among them are compounds selected from the compound group P, or pharmaceutically acceptable salts thereof.\n\n\n \n \n \n \nIn this case, the \"compound group P\" is a group consisting of\n\n \n \n \n(2Z)-N-(2-amino-2-oxoethyl)-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n \n(2Z)-N-(2-hydroxyethyl)-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n \n(2Z)-N-(2-hydroxyethyl)-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n \n(2Z)-2-{4,4-difluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,\n \n3-[((2Z)-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetyl)amino]propanamide, and\n \n(2Z)-N-[(2R)-2,3-dihydroxypropyl]-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide, and the \"compound group Q\" is a group consisting of\n \n(2Z)-N-(2-amino-2-oxoethyl)-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene} acetamide,\n \n(2Z)-2-{1-[4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,\n \n(2Z)-2-{4,4-difluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,\n \n(2Z)-2-{4,4-difluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,\n \n(2Z)-2-{1-[4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoyl]-4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,\n \n(2Z)-N-[(2R)-2,3-dihydroxypropyl]-2-{4,4,7-trifluoro-1-[4-propoxy-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n \n(2Z)-2-{4,4-difluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,\n \n(2Z)-2-{4,4-difluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2R)-2,3-dihydroxypropyl]acetamide,\n \n3-[((2Z)-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetyl)amino]propanamide,\n \n(2Z)-N-[(2R)-2,3-dihydroxypropyl]-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,\n \n3-[((2Z)-2-{1-[4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoyl]-4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetyl)amino]propanamide,\n \n(2Z)-2-{4,4-difluoro-1-[4-propoxy-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2R)-2,3-dihydroxypropyl]acetamide, and\n \n(2Z)-2-{4,4-difluoro-1-[4-propoxy-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide.\n \n\n\n \n \n \nIn this connection, regarding R\n1\n, the group represented by the aforementioned formula (II) or the aforementioned formula (III) is desirable; the group represented by the aforementioned formula (U), wherein Z\n1\n is single bond, R\n12\n is -H and R\n11\n is lower alkyl which may be substituted with a group selected from the group consisting of - OH,\n\n-O-lower alkyl, -CO\n2\nH -CO\n2\n-lower alkyl and carbamoyl which may be substituted with one or two lower alkyls, is further desirable; and the group represented by the aforementioned formula (II), wherein Z\n1\n is single bond, R\n12\n is -H and R\n11\n is lower alkyl which may be substituted with one or more substituent groups selected from a group consisting of -OH and carbamoyl, is particularly desirable.\n\n\n \n \n \n \nAlso, regarding R\n2\n, trifluoromethyl or chloro is desirable; and trifluoromethyl is particularly desirable.\n\n\n \n \n \n \nAlso, regarding R\n3\n, -H or fluoro is desirable; and -H or 7-fluoro is particularly desirable.\n\n\n \n \n \n \nAlso, regarding a, b, -X- and -Y-, it is desirable that a is single bond, b is double bond, -X- is -CH-CH-, and Y is CH.\n\n\n \n \n \n \nAlso, -O- is desirable as A-.\n\n\n \n \n \n \nIn addition, regarding -B, lower alkyl which may be substituted with one or more groups show in the (a) to (g) mentioned above is desirable; and lower alkyl which may be substituted with F is particularly desirable.\n\n\n \n \n \n \nThe following further describes the compound of the invention.\n\n\n \n \n \n \nAccording to the invention, the \"lower alkyl\" means a monovalent group of straight or branched C\n1-6\n carbon chain, and its illustrative examples include methyl, ethyl, propyl, butyl, pentyl and hexyl, and isopropyl, tert-butyl and the like structural isomers thereof, preferably a C\n1-4\n alkyl methyl, ethyl, propyl, butyl and isobutyl.\n\n\n \n \n \n \nThe \"lower alkylene\" means a divalent group of straight or branched C\n1-6\n carbon chain, and its illustrative examples include methylene, ethylene, trimethylene, methylmethylene, methylethylene, dimethylmethylene and the like.\n\n\n \n \n \n \nThe \"lower alkenyl\" means a monovalent group of straight or branched C\n2-6\n carbon chain having at least one double bond, and its illustrative examples include vinyl, allyl, 1-butenyl, 2-butenyl, 1-hexenyl, and 3-hexenyl, 2-methylallyl and the like structural isomers thereof, of which allyl and 2-methyl-1-propen-3-yl are preferable.\n\n\n \n \n \n \nThe \"lower alkynyl\" means a monovalent group of straight or branched C\n2-6\n carbon chain having at least one triple bond, and its illustrative examples include ethynyl, propargyl, 1-butynyl, 3-butynyl, 1-hexynyl, and 3-hexynyl, 3-methyl-1-butynyl and the like structural isomers thereof, of which propargyl and 1-butyn-4-yl are preferred.\n\n\n \n \n \n \nThe \"cycloalkyl\" means a monovalent group of C\n3-8\n non-aromatic hydrocarbon ring which may partially have a unsaturated bond, and its illustrative examples include cyclopropyl, cyclopentyl, cyclohexyl, cyclooctyl, cyclohexenyl, cyclooctanedienyl and the like.\n\n\n \n \n \n \nThe \"aryl\" means a monovalent group of monocyclic to tricyclic C\n6-14\n aromatic hydrocarbon ring, and its illustrative examples include phenyl, naphthyl and the like, of which phenyl is preferably.\n\n\n \n \n \n \nThe \"aromatic hetero ring\" means a monovalent group of monocyclic to tricyclic aromatic ring having hetero atom(s) such as nitrogen, oxygen, sulfur or the like, and its illustrative examples include pyridyl, thienyl, furyl, pyrazinyl, pyridazinyl, thiazolyl, pyrimidinyl, pyrazolyl, pyrrolyl, oxazolyl, isothiazolyl, isooxazolyl, imidazolyl and the like, of which pyridyl is preferred.\n\n\n \n \n \n \nThe \"non-aromatic hetero ring\" means a monovalent group of 5- to 7-membered ring having hetero atom(s) such as nitrogen, oxygen, sulfur or the like, which may partially have an unsaturated bond and may be condensed with aryl or aromatic hetero ring, and its illustrative examples include pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, azepinyl, morphonyl, thiomorphonyl, tetrahydrofuryl, tetrahydrothienyl and the like, of which pyrrolidinyl, piperidinyl and morphonyl are preferable.\n\n\n \n \n \n \nThe \"non-aromatic cyclic amino group\" means a monovalent group of 3- to 10-membered non-aromatic cyclic amine, preferably 5- to 7-membered non-aromatic cyclic amine, optionally having nitrogen, oxygen or sulfur, which may partially have an unsaturated bond, and its illustrative examples include pyrrolidinyl, piperidinyl, azepinyl, morphonyl, thiomorphonyl, piperazinyl, pyrazolidinyl, dihydropyrrolyl and the like, of which pyrrolidinyl, piperidinyl, piperazinyl and morphonyl are preferred.\n\n\n \n \n \n \nThe \"halogen\" means a monovalent group of halogen atom, and its illustrative examples include fluoro, chloro, bromo, iodo and the like.\n\n\n \n \n \n \nDepending on the kind of substituent groups, compounds of the invention represented by the general formula (I) sometimes contain asymmetric carbon atom, and optical isomers based thereon can be present therein. All of the mixtures and isolates of these optical isomers are included in the invention. Also, tautomers are present in the compounds of the invention in some cases, and isolates or mixtures of these isomers are included in the invention.\n\n\n \n \n \n \nAlso, the compounds of the invention sometimes form salts, and such salts are included in the invention with the proviso that they are pharmaceutically acceptable salts. Their illustrative examples include acid addition salts with hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid phosphoric acid and the like inorganic acids or with formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid and the like organic acids, salts with inorganic bases including sodium, potassium, calcium, magnesium and the like metals or with methylamine, ethylamine, ethanolamine, lysine, ornithine and the like organic bases, ammonium salts and the like. In addition, various hydrates, solvates and substances having polymorphism of the compounds of the invention and pharmaceutically acceptable salts thereof are also included in the invention.\n\n\n \n(Production methods)\n\n\n \n \n \nThe compounds of the invention and pharmaceutically acceptable salts thereof can be produced by employing various conventionally known synthesis methods, making use of characteristics based on their basic nuclei or the kind of substituent groups. Typical production methods are exemplified in the following. In this connection, depending on the kind of functional group, it is effective in some cases, in view of production techniques, to replace said functional group with an appropriate protecting group, namely a group which is easily converted into said functional group, at a stage of from the materials to intermediates. Thereafter, the compound of interest can be obtained by removing the protecting group as occasion demands. Examples of such a functional group include hydroxyl group, carboxy group, amino group and the like, and the protecting groups described in \"\nProtective Groups in Organic Synthesis (3rd Edition)\" edited by Greene and Wuts\n can be exemplified as their protecting groups which may be optionally used in response to the reaction conditions.\n\n\n \n<Intermediate production method>\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n(In the reaction scheme, R\n2\n, a, b, X, Y and A are as defined in the foregoing; Lv represents a leaving group; B\n1\n represents the aforementioned B or a protecting group of hydroxyl group, amino group or sulfanil group; R\na\n represents carboxyl group, a lower alkyl oxycarbonyl group or cyano group. The same shall apply hereinafter.)\n\n\n \n \n \n \nThis production method is a method in which the compound (c) is produced by substituting leaving group Lv of the compound (a) by the compound (b), and then the compound (d) is produced therefrom by carrying out hydrolysis of the same as occasion demands.\n\n\n \n(First step)\n\n\n \n \n \nExamples of the leaving group Lv in the compound (a) include fluoro, chloro, methanesulfonyloxy, p-toluenesulfonyloxy and trifluoromethanesulfonyloxy, of which fluoro, chloro and methanesulfonyloxy are preferred.\n\n\n \n \n \n \nThe reaction can be carried out at room temperature to heating under reflux using the compound (a) and compound (b) in equimolar amounts or one of them in an excess amount, without solvent or in a reaction inert solvent such as benzene, toluene, xylene or the like aromatic hydrocarbons; diethyl ether, tetrahydrofuran (THF), dioxane or the like ethers; dichloromethane, 1,2-dichloroethane, chloroform or the like halogenated hydrocarbons; N,N-dimethylformamide (DMF); dimethylacetamide (DMA); N-methylpyrrolidone; dimethyl sulfoxide (DMSO); ethyl acetate (EtOAc) or the like esters; acetonitrile or the like, or in methanol (MeOH), ethanol (EtOH), 2-propanol (iPrOH) or the like alcohols. Depending on the compound, it is advantageous in some cases to carry out the reaction in the presence of an organic base (preferably triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine or 4-(N,N-dimethylamino) pyridine) or a metal salt base (preferably potassium carbonate, cesium carbonate, sodium hydroxide or sodium hydride).\n\n\n \n(Second step)\n\n\n \n \n \nThe reaction can be carried out by treating the compound (c) under cooling to heating under reflux, in a solvent inert to the reaction such as an aromatic hydrocarbon, an ether, a halogenated hydrocarbon, an alcohol solvent, DMF, DMA, DMSO, pyridine, water or the like in the presence of sulfuric acid, hydrochloric acid, hydrobromic acid or the like mineral acid, formic acid, acetic acid or the like organic acid or sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate, ammonia or the like base.\n\n\n \n<First production method>\n\n\n \n \n \n\n\n\n\n\n\n\n\n\n\n \n \n \n \n(In the reaction scheme, R\n1\n is as defined in the foregoing, and R\nb\n represents a lower alkyl. The same shall apply hereinafter.)\n\n\n \n \n \n \nThis production method is a method in which a compound (1b) is produced by condensing the compound (d) produced in the aforementioned intermediate production method with a compound (1a), a compound (1c) is produced by hydrolyzing the former and then the product is condensed with a compound (1d), thereby producing the compound (I) of the invention in which B\n1\n is B or a compound (1e) in which B\n1\n is hydroxyl group, amino group or sulfanil group.\n\n\n \n(First step)\n\n\n \n \n \nThe compound (d) can be used in the reaction as free acid, but its reactive derivative can also be used in the reaction. Examples of the reactive derivative of compound (d) include methyl ester, ethyl ester, tert-butyl ester or the like general ester; acid chloride, acid bromide or the like acid halide; acid azide; active ester with N-hydroxybenzotriazole, p-nitrophenol, N-hydroxysuccinimide or the like; symmetric acid anhydride; mixed acid anhydride with alkyl carbonate halide or the like halocarboxylic acid alkyl ester, pivaloyl halide, p-toluenesulfonic acid chloride or the like; mixed acid anhydride such as a phosphoric acid system mixed acid anhydride obtained by reacting with diphenylphosphoryl chloride and N-methylmorpholine, and the like.\n\n\n \n \n \n \nWhen the compound (d) is allowed to undergo the reaction as free acid, or an active ester is allowed to undergo the reaction without isolation, it is desirable to use a condensing agent such as dicyclohexylcarbodiimide (DCC), 1,1'-carbonylbis-1H-imidazole (CDI), diphenylphosphoryl azide (DPPA), diethylphosphoryl cyanide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSCD) or the like.\n\n\n \n \n \n \nAccording to the invention, an acid chloride method, a method in which the reaction is carried out in the coexistence of an active esterification agent and a condensing agent and a method in which a general ester is treated with amine are particularly convenient, because the compound of the invention can be obtained conveniently and easily.\n\n\n \n \n \n \nThough it varies depending on the reactive derivative and condensing agent to be used, the reaction is carried out under cooling, under cooling to room temperature or under room temperature to heating, in a reaction inert solvent such as a halogenated hydrocarbon, an aromatic hydrocarbon, an ether, an ester, acetonitrile, DMF, DMSO or the like.\n\n\n \n \n \n \nIn this connection, it is advantageous in some cases in smoothly progressing the reaction to use the compound (1a) in an excess amount in carrying out the reaction, or to carry out the reaction in the presence of a base such as N-methylmorpholine, trimethylamine, triethylamine, diisopropylethylamine, N,N-dimethylaniline, pyridine, 4-(N,N-dimethylamino) pyridine, picoline, rutidine or the like. In addition, a salt consisting of pyridine hydrochloride, pyridine p-toluenesulfonate, N,N-dimethylaniline hydrochloride or the like weak base and a strong acid may be used. Pyridine can also be used as a solvent.\n\n\n \n \n \n \nParticularly, it is suitable to carry out the reaction in acetonitrile, DMF or the like solvent in the presence of pyridine, N,N-dimethylaniline or the like base or pyridine hydrochloride or the like salt.\n\n\n \n(Second step)\n\n\n \n \n \nThe reaction can be carried out in accordance with the second step of the intermediate production method.\n\n\n \n(Third step)\n\n\n \n \n \nThe reaction can be carried out in accordance with the first step of the first production method.\n\n\n \n \n \n \nThe compound (1e) can be made into the compound (I) of the invention by removing the protecting group as occasion demands or further introducing a necessary side chain in accordance with a general method. Introduction of the necessary side chain can also be carried out in accordance with the third step of the following second production method.\n\n\n \n<Second production method>\n\n\n \n \n \n \n \n \n\n(In the reaction scheme, B\n2\n is protecting group of hydroxyl group, amino group or sulfanil group. The same shall apply hereinafter.)\n\n\n \n \n \n \nThis production method is a method in which a compound (2a) is produced by condensing a compound (dd) produced by the aforementioned intermediate production method, wherein B\n2\n is not B, with a compound (1a), a compound (2b) is produced by removing the protecting group B\n2\n, a compound (2f) is produced by condensing with a compound (2c) or (2d), a compound (2f) is produced by hydrolyzing it, and then the compound (I) of the invention is produced by condensing with a compound (1d).\n\n\n \n(First step)\n\n\n \n \n \nThis reaction can be carried out in accordance with the first step of the first production method.\n\n\n \n(Second step)\n\n\n \n \n \nAs the protecting group of hydroxyl group, amino group or sulfanil group, the protecting groups described in the aforementioned \"\nProtective Groups in Organic Synthesis (3rd Editi\non)\" can be exemplified. The reaction can be carried out in accordance with the method described in \"Protective Groups in Organic Synthesis (3rd Edition)\".\n\n\n \n \n \n \nParticularly, when benzyl group is used as the protecting group of hydroxyl group, a method in which benzyl group is removed by allowing pentamethylbenzene to react therewith in a strongly acidic solution such as trifluoroacetic acid or the like can also be used.\n\n\n \n(Third step)\n\n\n \n \n \nAs the leaving group Lv in the compound (2c), chloro, bromo, iodo, methanesulfonyloxy, p-toluenesulfonyloxy and trifluoromethanesulfonyloxy can for example be cited, of which bromo, methanesulfonyloxy and p-toluenesulfonyloxy are preferable.\n\n\n \n \n \n \nRegarding the reaction which uses the compound (2c), a general alkylation reaction can be used, and preferably, it can be carried out using the compound (2b) and compound (2c) under cooling, under cooling to room temperature or under room temperature to heating in equimolar amounts or one of them in an excess amount in a reaction inert solvent such as acetonitrile, DMF, DMSO, an ether or the like, in the presence of potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide or the like base.\n\n\n \n \n \n \nThe reaction which uses the compound (2d) can be carried out under the Mitsunobu reaction condition in an aprotic solvent reaction inert to the reaction, such as an ether, DMF, N-methylpyrrolidone or the like, in the presence of triphenylphosphine or the like organic phosphine and diethyl azodicarboxylate, diisopropyl azodicarboxylate or the like dialkyl azodicarboxylate (\nSynthesis, 1981, p. 1\n).\n\n\n \n(Fourth step)\n\n\n \n \n \nThis reaction can be carried out in accordance with the second step of the first production method.\n\n\n \n(Fifth step)\n\n\n \n \n \nThis reaction can be carried out in accordance with the first step of the first production method.\n\n\n \n \n \n \nIn addition, some of the compounds of the invention represented by the formula (I) can be produced from the compounds of the invention obtained by the first production method or second production method, by optionally combining conventionally known alkylation, acylation, substitution reaction, oxidation, reduction, hydrolysis and the like steps which can be generally employed by those skilled in the art. Illustratively, oxidation of sulfur atom by metachloroperbenzoic acid or the like oxidizing agent, and the like can for example be cited, and such reactions carried out by employing or in accordance with the methods described in \"\nJikken Kagaku Koza (Experimental Chemistry Course) 4th edition\" (Maruzen, 1990 - 1992\n). In addition, these steps which can be generally employed by those skilled in the art are not limited to the application to the compounds of the invention, and they can also be applied to the production intermediates. Illustratively, they can be applied, for example, to the compound obtained by the third step of the second production method, and thereafter, the next step can be carried out.\n\n\n \n \n \n \nThe compounds of the invention produced in this manner are isolated and purified as free compounds or salts thereof by carrying out salt formation treatment in the usual way. Isolation and purification are carried out by employing usual chemical operations such as extraction, concentration, evaporation, crystallization, filtration, recrystallization, various types of chromatography and the like.\n\n\n \n \n \n \nVarious isomers can be isolated in the usual way by making use of differences in physicochemical properties among isomers. For example, a racemic mixture can be converted into optically pure isomers, for example, by a general racemic body resolution method such as a method in which they are converted into diastereomer salts with tartaric acid or the like general optically active acid and then subjected to optical resolution. Also, a diastereomer mixture can be separated, for example, by fractional crystallization or various types of chromatography. In addition, an optically active compound can also be produced using an appropriate optically active material.\n\n\n \nIndustrial Applicability\n\n\n \n \n \nThe compounds of the invention have excellent agonistic activity upon arginine vasopressin V\n2\n receptor. Accordingly, the compounds of the invention have antidiuretic action of a profile based on this action, and are effective in preventing and/or treating urinary frequency, urinary incontinence, enuresis, central diabetes insipidus, nocturia and nocturnal enuresis. Also, in addition to these, since they have the action to release blood coagulation factor VIII and von Willebrand factor based on the V\n2\n receptor agonistic activity, they are useful for various bleeding conditions and useful in diagnosing, preventing and treating spontaneous hemorrhage, hemophilia, von Willebrand disease, uremia, congenital or acquired platelet dysfunction, traumatic and operation hemorrhage, hepatic cirrhosis and the like.\n\n\n \n \n \n \nIn addition, the compounds of the invention have markedly low inhibitory activity upon drug metabolizing enzymes CYP3A4 and CYP2C9, possibility of causing drug interaction with other drugs which are metabolized via CYP3A4 or CYP2C9 is small in comparison with the conventionally known benzazepine derivatives having arginine vasopressin V\n2\n receptor agonistic activity, so that they are also excellent from the viewpoint that they can be safely used in the combined therapy with other medicaments.\n\n\n \n \n \n \nExamples of the drugs which are metabolized by CYP3A4 include simvastatin, lovastatin, fluvastatin, midazolam, nifedipine, amlodipine, nicardipine and the like, and examples of the drugs which are metabolized by CYP2C9 include diclofenac, ibuprofen, indometacin, tolbutamide, glibenclamide, losartan and the like (\nSogo Rinsho (General Clinics), 48(6), 1427 - 1431, 1999\n).\n\n\n \n \n \n \nPharmacological actions of the compounds of the invention were verified by the following test methods.\n\n\n \n(1) V\n2\n receptor binding test\n\n\n \n \n \nA human V\n2\n expression CHO cell membrane sample was prepared in accordance with the method of\n Tahara et al. (British Journal of Pharmacology, Vol. 125, pp. 1463 - 1470, 1998\n). A 2 µg portion of the membrane sample was incubated together with [\n3\nH]-arginine vasopressin (to be referred simply to as \"[\n3\nH]-vasopressin\" hereinafter) (0.5 nM, specific activity = 75 Ci/mmol) and each compound to be tested (10\n-10\n to 10\n-5\n M) at 25°C for 60 minutes in 250 µl in total volume of 50 mM Tris-HCl buffer (pH = 7.4) containing 10 mM MgCl\n2\n and 0.1% bovine serum albumin (BSA). Thereafter, free [\n3\nH]-vasopressin and receptor-bonded [\n3\nH]-vasopressin were separated using a cell harvester, and the receptor-bonded [\n3\nH]-vasopressin was adhered onto a uni-filter plate GF/B glass filter. After sufficient drying, this was mixed with a microplate scintillation cocktail, amount of the receptor-bonded [\n3\nH]-vasopressin was measured using top count and the inhibition ratio was calculated by the following formula. \n \n \nInhibition ratio\n \n \n \n \n%\n \n \n=\n \n100\n \n-\n \n \n \nC\n \n1\n \n \n-\n \n \nB\n \n1\n \n \n \n/\n \n \n \nC\n \n0\n \n \n-\n \n \nB\n \n1\n \n \n \n \n \nx\n \n \n \n100\n \n \n \n\n\n \n \n \nC\n1\n: Amount of [\n3\nH]-vasopressin bonded to the membrane sample when [\n3\nH]-vasopressin and the receptor membrane sample are treated in the coexistence of test compound having known concentration\n \nC\n0\n: Amount of [\n3\nH]-vasopressin bonded to the membrane sample when [\n3\nH]-vasopressin and the receptor membrane sample are treated in the absence of test compound\n \nB\n1\n: Amount of [\n3\nH]-vasopressin bonded to the membrane sample when [\n3\nH]-vasopressin and the receptor membrane sample are treated in the coexistence of excess amount of vasopressin (10\n-6\n M)\n \n\n\n \n \n \nConcentration of each test compound by which the inhibition ratio becomes 50% (IC\n50\n value) was calculated by the aforementioned formula, and affinity of the test compound for the receptor, namely dissociation constant (Ki), was calculated from this by the following formula. \n \n \nDissociation constant\n \n \n \n \nKi\n \n \n=\n \n \nIC\n \n50\n \n \n/\n \n \n1\n \n+\n \n \nL\n \n \n/\n \nKd\n \n \n \n \n\n\n \n \n \n[L]: Concentration of [\n3\nH]-vasopressin\n \nKd: Dissociation constant of [\n3\nH]-vasopressin against the receptor obtained by a saturation binding test\n \n\n\n \n(Table 1)\n \n \n \nAffinity for V\n2\n receptor\n \n \n \nCompounds\n \nKi (nM)\n \nCompounds\n \nKi (nm)\n \n \n \n \nExample 3\n \n11\n \nExample 31\n \n10\n \n \n \nExample 9\n \n19\n \nExample 54\n \n17\n \n \n \nExample 14\n \n18\n \nExample 55\n \n16\n \n \n \nExample 24\n \n4.3\n \nExample 134\n \n12\n \n \n \nExample 46\n \n5.8\n \nExample 136\n \n11\n \n \n \nExample 98\n \n6.2\n \nComparative compound\n \n68\n \n \n \n \n\n\n \n \n \nIn this connection, the comparative compound is the compound of Example 32 described in International Publication\n \n WO 97/22591\n \n (compound name: 2-[(5R)-1-(2-chloro-4-pyrrolidin-1-ylbenzoyl)-2,3,4,5-tetrahydrobenzazepin-5-yl]-N-isopropylacetamide).\n\n\n \n \n \n \nAs shown in Table 1, it was confirmed that the compounds of the invention have high affinity for V\n2\n receptor.\n\n\n \n(2) Antidiuretic test (intravenous administration)\n\n\n \n \n \nFive animals per group of male Wistar rats (10 to 12 weeks of age) were used in the test. The compound of Example 3 was intravenously administered to group A at a dose of 0.3 mg/kg, and the compound of Example 9 to group B at a dose of 0.3 mg/kg, both after dissolving in a solvent (physiological saline containing DMSO), and the solvent alone at a dose of 1 ml/kg to group C as a control, and then 30 ml/kg of distilled water was orally administered by force 15 minutes thereafter (water loading). Urine samples until 2 hours after the water loading were collected using a metabolism cage, and the amount of urine when the water loading amount was defined as 100% was calculated as the urine excretion ratio. In this connection, average value of the urine excretion ratio until after 1 hour and the urine excretion ratio until after 2 hours in each group was used in the evaluation. The results are shown in Table 2.\n\n \n(Table 2)\n \n \n \nAntidiuretic effects (intravenous administration)\n \n \n \n \n \nCompounds\n \nUrine excretion ratio (%)\n \n \n \nAfter 1 hour\n \nAfter 2 hours\n \n \n \n \nGroup A\n \nExample 3\n \n1.3\n \n6.2\n \n \n \nGroup B\n \nExample 9\n \n0\n \n5.3\n \n \n \nGroup C\n \nSolvent\n \n64.0\n \n80.0\n \n \n \n \n \n\n\n \n \n \n \nAs shown in Table 2, it was revealed that the compounds of the invention have excellent antidiuretic effects.\n\n\n \n(3) Antidiuretic test (oral administration)\n\n\n \n \n \nMale-Wistar rats (10 to 12 weeks of age) were used in the test. Each compound to be tested was orally administered, and then 30 ml/kg of distilled water was orally administered by force 15 minutes thereafter (water loading). Urine samples until 4 hours after the water loading were collected using a metabolism cage, and the amount of urine when the water loading amount was defined as 100% was calculated as the urine excretion ratio. In this connection, the dose each test compound necessary for reducing 50% of the urine excretion ratio (ED\n50\n) was used in the evaluation. As a result, it was revealed that the compounds of the invention show excellent antidiuretic action not only by intravenous administration but also by oral administration.\n\n\n \n(4) Cytochrome P450 (3A4) enzyme inhibition test\n\n\n \n \n \nThis test was carried out in accordance with the method of \nCrespi et al. (Analytical Biochemistry, 248, 188 - 190, 1997\n).\n\n\n \n \n \n \nUsing a 96 well plate, 7-benzyloxy-4-(trifluoromethyl)cumarin as the substrate (5 x 10\n-5\n M), each test compound (from 4.9 x 10\n-8\n to 5 x 10\n-5\n M) and the enzyme (5 x 10\n-9\n M) were incubated at 37°C for 30 minutes in 200 µl in total volume of 200 mM phosphate buffer (pH = 7.4) containing 8.2 µM NADP+, 0.41 mM glucose-6-phosphate, 0.41 mM MgCl\n2\n and 0.4 units/ml glucose-6-phosphate dehydrogenase. Thereafter, the reaction was stopped by adding 0.5 M 2-amino-2-hydroxymethyl-1,3-propanediol aqueous solution containing 80% acetonitrile, and the fluorescence intensity (excitation wavelength; 409 nm, fluorescence wavelength; 530 nm) was measured using a fluorescence plate reader. The inhibition ratio was calculated based on the following formula, and concentration of each test compound by which the inhibition ratio becomes 50% (IC\n50\n) was obtained. The results are shown in Table 3. \n \n \nInhibition ratio\n \n \n%\n \n \n=\n \n100\n \n-\n \n \n \nC\n \n1\n \n \n-\n \n \nB\n \n1\n \n \n \n/\n \n \n \nC\n \n0\n \n \n-\n \n \nB\n \n1\n \n \n \n \n \nx\n \n \n \n100\n \n \n \n\n\n \n \n \nC\n1\n: Fluorescence intensity in the presence of test compound having known concentration, enzyme and substrate\n \nC\n0\n: Fluorescence intensity in the absence of test compound and in the presence of enzyme and substrate\n \nB\n1\n: Fluorescence intensity of blank well\n \n\n\n(5) Cytochrome P450 (2C9) enzyme inhibition test\n\n\n \n \n \nThis test was carried out in accordance with the method of \nCrespi et al. (Analytical Biochemistry, 248, 188 - 190, 1997\n).\n\n\n \n \n \n \nUsing a 96 well plate, 7-methoxy-4-(trifluoromethyl)cumarin as the substrate (7.5 x 10\n-5\n M), each test compound (from 4.9 x 10\n-8\n to 5 x 10\n-5\n M) and the enzyme (10\n-8\n M) were incubated at 37°C for 45 minutes in 200 µl in total volume of 200 mM phosphate buffer (pH = 7.4) containing 8.2 µM NADP+, 0.41 mM glucose-6-phosphate, 0.41 mM MgCl\n2\n and 0.4 units/ml glucose-6-phosphate dehydrogenase. Thereafter, the reaction was stopped by adding 0.5 M 2-amino-2-hydroxymethyl-1,3-propanediol aqueous solution containing 80% acetonitrile, and the fluorescence intensity (excitation wavelength; 409 nm, fluorescence wavelength; 530 nm) was measured using a fluorescence plate reader. The inhibition ratio was calculated based on the same formula of aforementioned (4), and concentration of each test compound by which the inhibition ratio becomes 50% (IC\n50\n) was obtained. The results are shown in Table 3.\n\n \n(Table 3)\n \n \n \nCYP (3A4 and 2C9) inhibitory activity\n \n \n \nCompounds\n \nIC\n50\n (µM)\n \n \n \nCYP3A4\n \nCYP2C9\n \n \n \n \nExample 3\n \n>50\n \n>50\n \n \n \nExample 9\n \n13\n \n11\n \n \n \nExample 51\n \n>50\n \n34\n \n \n \nExample 54\n \n>50\n \n43\n \n \n \nExample 130\n \n>50\n \n>50\n \n \n \nExample 136\n \n>50\n \n>50\n \n \n \nComparative compound\n \n<0.091\n \n<0.091\n \n \n \n \n \n\n\n \n \n \n \nAs shown in Table 3, the compounds of the invention showed markedly low inhibitory action upon the drug metabolizing enzymes CYP3A4 and CYP2C9. In this connection, the comparative compound is the same comparative compound shown in Table 1.\n\n\n \n \n \n \nThe medicament of the invention can be prepared by a generally used method using one or more of the compounds of the invention represented by the general formula (I) and carriers for drug, fillers and other additive agents which are generally used in preparing medicines. Its administration may be either oral administration in the form of tablets, pills, capsules, granules, powders, solutions and the like, or parenteral administration in the form of intravenous injections, intramuscular injections or the like injections, or suppositories, transnasal preparations, transmucosal preparations, percutaneous preparations and the like.\n\n\n \n \n \n \nThe solid composition for use in the oral administration according to the present invention is used in the form of tablets, powders, granules and the like. In such a solid composition, one or more active substances are mixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinyl pyrrolidone, aluminum magnesium silicate or the like. In the usual way, the composition may contain other additives than the inert diluent, such as magnesium stearate or the like lubricant, calcium cellulose glycolate or the like disintegrating agent, lactose or the like stabilizing agent and glutamic acid, aspartic acid or the like solubilization assisting agent. As occasion demands, tablets or pills may be coated with a sugar coating a film of a gastric or enteric substance, such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate or the like.\n\n\n \n \n \n \nThe liquid composition for oral administration includes pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like and contains a generally used inert diluent such as purified water or ethanol. In addition to the inert diluent, this composition may also contain a moistening agent, a suspending agent and the like auxiliary agents, as well as sweeteners, flavors, aromatics and antiseptics.\n\n\n \n \n \n \nThe injections for parenteral administration includes aseptic aqueous or non-aqueous solutions, suspensions and emulsions. Examples of the diluent for use in the aqueous solutions and suspensions include distilled water for injection and physiological saline. Examples of the diluent for use in the non-aqueous solutions and suspensions include propylene glycol, polyethylene glycol, olive oil or the like plant oil, EtOH or the like alcohol, polysorbate 80 and the like. Such a composition may further contain additive agents including an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent such as lactose, and a solubilization assisting agent such as glutamic acid or aspartic acid. These are sterilized, for example, by filtration through a bacteria retaining filter, blending of a germicide or irradiation. Alternatively, they can also be used by firstly making into sterile solid compositions and dissolving them in sterile water or a sterile solvent for injection prior to their use.\n\n\n \n \n \n \nIn the case of oral administration, the appropriate daily dose is generally from about 0.0001 to 50 mg/kg, preferably from about 0.001 to 10 mg/kg, more preferably from 0.01 to 1 mg/kg, per body weight, and this is administered once a day or dividing it into 2 to 4 doses. In the case of intravenous administration, the appropriate daily dose is generally from about 0.0001 to 1 mg/kg, preferably from about 0.0001 to 0.1 mg/kg, per body weight, and this is administered once a day or dividing it into two or more doses. The dose is optionally decided in response to individual cases by taking into consideration symptoms, age, sex and the like. However, since the dose varies under various conditions, a smaller dose than the above range may be sufficient enough in some cases.\n\n\n \nBest Mode for Carrying Out the Invention\n\n\n \n \n \nThe following illustratively describes the invention based on examples, but the invention is not restricted by these examples. In this connection, since novel substances are included in the material compounds to be used in the examples, methods for producing such material compounds from conventionally known substances are described as reference examples.\n\n\n \nReference Example 1\n\n\n \n \n \nA 5.2 g portion of 60% sodium hydride oil dispersion was suspended in 50 ml of DMF, and 6.73 ml of benzyl alcohol was added thereto under ice-cooling. After warming up to room temperature, 12.3 g of 4-fluoro-2-trifluoromethylbenzoic acid was added thereto and stirred at room temperature for 6 hours. A 1 M hydrochloric acid aqueous solution was added to the reaction mixture, and the thus precipitated crystals were collected by filtration to obtain 16.39 g of 4-(benzyloxy)-2-(trifluoromethyl)benzoic acid.\n\nMS(+); 297\n\n\n \n \n \n \nIn the same manner as in Reference Example 1, Reference Examples 2 to 4 shown in Table 4 were produced using respective corresponding materials.\n\n\n \n \n \n \nIn this connection, signs in the table show the following meanings (the same shall apply hereinafter).\n\n \n \n \nRf: Reference Example number,\n \nData: physicochemical date (NMR: uses (CH\n3\n)\n4\nSi as the internal standard, and unless otherwise noted, shows peak δ (ppm) by \n1\nH-NMR using DMSO-d\n6\n as the measuring solvent,\n \nMS(+): FAB-MS [M + H]\n+\n, MS(-): FAB-MS [M - H]\n+\n, EMS(+): ESI-MS [M + H]\n+\n,\n \nEMS(-): ESI-MS [M - H]\n+\n,\n \nR\nA\n, R\nB\n: substituent groups in the general formula,\n \nnPr: normal propyl, cPr: cyclopropyl.\n \n\n\n \n \n \nIn this connection, regarding the NMR data, there is a case in which a compound gives a complex data due to the presence of two or more conformers, but among them, only a peak which corresponds to a conformer considered to be mainly present was described. In addition, these peaks were converged on a peak showing one kind of compound, by measuring under heating.\n\n \n(Table 4)\n \n \n \n \n \n \n \n \n \n \n \n \nRf\n \nR\nA\n \n \nR\nB\n \n \nData\n \n \n \n \n2\n \nCF\n3\n \n \ncPr-CH\n2\nO-\n \nEMS(-) : 259\n \n \n \n3\n \nCl\n \nnPr-S-\n \nMS(+) : 231\n \n \n \n4\n \nCF\n3\n \n \nnPr-S-\n \nMS(-) : 263\n \n \n \n \n \n\n\n \nReference Example 5\n\n\n \n \n \nA 4.44 g portion of methyl 4-fluoro-2-trifluorobenzoate was dissolved in 40 ml of DMF, 3.32 g of potassium carbonate and 4.10 ml ofN-methyl-N-propylamine were added thereto, and the mixture was stirred at 80°C for 14 hours. After cooling the reaction mixture, phase separation operation was carried out by adding water and EtOAc. The organic layer was washed with saturated brine and dried with anhydrous sodium sulfate, and then the crude product obtained by evaporating the solvent was subjected to a silica gel column chromatography, eluted with hexane-EtOAc (4:1) and concentrated under a reduced pressure to obtain 4.79 g of methyl 4-[methyl(propyl)amino]-2-(trifluoromethyl)benzoate.\n\nMS(+): 276\n\n\n \nReference Example 6\n\n\n \n \n \nA 4.78 g portion of the compound of Reference Example 5 was dissolved in 20 ml of MeOH, and 6.94 g of 5 M sodium hydroxide aqueous solution was added thereto and stirred at 70°C for 5 hours. The reaction mixture was cooled and then concentrated under a reduced pressure. The thus obtained residue was neutralized with 1 M hydrochloric acid aqueous solution, and the precipitated crystals were collected by filtration to obtain 4.36 g of 4-[methyl(propyl)amino]-2-(trifluoromethyl)benzoic acid.\n\nMS(+): 262.\n\n\n \nReference Example 7\n\n\n \n \n \nA 8.0 g portion of the compound of Reference Example 1 was dissolved in 80 ml of THF, 8 ml of thionyl chloride and 3 drops of DMF were added thereto under ice-cooling, and then this was stirred at room temperature for 3 hours. By evaporating the reaction solvent and then carrying out drying, an acid chloride compound was obtained. This was mixed with 6.84 g of (Z)-methyl (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetate, mixed with 50 ml of pyridine under ice-cooling and then stirred at room temperature for 12 hours. After completion of the reaction, the solvent was evaluated and separation of layers was carried out by adding 1 M hydrochloric acid aqueous solution and EtOAc. The organic layer was washed with water and saturated brine and dried with anhydrous sodium sulfate. The solvent was evaporated and the thus obtained residue was recrystallized from EtOH to obtain 9.12 g of methyl (2Z)-{1-[4-(benzyloxy)-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetate.\n\nEMS(+): 532\n\n\n \n \n \n \nIn the same manner as in Reference Example 7, the Reference Examples 8 to 11 shown in Table 5 were produced using respective corresponding materials.\n\n\n \n \n \n \nIn this connection, the sign in the table represents the following meaning (the same shall apply hereinafter).\n\nMe: methyl.\n\n \n(Table 5)\n \n \n \n \n \n \n \n \n \n \n \n \nRf\n \nR\nA\n \n \nR\nB\n \n \nData\n \n \n \n \n8\n \nCF\n3\n \n \ncPr-CH\n2\nO-\n \nEMS(+) :496\n \n \n \n9\n \nCl\n \nnPr-S-\n \nMS(+) : 466\n \n \n \n10\n \nCF\n3\n \n \nnPr-S-\n \nMS(+) : 500\n \n \n \n11\n \nCF\n3\n \n \nnPr-N(Me)-\n \nMS(+) : 497\n \n \n \n \n \n\n\n \nReference Example 12\n\n\n \n \n \nA 9.1 g portion of the compound of Reference Example 7 was dissolved in 100 ml of trifluoroacetic acid, and 5.1 g of pentamethylbenzene was added thereto and stirred at room temperature for 12 hours. The insoluble matter was filtered, and then the filtrate was concentrated under a reduced pressure. Diethyl ether was added to the thus obtained residue, and the precipitated crystals were collected by filtration to obtain 6.22 g of methyl (2Z)- {4,4-difluoro-1-[4-(benzyloxy)-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetate.\n\nEMS(+): 442\n\n\n \nReference Example 13\n\n\n \n \n \nA 3.89 g portion of the compound of Reference Example 12 was dissolved in 20 ml of DMSO, and 2.06 g of tert-butyl bromoacetate and 1.46 g of potassium carbonate were added thereto and stirred at room temperature for 2 hours. After filtration of the insoluble matter, separation of layers was carried out by adding water and EtOAc. The organic layer was washed with saturated brine and dried with anhydrous sodium sulfate. The solvent was evaporated and the thus obtained residue was subjected to a silica gel column chromatography to obtain 3.55 g of methyl (2Z)-{1-[4-(2-tert-butoxy-2-oxoethoxy)-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetate from chloroform-MeOH (80:1) eluate.\n\nEMS(+): 556\n\n\n \nReference Example 14\n\n\n \n \n \nA 3.75 g portion of the compound of Reference Example 13 was dissolved in 20 ml of trifluoroacetic acid and stirred at room temperature for 30 minutes. By evaporating the solvent under a reduced pressure, 3.25 g of [4-{[(5Z)-4,4-difluoro-5-(2-methoxy-2-oxoethylidene)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-(trifluoromethyl)phenoxy]acetic acid was obtained.\n\nMS(+): 450\n\n\n \nReference Example 15\n\n\n \n \n \nA 1.09 g portion of the compound of Reference Example 14 was dissolved in 10 ml of DMF, 324 mg of HOBt, 460 mg of WSCD, 1.20 ml of dimethylamine (2.0 M THF solution) and 0.335 ml of triethylamine were added thereto, and then this was stirred at room temperature for 6 hours. Sodium bicarbonate aqueous solution was added to the reaction liquid, the thus formed precipitate was collected by filtration, and the thus obtained crude product was washed with water and then dried under a reduced pressure to obtain 1.14 g of methyl (2Z)-{1-[4-(2-dimethylamino-2-oxoethoxy)-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetate.\n\nMS(+): 527\n\n\n \nReference Example 16\n\n\n \n \n \nA 1.00 g portion of the compound of Reference Example 12 was dissolved in 15 ml of THF, 0.415 ml of 1-butanol, 1.19 g of triphenylphosphine and 2.08 ml of diethyl azodicarboxylate were added thereto, and then this was stirred at room temperature for 17 hours. Water and EtOAc were added to the reaction mixture to carry out separation of layers. The organic layer was washed with water and saturated brine and dried with anhydrous magnesium sulfate. The solvent was evaporated and the thus obtained residue was subjected to a silica gel column chromatography, eluted with chloroform-MeOH (50:1) and then concentrated under a reduced pressure to obtain 1.41 g of crude methyl (22)-{1-[4-butoxy-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetate.\n\n\n \n \n \n \nThe compound obtained in the above was dissolved in 5 ml MeOH-10 ml THF, mixed with 1 M sodium hydroxide aqueous solution and then stirred at room temperature for 2 hours. After evaporation of the solvent, 1 M hydrochloric acid and chloroform-iPrOH (3:1 mixed solvent) was added thereto to carry out separation of layers. The organic layer was washed with saturated brine and dried with anhydrous sodium sulfate. By evaporating the solvent, 1.01 g of (2Z)-{1-[4-butoxy-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetic acid was obtained.\n\nMS(+): 484\n\n\n \n \n \n \nIn the sama manner as in Reference Example 16, the Reference Examples 17 to 19 shown in Table 6 were produced using respective corresponding materials.\n\n\n \n \n \n \nIn this connection, the sign in the table represents the following meaning (the same shall apply hereinafter).\n\niBu: isobutyl.\n\n \n(Table 6)\n \n \n \n \n \n \n \n \n \n \n \n \nRf\n \nR\nA\n \n \nR\nB\n \n \nData\n \n \n \n \n17\n \nCF\n3\n \n \nnPr-O-\n \nMS(+) : 470\n \n \n \n18\n \nCF\n3\n \n \niBu-O-\n \nMS(+) : 483\n \n \n \n19\n \nCl\n \niBu-O-\n \nMS(+) : 450\n \n \n \n \n \n\n\n \nReference Example 20\n\n\n \n \n \nA 1.43 g portion of the compound of Reference Example 7 was dissolved in a mixed solvent of 15 ml MeOH-25 ml THF, mixed with 1 M sodium hydroxide aqueous solution and stirred at room temperature for 2 hours. After evaporation of the solvent, the liquid property was changed to acidic by adding 1 M hydrochloric acid, and then the thus precipitated white solid was collected by filtration and dried under a reduced pressure to obtain 1.39 g of (2Z)-{1-[4-(benzyloxy)-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetic acid.\n\nMS(+): 518\n\n\n \n \n \n \nIn the sama manner as in Reference Example 20, the Reference Examples 21 to 25 shown in Table 7 were produced using respective corresponding materials.\n\n \n(Table 7)\n \n \n \n \n \n \n \n \n \n \n \n \nRf\n \nR\nA\n \n \nR\nB\n \n \nData\n \n \n \n \n21\n \nCF\n3\n \n \ncPr-CH\n2\nO-\n \nEMS(+) : 482\n \n \n \n22\n \nCl\n \nnPr-S-\n \nMS(+) : 452\n \n \n \n23\n \nCF\n3\n \n \nnPr-S-\n \nMS(+) : 486\n \n \n \n24\n \nCF\n3\n \n \nnPr-N(Me)-\n \nMS(+) : 483\n \n \n \n25\n \nCF\n3\n \n \nMe\n2\nNOCCH\n2\n-O-\n \nMS(+) : 513\n \n \n \n \n \n\n\n \nReference Example 26\n\n\n \n \n \nConcentrated sulfuric acid was added to MeOH solution of the compound of Reference Example 1, and heating under reflux was carried out for 3 days. The reaction mixture was poured into ice water to carry out extraction operation with ether. After evaporation of the solvent, the thus obtained residue was dissolved in EtOH, mixed with 10% palladium on carbon and, in an atmosphere of hydrogen, stirred at room temperature for 24 hours to obtain methyl 4-hydroxy-2-(trifluoromethyl)benzoate.\n\nMS(+): 221\n\n\n \nReference Example 27\n\n\n \n \n \nBromoacetone and potassium carbonate was added to acetonitrile solution of the compound of Reference Example 26 and stirred at 60°C for 1 hour to obtain methyl 4-(2-oxopropoxy)-2-(trifluoromethyl)benzoate.\n\nESI-MS(+): 299 [M+23]\n+\n.\n\n\n \nReference Example 28\n\n\n \n \n \n(Diethylamino)sulfur trifluoride was added at -78°C to methylene chloride solution of the compound of Reference Example 27, and stirred at room temperature for 24 hours to obtain methyl 4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoate.\n\nEI-MS: 298 [M]\n+\n \n\n\n \nReference Example 29\n\n\n \n \n \n5 M Sodium hydroxide aqueous solution was added to MeOH solution of the compound of Reference Example 28, and stirred at 90°C for 2.5 hours to obtain 4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoic acid.\n\nMS(-): 283\n\n\n \nReference Example 30\n\n\n \n \n \nTriethylamine was added to methylene chloride solution of (2S)-propane-1,2-diol, and then methylene chloride solution of p-toluenesulfonyl chloride was added thereto at -20°C and stirred at room temperature for 18 hours to obtain (2S)-2-hydroxypropyl-4-methylbenzene sulfonate.\n\nMS(+): 231\n\n\n \nReference Example 30A\n\n\n \n \n \nN,N-Dimethylaniline and acetic anhydride were added to THF solution of the compound of Reference Example 30 and stirred at 0°C for 1 hour to obtain (1S)-1-methyl-2-{[(4-methylphenyl)sulfonyl]oxy}ethyl acetate.\n\nMS(+): 273\n\n\n \nReference Example 30B\n\n\n \n \n \nThe compound of Reference Example 26 and potassium carbonate were added to DMF solution of the compound of Reference Example 30A and stirred at 70°C for 17 hours to obtain methyl 4-{[(2S)-2-(acetyloxy)propyl]oxy}-2-(trifluoromethyl)benzoate.\n\nMS(+):321\n\n\n \nReference Example 31\n\n\n \n \n \n1 M Potassium hydroxide-MeOH solution was added at 0°C to MeOH solution of the compound of Reference Example 30B and stirred at room temperature for 1 hour to obtain methyl 4-{[(2S)-2-hydroxypropyl]oxy}-2-(trifluoromethyl)benzoate.\n\nMS(+): 279\n\n\n \nReference Example 32\n\n\n \n \n \n(Diethylamino)sulfur trifluoride was added at -78°C to methylene chloride solution of the compound of Reference Example 31 and stirred at room temperature for 15 hours to obtain methyl 4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoate.\n\nFAB-MS(+): 280 [M]\n+\n \n\n\n \nReference Example 33\n\n\n \n \n \n5 M Sodium hydroxide aqueous solution was added to MeOH solution of the compound of Reference Example 32 and stirred at 70°C for 6 hours to obtain 4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoic acid.\n\nMS(+): 267\n\n\n \nReference Example 34\n\n\n \n \n \nSodium borohydride was added at 0°C to EtOH solution of the compound of Reference Example 27 and stirred at room temperature for 1 hour to obtain methyl 4-(2-hydroxypropoxy)-2-(trifluoromethyl)benzoate.\n\nESI-MS(+): 301 [M+23]\n+\n \n\n\n \nReference Example 35\n\n\n \n \n \nIn the same manner as in Reference Example 30, (2R)-2-hydroxypropyl-4-methylbenzene sulfonate was produced using (2R)-propane-1,2-diol.\n\nMS(+): 231\n\n\n \nReference Example 35A\n\n\n \n \n \nIn the same manner as in Reference Example 30A, (1R)-1-methyl-2-{[(4-methylphenyl)sulfonyl]oxy}ethyl acetate was produced using the compound of Reference Example 35.\n\nMS(+): 273\n\n\n \nReference Example 35B\n\n\n \n \n \nIn the same manner as in Reference Example 30B, methyl 4-{[(2R)-2-(acetyloxy)propyl]oxy}-2-(trifluoromethyl)benzoate was produced using the compound of Reference Example 35A.\n\nMS(+): 321\n\n\n \nReference Example 36\n\n\n \n \n \nIn the same manner as in Reference Example 31, methyl 4-{[(2R)-2-hydroxypropyl]oxy}-2-(trifluoromethyl)benzoate was produced using the compound of Reference Example 35B.\n\nMS(+): 279\n\n\n \nReference Example 37\n\n\n \n \n \nIn the same manner as in Reference Example 32, methyl 4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoate was produced using the compound of Reference Example 36.\n\nMS(+): 281\n\n\n \nReference Example 38\n\n\n \n \n \nIn the same manner as in Reference Example 33, 4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoic acid was produced using the compound of Reference Example 37.\n\nMS(+): 267\n\n\n \n \n \n \nIn the same manner as in Reference Example 7, the Reference Examples 39 to 41 shown in Table 8 were produced using respective corresponding materials.\n\n \n(Table 8)\n \n \n \n \n \n \n \n \n \n \n \n \nRf\n \nR\nB\n \n \nR\nD\n \n \nData\n \n \n \n \n39\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \nH\n \nEMS(+) : 502\n \n \n \n39A\n \n(R)-O-CH\n2\nCHFCH\n3\n H\n \nH\n \nEMS(+) : 502\n \n \n \n40\n \n(S)-O-CH\n2\nCHFCH\n3\n F MS(+) :\n \nF\n \nMS(+) : 520\n \n \n \n40A\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \nF\n \nMS(+) : 520\n \n \n \n41\n \n-O-CH\n2\nCF\n2\nCH\n3\n MS(+) :\n \nH\n \nMS(+) : 520\n \n \n \n \n \n\n\n \n \n \n \nIn the same manner as in Reference Example 20, the Reference Examples 42 to 46 shown in Table 9 were produced using respective corresponding materials.\n\n \n(Table 9)\n \n \n \n \n \n \n \n \n \n \n \n \nRf\n \nR\nB\n \n \nR\nD\n \n \nData\n \n \n \n \n42\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \nH\n \nMS(+) : 488\n \n \n \n43\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \nH\n \nMS(+) : 488\n \n \n \n44\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \nF\n \nMS(+) : 506\n \n \n \n45\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \nF\n \nMS(+) : 506\n \n \n \n46\n \n-O-CH\n2\nCF\n2\nCH\n3\n \n \nH\n \nMS(+) : 506\n \n \n \n \n \n\n\n \nExample 1\n\n\n \n \n \nA 150 mg portion of the compound of Reference Example 20 was dissolved in 5 ml of DMF, mixed with 43 mg of HOBt, 61 mg of WSCD, 35 mg of glycine amide hydrochloride and 0.045 ml of triethylamine, and then stirred at room temperature for 4 hours. Saturated sodium bicarbonate aqueous solution and EtOAc were added to the reaction mixture to carry out separation of layers. The organic layer was washed with water and saturated brine and dried with anhydrous magnesium sulfate. The solvent was evaporated, and the thus obtained residue was recrystallized from EtOH to obtain 139 mg of (2Z)-N-(2-amino-2-oxoethyl)-2-{1-[4-(benzyloxy)-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide.\n\n\n \n \n \n \nIn the same manner as in Example 1, the Examples 2 to 16 as shown in Table 10 were produced using respective corresponding materials.\n\n\n \nExample 17\n\n\n \n \n \nA 150 mg portion of the compound of Example 20 was dissolved in 3.5 ml of THF, mixed with 0.3 ml of thionyl chloride and 2 to 3 drops of DMF and stirred at room temperature for 1 hour. The solvent was evaporated under a reduced pressure, and thionyl chloride was further removed by azeotropic evaporation using toluene. The thus obtained residue was dissolved in THF, and this solution was added dropwise to aqueous ammonia. Separation of layers was carried out by adding EtOAc to the reaction mixture. The organic layer was washed with saturated brine and then dried with anhydrous magnesium sulfate. The thus obtained crude product was recrystallized from iPrOH-diisopropyl ether mixed solvent to obtain 126 mg of (2Z)-2-{1-[4-(benzyloxy)-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide.\n\n\n \n \n \n \nIn the same manner as in Example 17, the Example 18 as shown in Table 10 was produced using respective corresponding materials. Also, in the same manner as in Reference Example 12, the Examples 19 and 20 as shown in Table 10 were produced using respective corresponding materials.\n\n\n \nExample 21\n\n\n \n \n \nA 325 mg portion of the compound of Example 6 was dissolved in 5 ml of 1,2-dichloroethane, mixed with 148 mg of m-chlorobenzoic acid under ice-cooling, and stirred at room temperature for 4 hours. The reaction mixture was mixed with 10% (w/v) Na\n2\nS\n2\nO\n3\n·5H\n2\nO aqueous solution, water and chloroform to carry out separation of layers. The organic layer was washed with saturated sodium bicarbonate aqueous solution and dried with anhydrous sodium sulfate, the solvent was evaporated, and then the thus obtained crude product was subjected to a silica gel column chromatography, eluted with chloroform-MeOH (23:2) and concentrated under a reduced pressure to obtain 121 mg of (2Z)-N-(2-amino-2-oxoethyl)-2-{4,4-difluoro-1-[4-(propylsulfinyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene} acetamide.\n\n\n \n \n \n \nIn the same manner as in Example 21, the Example 22 as shown in Table 10 was produced using respective corresponding materials. Also, the Examples 23 to 147 as shown in Tables 11 to 18 were produced using respective corresponding materials, by the aforementioned production methods or the methods described in Examples, or methods obvious to those skilled in the art or modified methods thereof.\n\n\n \n \n \n \nIn this connection, signs in the tables represent the following meanings (the same shall apply hereinafter).\n\n\nEx: example number,\n\nR\nC\n: substituent group in the general formula,\n\nEt: ethyl, nBu: normal butyl, Ph: phenyl, Py: pyridyl, Bn: benzyl, Gly: carbamoylmethylamino (-NHCH\n2\nCONH\n2\n), Etha: 2-hydroxyethylamino (-NHCH\n2\nCH\n2\nOH), Car: amino (-NH\n2\n). In this connection, the numeral before each substituent group represents the substituting position. Illustratively, for example, - NHPh(2-OH) means 2-hydroxyphenylamino, and -NHCH\n2\n(2-Py) means pyridine-2-ylmethylamino.\n\n \n(Table 10)\n \n \n \n \n \n \n \n \n \n \n \n \nEx\n \nR\nA\n \n \nR\nB\n \n \nR\nC\n \n \nMS(+)\n \n \n \n \n1\n \n-CF\n3\n \n \nBn-O-\n \n-CH\n2\n-CONH\n2\n \n \n574\n \n \n \n2\n \n-CF\n3\n \n \nBn-O-\n \n-(CH\n2\n)\n2\n-OH\n \n561\n \n \n \n3\n \n-CF\n3\n \n \ncPr-CH\n2\nO-\n \n-CH\n2\nCONH\n2\n \n \n538\n \n \n \n4\n \n-CF\n3\n \n \ncPr-CH\n2\nO-\n \n-(CH\n2\n)\n2\n-OH\n \n525\n \n \n \n5\n \n-Cl\n \nnPr-S-\n \n-CH\n2\n-CONH\n2\n \n \n508\n \n \n \n6\n \n-CF\n3\n \n \nnPr-S-\n \n-CH\n2\n-CONH\n2\n \n \n542\n \n \n \n7\n \n-CF\n3\n \n \nnPr-O-\n \n-CH\n2\n-CONH\n2\n \n \n526\n \n \n \n8\n \n-CF\n3\n \n \nnPr-O-\n \n-(CH\n2\n)\n2\n-OH\n \n513\n \n \n \n9\n \n-CF\n3\n \n \nnBu-O-\n \n-CH\n2\n-CONH\n2\n \n \n540\n \n \n \n10\n \n-CF\n3\n \n \nnBu-O-\n \n-(CH\n2\n)\n2\n-OH\n \n527\n \n \n \n11\n \n-CP\n3\n \n \niBu-O-\n \n-CH\n2\n-CONH\n2\n \n \n540\n \n \n \n12\n \n-CF\n3\n \n \niBu-O-\n \n-(CH\n2\n)\n2\n-OH\n \n527\n \n \n \n13\n \n-Cl\n \niBu-O-\n \nCH\n2\n-CONH\n2\n \n \n506\n \n \n \n14\n \n-CF\n3\n \n \nnPr-N(Me)-\n \n-CH\n2\n-CONH\n2\n \n \n539\n \n \n \n15\n \n-CF\n3\n \n \nMe\n2\nNOCCH\n2\n-O-\n \n-CH\n2\n-CONH\n2\n \n \n569\n \n \n \n16\n \n-CF\n3\n \n \nnPr-O-\n \n-H\n \n469\n \n \n \n17\n \n-CF\n3\n \n \nBn-O-\n \n-H\n \n517\n \n \n \n18\n \n-CF\n3\n \n \nnPr-N(Me)-\n \n-H\n \n482\n \n \n \n19\n \n-CF\n3\n \n \nHO-\n \n-CH\n2\nCONH\n2\n \n \n484\n \n \n \n20\n \n-CF\n3\n \n \nHO-\n \n-H\n \n427\n \n \n \n21\n \n-CF\n3\n \n \nnPr-S(=O)-\n \nCH\n2\n-CONH\n2\n \n \n558\n \n \n \n22\n \n-CF\n3\n \n \nnPr-S(=O)\n2\n-\n \n-CH\n2\n-CONH\n2\n \n \n574\n \n \n \n \n\n\n \n(Table 11)\n \n \n \n \n \n \n \n \n \n \n \n \nEx\n \nR\nB\n \n \nR\nD\n \n \nMS(+)\n \n \n \n \n23\n \n-OnPr\n \nF\n \n544\n \n \n \n24\n \n-OnPr\n \nCl\n \n560\n \n \n \n25\n \n-OnPr\n \nBr\n \n604,606\n \n \n \n26\n \n-O-CH\n2\nC(CH\n3\n)=CH\n2\n \n \nH\n \n538\n \n \n \n27\n \n-O-(CH\n2\n)\n2\nCH\n2\nF\n \nH\n \n544\n \n \n \n28\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \nH\n \n544\n \n \n \n29\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \nH\n \n544\n \n \n \n30\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \nF\n \n562\n \n \n \n31\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \nF\n \n562\n \n \n \n32\n \nO-CH\n2\nCHFCH\n3\n \n \nH\n \n544\n \n \n \n33\n \nO-CH\n2\nCHCH\n3\n \n \nH\n \n562\n \n \n \n34\n \nO-CH\n2\nCHCH\n3\n \n \nF\n \n580\n \n \n \n35\n \n-N(Me)Et\n \nH\n \n525\n \n \n \n36\n \n-N(Et)nPr\n \nH\n \n553\n \n \n \n37\n \n-N(Me)nBu\n \nH\n \n553\n \n \n \n38\n \n-N(Me)iBu\n \nH\n \n553\n \n \n \n39\n \n-NnPr\n2\n \n \nH\n \n567\n \n \n \n40\n \n-SEt\n \nH\n \n528\n \n \n \n41\n \n-SiBu\n \nH\n \n556\n \n \n \n42\n \n-SCH=CH\n2\n \n \nH\n \n526\n \n \n \n43\n \n-SCH\n2\nCH\n2\nF\n \nH\n \n546\n \n \n \n44\n \n-S(CH\n2\n)\n2\nCH\n2\nF\n \nH\n \n560\n \n \n \n45\n \nSCH\n2\nCHFCH\n3\n \n \nH\n \n560\n \n \n \n \n\n\n \n(Table 12)\n \n \n \n \n \n \n \n \n \n \n \n \nEx\n \nR\nB\n \n \nR\nD\n \n \nMS(+)\n \n \n \n \n46\n \n-OnPr\n \nF\n \n531\n \n \n \n47\n \n-OnPr\n \nCl\n \n547\n \n \n \n48\n \n-OCH\n2\ncPr\n \nH\n \n525\n \n \n \n49\n \nO-(CH\n2\n)\n2\nCH\n2\nF\n \nH\n \n531\n \n \n \n50\n \nO-CH\n2\nCHFCH\n3\n \n \nH\n \n531\n \n \n \n51\n \nO-CH\n2\nCF\n2\nCH\n3\n \n \nH\n \n549\n \n \n \n52\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \nH\n \n531\n \n \n \n53\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \nH\n \n531\n \n \n \n54\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \nF\n \n549\n \n \n \n55\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \nF\n \n549\n \n \n \n56\n \nO-CH\n2\nCF\n2\nCH\n3\n \n \nF\n \n567\n \n \n \n57\n \n-N(Me)(CH\n2\n)\n2\nCH\n2\nF\n \nH\n \n544\n \n \n \n58\n \n-N(Et)nPr\n \nH\n \n540\n \n \n \n59\n \n-SCH=CH\n2\n \n \nH\n \n513\n \n \n \n60\n \n-SCH\n2\nCH\n2\nF\n \nH\n \n533\n \n \n \n61\n \n-S(CH\n2\n)\n2\nCH\n2\nF\n \nH\n \n547\n \n \n \n \n\n\n \n(Table 13)\n \n \n \n \n \n \n \n \n \n \n \n \nEx\n \nR\nB\n \n \nR\nD\n \n \nMS(+)\n \n \n \n \n62\n \n-OnPr\n \nF\n \n487\n \n \n \n63\n \n-OnPr\n \nCl\n \n503\n \n \n \n64\n \n-OnPr\n \nBr\n \n547,549\n \n \n \n65\n \nO-(CH\n2\n)\n2\nCH\n3\nF\n \nH\n \n487\n \n \n \n66\n \nO-CH\n2\nCHFCH\n3\n \n \nH\n \n487\n \n \n \n67\n \n-O-CH\n2\nCF\n2\nCH\n3\n \n \nH\n \n505\n \n \n \n68\n \n-O-CH\n2\nCF\n2\nCH\n3\n \n \nF\n \n523\n \n \n \n69\n \n(S)-O-CH\n2\nCF\n2\nCH\n3\n \n \nH\n \n487\n \n \n \n70\n \n(R)-O-CH\n2\nCHF\n2\nCH\n3\n \n \nH\n \n487\n \n \n \n71\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \nF\n \n505\n \n \n \n72\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \nF\n \n505\n \n \n \n73\n \n-N(Me)(CH\n2\n)\n2\nCH\n2\nF\n \nH\n \n500\n \n \n \n74\n \n-N(Me)CH\n2\nCF\n2\nCH\n3\n \n \nH\n \n518\n \n \n \n75\n \n-N(Et)nPr\n \nH\n \n496\n \n \n \n76\n \n-N(Et)(CH\n2\n)\n2\nCHF\n \nH\n \n514\n \n \n \n77\n \n-NnPr\n2\n \n \nH\n \n510\n \n \n \n \n\n\n \n(Table 14)\n \n \n \n \n \n \n \n \n \n \n \n \nEx\n \nR\nC\n \n \nR\nD\n \n \nMS(+)\n \n \n \n \n78\n \n-NH(CH\n2\n)\n2\nOMe\n \nH\n \n527\n \n \n \n79\n \n-NHC(Me)\n2\nCH\n2\nOH\n \nH\n \n541\n \n \n \n80\n \n-NH(CH\n2\n)\n2\nF\n \nH\n \n515\n \n \n \n81\n \n-NH(CH\n2\n)\n3\nOH\n \nH\n \n527\n \n \n \n82\n \n-NH(CH\n2\n)\n3\nF\n \nH\n \n529\n \n \n \n83\n \n-NHCH\n2\nCH(OH)CH\n2\nOH\n \nH\n \n543\n \n \n \n84\n \n-NHCH\n2\nCH(R-OH)CH\n2\nOH\n \nH\n \n543\n \n \n \n85\n \n-NHCH\n2\nCH(S-OH)CH\n2\nOH\n \nH\n \n543\n \n \n \n86\n \n-NHCH\n2\nCH(R-OH)CH\n2\nOH\n \nF\n \n561\n \n \n \n87\n \n-NH(CH\n2\n)\n2\nO(CH\n2\n)\n2\nOH\n \nH\n \n557\n \n \n \n88\n \n-NH(CH\n2\n)\n2\nNMe\n2\n \n \nH\n \n540\n \n \n \n89\n \n-NH(CH\n2\n)\n2\nCONH\n2\n \n \nH\n \n540\n \n \n \n90\n \n-NHCH(CONH\n2\n)\n2\n \n \nH\n \n569\n \n \n \n91\n \n-NHCH\n2\nCONHMe\n \nH\n \n540\n \n \n \n92\n \n-NHCH\n2\nCONMe\n2\n \n \nH\n \n554\n \n \n \n93\n \n-NH(CH\n2\n)\n2\nNHCOCH\n3\n \n \nH\n \n554\n \n \n \n94\n \n-N(CH\n2\nCH\n2\nOH)\n2\n \n \nH\n \n557\n \n \n \n95\n \n-N(CH\n2\nCONH\n2\n)\n2\n \n \nH\n \n583\n \n \n \n96\n \n-NHPh\n \nH\n \n545\n \n \n \n97\n \n-NHPh(2-OH)\n \nH\n \n561\n \n \n \n98\n \n-NHPh(3-OH)\n \nH\n \n561\n \n \n \n99\n \n-NHPh(4-OH)\n \nH\n \n561\n \n \n \n100\n \n-NHPh(2-CONH\n2\n)\n \nH\n \n588\n \n \n \n101\n \n-NHPh(3-CONH\n2\n)\n \nH\n \n588\n \n \n \n102\n \n-NHPh(4-CONH\n2\n)\n \nH\n \n588\n \n \n \n103\n \n-NHPh(3-SO\n2\nNH\n2\n)\n \nH\n \n624\n \n \n \n104\n \n-NHPh(4-SO\n2\nNH\n2\n)\n \nH\n \n624\n \n \n \n105\n \n-NHPh(3-NHCOMe)\n \nH\n \n602\n \n \n \n \n\n\n \n(Table 15)\n \n \n \n \n \n \n \n \n \n \n \n \nEx\n \nR\nC\n \n \nR\nD\n \n \nMS(+)\n \n \n \n \n106\n \n-NHCH\n2\nPh(3-OH)\n \nH\n \n575\n \n \n \n107\n \n-NHCH\n2\nPh(4-OH)\n \nH\n \n575\n \n \n \n108\n \n-HCH\n2\nPh(4-SO\n2\nNH\n2\n)\n \nH\n \n638\n \n \n \n109\n \n-NHCH\n2\n(2-Py)\n \nH\n \n560\n \n \n \n110\n \n \n \n \n \n \nH\n \n580\n \n \n \n111\n \n \n \n \n \n \nH\n \n596\n \n \n \n112\n \n \n \n \n \n \nH\n \n594\n \n \n \n113\n \n \n \n \n \n \nH\n \n610\n \n \n \n \n\n\n \n(Table 16)\n \n \n \n \n \n \n \n \n \n \n \n \nEx\n \nR\nC\n \n \nR\nD\n \n \nMS(+)\n \n \n \n \n114\n \n \n \n \n \n \nH\n \n539\n \n \n \n115\n \n \n \n \n \n \nH\n \n553\n \n \n \n116\n \n \n \n \n \n \nH\n \n580\n \n \n \n117\n \n \n \n \n \n \nH\n \n580\n \n \n \n118\n \n \n \n \n \n \nH\n \n555\n \n \n \n119\n \n \n \n \n \n \nH\n \n573\n \n \n \n120\n \n \n \n \n \n \nH\n \n567\n \n \n \n121\n \n \n \n \n \n \nH\n \n552\n \n \n \n122\n \n \n \n \n \n \nH\n \n539\n \n \n \n \n\n\n \n(Table 17)\n \n \n \n \n \n \n \n \n \n \n \n \nEx\n \nR\nB\n \n \nR\nC\n \n \nR\nD\n \n \nMS(+)\n \n \n \n \n123\n \n-O(CH\n2\n)\n2\nCH\n2\nF\n \n-NHCH\n2\nCH(R-OH)CH\n2\nOH\n \nH\n \n561\n \n \n \n124\n \n-O(CH\n2\n)\n2\nCH\n2\nF\n \n-NHCH\n2\nCH(S-OH)CH\n2\nOH\n \nH\n \n561\n \n \n \n125\n \n-O(CH\n2\n)\n2\nCH\n2\nF\n \n-NH(CH\n2\n)\n2\nCOH\n2\n \n \nH\n \n558\n \n \n \n126\n \n-O(CH\n2\n)\n2\nCH\n2\nF\n \n \n \n \n \n \nH\n \n628\n \n \n \n127\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \n-NH(CH\n2\n)\n2\nCONH\n2\n \n \nH\n \n558\n \n \n \n128\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \n-NH(CH\n2\n)\n2\nCHONH\n2\n \n \nH\n \n558\n \n \n \n129\n \n(S)O-CH\n2\nCHFCH\n3\n \n \n-NHCH\n2\nCH(S-OH)CH\n2\nOH\n \nH\n \n561\n \n \n \n130\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \n-NHCH\n2\nCH(S-OH)CH\n2\nOH\n \nH\n \n561\n \n \n \n131\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \n-NHCH\n2\nCH(R-OH)CH\n2\nOH\n \nH\n \n561\n \n \n \n132\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \n-NHCH\n2\nCH(R-OH)CH\n2\nOH\n \nH\n \n561\n \n \n \n133\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \n-NH(CH\n2\n)CONH\n2\n \n \nF\n \n576\n \n \n \n134\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \n-NH(CH\n2\n)\n2\nCONH\n2\n \n \nF\n \n576\n \n \n \n135\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \nNHCH\n2\nCH(R-OH)CH\n2\nOH\n \nF\n \n579\n \n \n \n136\n \n(R)-O-CH\n2\nCHFCH\n3\n \n \n-NHCH\n2\nCH(R-OH)CHOH\n \nF\n \n579\n \n \n \n137\n \n-O-CH\n2\nCF\n2\nCH\n3\n \n \n-NHCH\n2\nCH(R-OH)CH\n2\nOH\n \nH\n \n579\n \n \n \n138\n \n-O-CH\n2\nCF\n2\nCH\n3\n \n \n-NHCH\n2\nCH(S-OH)CH\n2\nOH\n \nH\n \n579\n \n \n \n139\n \n-O-CH\n2\nCF\n2\nCH\n3\n \n \n-NH(CH\n2\n)\n2\nCONH\n2\n \n \nH\n \n576\n \n \n \n140\n \n-O-CH\n2\nCF\n2\nCH\n3\n \n \n-NH(CH\n2\n)\n2\nCONH\n2\n \n \nF\n \n594\n \n \n \n141\n \n-O-CH\n2\nCF\n2\nCH\n3\n \n \n-NHCH\n2\nCH(S-OH)CH\n2\nOH\n \nF\n \n597\n \n \n \n142\n \n-O-CH\n2\nCF\n2\nCH\n3\n \n \n-NHCH\n2\nCH(R-OH)CH\n2\nOH\n \nF\n \n597\n \n \n \n143\n \n-SEt\n \n-NH(CH\n2\n)\n2\nCONH\n2\n \n \nH\n \n542\n \n \n \n144\n \n-SEt\n \n-NHCH(CONH\n2\n)\n2\n \n \nH\n \n571\n \n \n \n145\n \n-SEt\n \n-NHPh(3-CONH\n2\n)\n \nH\n \n590\n \n \n \n \n\n\n \n(Table 18)\n \n \n \n \n \n \n \n \n \n \n \n \nEx\n \nR\n1A\n \n \nMS(+)\n \n \n \n \n146\n \nGly\n \n493\n \n \n \n147\n \nCar\n \n436\n \n \n \n \n \n\n\n \n \n \n \nIn the following, NMR data of some Example compounds are shown in Table\n\n \n(Table 19)\n \n \n \nEx\n \nNMR\n \n \n \n \n1\n \n235-255(1H,br),2.60-2.80(1H,br),3.00-3.15(1H,br),3.76(2H,s),4.75-4.90(1H,br),5.09(2H,s),6.45(1H,s),6.73(1H,d,\nJ\n=7.8Hz),6.87(1H,d,\nJ\n=7.8Hz),7.03(1H,dd,\nJ\n=7.8, 4 Hz),7.1 0-7.19(2H,m),7.24-7.40(9H, m),8.68(1H,t,\nJ\n=5.7Hz).\n \n \n \n2\n \n2.55-255(1H,br),2.60-280(1H,br),3.20-3.25(2H,m),3.42-350(2H,m),4.72(1H,t,\nJ\n=5.4Hz),4.75-490(1H,br),5.09(2H,s),6.39(1H,s),6.72(1H,d,\nJ\n=7.8Hz),6.87(1H,d,\nJ\n=73Hz),7.04(1H,d,\nJ\n=2.0,8.3Hz),7.1 6(1H,t,\nJ\n=7.6Hz),7.22-7.42(8H,m),8.46(1H,t,\nJ\n=5.4Hz).\n \n \n \n3\n \n024-0.30(2H,m),0.49-0.58(2H,m),1.08-120(1H,m),2.33-245(1H,br),260-297(1H,br),3.02-3.29(1H,br),3.68-3.88(4H,m),4.60-5.05(1H,br),6.44(1H,s),6.71(1H,d,J=8.8Hz),6.85(1H,d,J=8.8Hz),693(1HH,dd,J=2.0,8.8Hz),7.11-738(6H,m),8.48(1H,t,J=5.4Hz).\n \n \n \n4\n \n0.24-031(2H,m),0.48-0.56(2H,m),1.09-1.21(1H,m),2.27-2.46(1H,br),2.65-2.90(1H,br),3.00-3.26(3H,m),3.43-3.52(2H,m),3.80(2H,d,J=6.8Hz),4.73(1H,d,J=53Hz),4.75-4.92(1H,br),639(1H,s),6.71(1H,d,J=73Hz).6.84(1H,d, J=8.8Hz),6.93(1H,dd,J=25,8.8Hz),7.13-7.18(2H,m),724(1H,t,J=7.3Hz)730-734(1H,m),8.48(1H,t,J=53Hz).\n \n \n \n5\n \n0.92(3H,t,J=7.6Hz),1.46-1.55(2H,m),2.24-2.50(1H,br),2.65-2.84(1H,br),2.89-2.93(2H,m),3.04-322(1H,br),3.75(2H,s),4.70-4.92(1H,br),637(1H,s),6.87(1H,s),6.94(1H,d,J=7.6Hz),7.01(1H,d,J=8.0Hz),7.14-7.53(6H,m),8.62(1H,s).\n \n \n \n6\n \n0.93(3H,t,J=7.2Hz),1.48-1.57(2H,m),2.28-2.52(1H,br),2.63-2.87(1H,br),2.94-2.97(2H,m),3.08-3.20(1H,br),3.73-3.76(2H,m),4.73-4.88(1H,br),6.48(1H,s),6.73(1H,d,J=8.0Hz),6.84(1H,d,J=8.0Hz),7.14-7.76(7H,m),8.69(1H,t,J=52Hz).\n \n \n \n7\n \n0.92(3H,t,J=3Hz),1.62-1.72(2H,m),2.30-250(1H,br),2.60-2.80(1H,br),3.00-3.10(1H,br),3.76(2H,s),3.90(2H,t,J=6.6Hz),4.70-4.90(1H,br),6.45(1H,s),6.72(1H,d,\nJ\n=7.8Hz),6.85(1H,d,\nJ\n=7.8Hz),6.85(1H,dd,\nJ\n=2.1,7.6Hz),7.10-738(6H,m),8.68(1H,t,\nJ\n=5.4Hz).\n \n \n \n8\n \n0.92(3H,t,\nJ\n=7.3Hz),1.62-1.72(2H,m),2.30-2.50(1H,br),2.60-2.80(1H,br),300-3.20(1H,br),3.23(2H,t,\nJ\n=59Hz),3.44-350(2H,m),3.90(2H,t,\nJ\n=6.6Hz),4.72(1H,t,\nJ\n=5.4Hz),4.75-4.86(1H,br),6.40(1H,s),6.71(1H,d,\nJ\n=7.8Hz),6.85(1H,d,\nJ\n=8.3Hz),6.95(1H,dd,\nJ\n=2.5,8.8Hz),7.10-7.18(2H,m),725(1H,t,\nJ\n=7.1Hz),730-734(1Hm),8.46(1H,t,\nJ\n=5.6Hz).\n \n \n \n \n \n0.89(3H,t,\nJ\n=7.3Hz),1.31-1.42(2H,m),1.57-1.67(2H,m),2.30-2.50(1H,br),3.70-285(1H,br),3.00-9 3.20(1H,br),3.76(2H,s),3.94(1H,t,\nJ\n=6.6Hz),4.65-4.95(1H,br),6.45(1H,s),6.72(1H,d,\nJ\n=7.8Hz),6.85(1H,d,\nJ\n=8.8Hz),6.94(1H,dd,\nJ\n=2.4,8.8Hz),7.10-7.20(3H,m),7.22-7.32(1H,m),7.33-7.37(1H,m),8.68(1H,t,\nJ\n=53Hz).\n \n \n \n10\n \n0.89(3H,t,\nJ\n=7.4Hz),1.32-1.42(2H,m),1.58-1.67(2H,m),2.25-2.45(1H,br),2.60-2.80(1H,br),3.00-3.15(1H,br),3.20-3.30(2H,m),3.44-350(2H,m),3.94(2H,t,\nJ\n=6.4Hz),4.73(1H,t,\nJ\n=5.2Hz),4.75-4.87(1H,br),6.39(1H,s),6.71(1H,d,\nJ\n=7.8Hz),6.84(1H,d,\nJ\n=8.8Hz),6.95(1H,dd,\nJ\n=2.5,8.8Hz),7.12-7.18(2H,m),7.21-7.26(1H,m),7.30-7.33(1H,m),8.46(1H,t,\nJ\n=5.6Hz).\n \n \n \n11\n \n0.92(6H,d,\nJ\n=6.8Hz),1.89-2.00(1H,m),2.30-2.50(1H,br),2.60-2.80(1H,br),3.00-3.20(1H,br),3.70-3.82(4H,m),4.75-4.85(1H,br),6.45(1H,s),6.72(1H,d,\nJ\n=7.9Hz),6.86(1H,d,\nJ\n=8.8Hz),695(1H,dd,\nJ\n=2.4,8.3Hz),7.12-7.19(3H,m),723-730(2H,m),736(1H,dd,\nJ\n=7.8Hz,1.5Hz),8.68(1H,t,\nJ\n=5.6Hz).\n \n \n \n12\n \n0.92(6H,d,\nJ\n=6.4Hz),1.89-2.00(1H,m),2.30-2.50(1H,br),260-280(1H,br),3.00.3-15(1H,br),3.19-3.25(2H,m),3.44-3.50(2H,m),3.72(2H,d,\nJ\n=63Hz),4.73(1H,t,\nJ\n=51Hz),4.76-4.88(1H,br),6.40(1H,s),6.71(1H,d,\nJ\n=73Hz),6.85(1H,d,\nJ\n=8.8Hz),6.96(1H,dd,\nJ\n=25,83Hz),7.13-7.18(2H,m),7.22-7.27(1H,m),7.32(1H,dd,\nJ\n=7.8Hz,5Hz),8.46(1H,\nJ\n=5.6Hz).\n \n \n \n13\n \n0.91(6H,d,J=6.8Hz),1.86-1.98(1H,m),2.25-2.50(1H,br),2.60-2.80(1H,br),3.00 3.15(1H,br),3.67(2H,d,J=6.3Hz),3.70-3.78(2H,Br),4.73-4.90(1H,Br),635(1H,s),6.63-6.69(1H,m),6.89-6.96(3H,m),7.11-720(2H,m),7.22-7.33(3H,m),8.62(1H,s)\n \n \n \n14\n \n0.80(2H,t,J=7.2Hz),1.40-1.45(2H,m),2.27-25.3(1H,br),2.53-2.77(1H,br),2.55-2.77(3H,s),2.92-3.15(1H,br),3.24(2H,s),3.7S(2H,s),4.71-5.05(1H,br),6.44(1H,s),6.58(1H,d,J=8.4Hz),6.67(1H,d,J=8.4Hz),6.71(1H,d,J=7.6Hz),6.77(1H,s),7.14-7.36(5H,m),8.64(1H,s).\n \n \n \n15\n \n2.30(1H,br),2.65-285(1H,br),2.80(3H,s).2.92(3H,s),3.00-3.20(1H,br),3.70-3.82(2H,m),4.75-4.90(1H,br),4.86(2H,s),6.44(1H,s),6.73(1H,d,\nJ\n=7.8Hz),6.83(1H,d,\nJ\n=83Hz),6.90(1H,dd,\nJ\n=2.4,8.33Hz),7.1 1-7.20(3H,m),7.24-730(2H,m),7.36(1H,dd,\nJ\n=7.3Hz,1.4Hz),8.68(1H,t,\nJ\n=5.7Hz).\n \n \n \n16\n \n0.92(3H,t,\nJ\n=7.8Hz),1.61-1.71(2H,m),2.35-2.55(1H,br),2.60-280(1H,br),3.00-3.20(1H,br),3.90(2H,t,\nJ\n=6.4Hz),4.70-4.90(1H,br),6.38(1H,s),6.72(1H,d,\nJ\n=7.8Hz),6.84(1H,d,\nJ\n=8.7Hz),6.96(1H,dd,\nJ\n=2.5,8.6Hz),7.10-7.18(2H,m),7.22-7.27(1H,m),7.28-7.31(1H,m),7.35(1H,s),7.87(1H,s).\n \n \n \n17\n \n2.30-2.55(1H,br),2.60-2.80(1H,br),3.05-3.25(1H,br),4.75-4.95(1H,br),5.09(2H,s),638(1H,s),6.73(1H,d,\nJ\n=7.8Hz),6.86(1H,d,\nJ\n=8.7Hz),7.05(1H,dd,\nJ\n=2.4,8.4Hz),7.1 3-7.18(1H,m),7.22-7.42(9H,m),7.88(1H,s).\n \n \n \n18\n \n0.81(3H,t,J=7.2Hz),1.40-1.46(2H,m),2.24-2.52(1H,br),2.57-2.78(1H,r),2.85(3H,s),2.95-3.17(1H,br),3.23(2H,s),4.70-5.02(1H,br).6.36(1H,s),6.62-6.76(4H,m),7.16-7.34(4H,m),7.84(1H,s)\n \n \n \n19\n \n2.30-2.50(1H,br),2.55-2.80(1H,br),3.00-3.20(H,br),3.75(2H,s),4.70-4.90(1H,br),6.47(1H,s),6.66-6.76(3H,m),7.00(1H,d,\nJ\n=1.5Hz),7.10-7.19(1H,m),7.22-7.30(2H,m),7.35(1H,d,\nJ\n=7.8Hz),8.65(1H,t,\nJ\n=5.6Hz),10.3(1H,s).\n \n \n \n20\n \n2.30-2.50(1H,br),2.55-2.80(1H,br),3.00-3.20(1H,br),4.70-4.90(1H,br),6.41(1H,s),6.67-6.74(3H,m),7.00(1H,s),7.15(1H,td,J=1.4,7.8Hz),7.24(1H,t,J=7.6Hz),7.27-732(1H,m),7.34(1H,s),7.85(1H,s),1.03(1H,s).\n \n \n \n21\n \n0.87(1H,t,J=7.2Hz),1.19-1.27(1H,m),1.45-1.58(1H,m),2.18-252(1H,br),2.65-278(1H,br),2.93-3.00(2H,m),3.06-3.25(1H,br),3.74-3.76(2H,m),4.75-4.92(1H,br),6.55(1H,s),6.73(1H,d,J=7.6Hz),7.12-7.15(1H,m),7.24-7.33(2H,m),7.36(1H,dd,J=1.6,7.2Hz),7.71(1H,d,J=8.0Hz),7.98(1H,s),8.70(1H,s)-\n \n \n \n22\n \n0.84(3H,t,J=7.6Hz),1.38-1.47(2H,m),2.15-2.54(1H,br),2.67-2.90(1H,br),3.15-3.30(1H,br),3.34-3.52(2H,m),3.75-3.77(2H,m),4.75-4.90(1H,br),6.61(1H,s),6.74(1H,d,J=8.0Hz),7.13-7.17(3H,m),7.26-7.39(2H,m),7.37-7.39(1H,m),7.97(1H,d,J=8.4Hz),8.16(1H,s),8.71(1H,s).\n \n \n \n30\n \n132(3H,dd,J=6.4,29 2Hz),2.31-2.43(1H,br),2.60-2.80(1H,br),3.18-3.27(1H,br),3.20-3.34(2H,m),4.00-437(2H,m),4.64-5.10(2H,m),6.56(1H,s),6.73-6.80(1H,m),6.87(1H,d,J=8.8Hz),7.02-7.08(2H,m),7.14(1H,s),7.24-7.26(2H,m),7.32(1H,s),8.64-8.64(1H,br).\n \n \n \n31\n \n1.33(3H,dd,J=6.3,29.3Hz),2.33-2.47(1H,br),2.59-2.83(1H,br),3.03-3.25(1H,br),3.72-3.85(2H,m),4.02-4.24(2H,m),4.72-4.84(1H,br),4.86-5.07(1H,m),6.56(1H,s),6.74-6.80(1H,m),6.88(1H,d, J=8.8Hz),7.00-7.08(2H,m),7.14(1H,s),7.21-7.26(2H,m),7.32(1H,s),8.65(1H,t,J=5.4Hz)-\n \n \n \n51\n \n1.67(3H,t,J=19.5Hz),2.30-2.48(1H,br),2.46-2.90(1H,br),3.08-3.34(3H,m),3.39-4.00(2H,m),4.32(2H,t,J=12.7Hz),4.70-4.78(2H,m),638(1H,s),6.71(1H,d,J=7.8Hz),6.89(1H,d,J=8.8Hz),7.04(1H,dd,J=2.4,8.8Hz),7.15(1H,d,t, J=1. 5,7.8Hz),7.22-7.34(3H,m),8.47(1H,t,J=5.3Hz).\n \n \n \n52\n \n132(3H,dd,J=6.4,23.5Hz),2.36-2.47(1H,br),2.65-2.76(1H,br),3.18-3.30(3H,m);3.43-3.49(2H,m),4.00-4.20(2H,m),4.68-5.06(3H,m),6.39(1H,s),6.72(1H,d,J=8.8Hz),6.87(1H,d,J=8.8Hz),6.98(1H,dd,J=2.4,8.8Hz),7.15(1H,dt,J=1. 4,8.8Hz),7.21-7.27(2H,m),7.32(1H,dd,J=1.4,8.8Hz),8.46(1H,t,J=5.8Hz).\n \n \n \n53\n \n1.32(3H,dd,J=6.8.23.9Hz),2.37-2.46(1H,br),2.65-2.83(1H,br),3.19-3.28(3H,m),3.44-350(2H,m),4.00-4.20(2H,m),4.69-5.05(3H,m),6.39(1H,s),6.73(1H,d,J=8.8Hz),6.87(1H,d,J=8.8Hz),6.99(1H,dd,J=2.4,8.8Hz),7.15(1H,dt,J=1. 4,8.8Hz),7.21-7.27(2H,m),7.32(1H,dd,J=1.4,8.8Hz),8.46(1H,t,J=5.4Hz).\n \n \n \n54\n \n1.33(3H,dd,J=5.9,29.8Hz),2.31-2.46(1H,br),2.61-2.84(1H,br),3.18-3.26(2H,m),3.44-3.50(2H,m)4.01-4.22(2H,m),4.74(1H,t,J=53Hz),4.76-4.85(1H,br),4.96-5.06(1H,m),6.51(1H,s),6.70-6.77(1H,m),6.86(1H,d,J=8.8Hz),7.01-7.08(1H,m),7.19(2H,dd,J=2.9,8.8Hz),7.25(1H,d,J=2.9Hz),7.66(1H,d,J=8.8Hz),8.46(1H,t,J=5.9Hz).\n \n \n \n55\n \n1.32(3H,dd,J=5.9,29.8Hz),2.32-246(1H,br),261-284(1H,br),3.03-327(2H,m),3.44-3.51(2H,m),4.02-4.22(2H,m),4.74(1H,t,J=5.3Hz),4.76-4.85(1H,br),4.87-5.06(1H,m),6.52(1H,s),6.70-6.78(1H,m),6.87(1H,d,J=8.8Hz),7.00-7.08(1H,m),7.19(2H,dd,J=2.9,8.8Hz),7.24(1H,d,J=2.9Hz),7.67(1H,d,J=8.8Hz),8.47(1H,t,J=5.4Hz).\n \n \n \n56\n \n1.69(3H,t,J=19.6Hz),2.31-2.46(1H,br),2.61-2.83(1H,br),3.05-3.27(3H,m),3.43-3.50(2H,m),4.34(2H,t,J=12.7Hz),4.68-4.86(2H,m),6.50(1H,s),6.73-6.78(1H,m),6.89(1H,d,J=8.8Hz),7.01-7.13(2H,m),7.20(1H,dd,J=2.9,8.8Hz),7.31(1H,d,J=29Hz),8.43(1H,t,J=5.4Hz).\n \n \n \n84\n \n0.97(3H,t,J=7.3Hz),1.61-1.72(2H,m),2.31-2.47(1H,br),2.65-2.81(1H,br),2.99-3.17(3H,m),3.32-3.40(2H,m),352-3.61(1H,m),3.90(2H,t,J=7.3Hz),4.54(1H,t,J=5.9Hz),4.75-4.87(2H,m),6.40(1H,s),6.71(1H,d,J=8.8Hz),6.85(1H,d,J=8.8Hz),6.95(1H,dd,J=2.5,8.8Hz),7.12-7.19(2H,m),7.24(1H,t,J=8.8Hz),7.34(1H,dd,J=1.4,8.8Hz),8.45(1H,t,J=5.4Hz).\n \n \n \n85\n \n0.98(3H,t,J=7.3Hz),1.61-1.71(2H,m),2.30-2.46(1H,br),2.65-2.80(1H,br),2.99-3.20(1H,m),3.32-3.39(2H,m),3.51-3.62(1H,m),3.90(2H,t,J=7.3Hz),4.54(1H,t,J=5.9Hz),4.76-4.90(2H,m),6.40(1H,s),6.71(1H,d,J=8.8Hz),6.86(1H,d,J=8.8Hz),6.94(1H,dd,J=2.5,8.8Hz),7.12-7.19(2H,m),7.24(1H,t,J=8.8Hz),7.34(1H,dd,J=1.4,8.8Hz),8.45(1H,t,J=5.4Hz).\n \n \n \n86\n \n0.93(3H,t,J=6.8Hz),1.61-1.72(2H,m),2.31-246(1H,br),2.61-2.83(1H,br),3.00-3.21(3H,m),3.31-3.39(2H,m),3.52-3.63(1H,m),3.92(2H,t,J=6.8Hz),4.56(1H,t,J=5.9Hz),4.52-4.86(2H,m),6.53(1H,s),6.71-6.77(1H,m),6.85(1H,8Hz),6.99(1H,dd,J=2.0.8.sHz),7.04(1H,dt,J=2.0,8.8Hz),7.17(1H,d,J=2.0Hz),7. 21(1H,dd,J=2.0,8.8Hz),8.42(1H,t,J=53Hz).\n \n \n \n129\n \n1.32(3H,dd,J=6.3,23.4Hz),2.34-2.46(1H,br),2.25-283(1H,br),3.20-332(3H,m),3.35-3.40(2H,m),3.52-3.60(1H,m),4.00-4.20(2H,m),4.50(1H,m),4.73. 5.05(3H,m),6.39(1H,s),6.72(1H,d,J=8.8Hz),6.67(1H,d,J=8.8Hz),6.9(1H,d,J=2.5,8.8Hz),7.15(1H,dt,J=2. 5,8.8Hz),7.19-7-27(2H,m),734(1H,dd,J=1.4,8.8Hz).47(1H,t,J=5.4Hz).\n \n \n \n130\n \n1.31(3H,dd,J=6.3,23.4Hz),2.26-2.47(1H,br),2.62-2.47(1H,br),3.00-3.23(3H,m),3.32-3.38(2H,m),3.53-3.62(1H,m),4.00-4.20(2H,m),4.45(1H,t,J=5.4Hz),4.76-5.05(3H,m),6.40(1H,s),6.72(1H,d,J=7.8Hz),6.88(1H,d,J=8.8Hz),6.99(1H,dd,J=2.5,8.8Hz),7.15(1H,dt,J=1. 4,7.8Hz),720-7.28(2H,m),7.34(1H,dd,J=1.4,7.8Hz),8.47(1H,t,J=5.9Hz).\n \n \n \n132\n \n1.31(3H,dd,J=6.4,23.4Hz),2.30-2.46(1H,br),2.54-2.80(1H,br),3.00-3.32(3H,m),3.34-3.40(2H,m),3.52-3.61(1H,m),4.00-4.20(2H,m),4.51-4.6(1H,m),4.72-5.05(3H,m),6.40(1H,s),6.12(1H,d,J=8.8Hz),6.87(1H,d,J=8.8Hz),6.99(1H,dd,J=2.5,8.8Hz),7.15(1H,dd,J=2 .5,8.8Hz),7.19-7.29(2H,m),731-7.36(1H,m),8.46(1H,t,J=5.4Hz)\n \n \n \n133\n \n(3H,dd,J=6.3,23.9Hz),2.27-246(3H,m),2.60-2.84(1H,br),3.22-3.34(1H,br),3.34-3.402(H,m),4.00-4.22(2H,m),4.70-5.06(2H,m),6.44(1H,s),6.71-6.76(1H,m),6.81-6.89(2H,m),7.01-7.07(2H,m),7.19(1H,dd,J=2.9,8.8Hz),7.24(1Hz),7.33-7.38(1H,br),8.45-8.52(1H,br).\n \n \n \n134\n \n1.33(3H,dd,J=6.4,29.8Hz),2.26-246(3H,m),264-287(1H,br),3.00-3.23(1H,br),3.27-3.42(2H,m),4.01-4.22(2H,m),4.66-5.07(2H,m),6.49(1H,s),6.71-6.78(1H,m),6.87(2H,d,J=8.8Hz),7.00-7.08(2H,m),7.19(1H,dd,J=2.9,8.8Hz),724(1H,d,J=2.9),733-7.39(1H,br),8.50(1H,t,J=5.4Hz).\n \n \n \n135\n \n1.32(3H,dd,J=6.3,23.9Hz),2.32-246(1H,br),2.63-2.84(1H,br),3.00-3.24(3H,m),3.33-3.40(2H,m),3.52-3.61(1H,m),4.01-4.21(2H,m),4.57(1H,t,J=53Hz),4.73-5.06(3H,m),6.52(1H,s),6.72-6.78(1H,m),6.87(1H,d,J=8.8Hz),7.00-7.08(2H,m),7.18-7.26(2H,m),8.38-8.48(1H,m)-\n \n \n \n136\n \n1.33(3H,dd,J=6.3,1.3.4Hz),2.34-247(1H,br),2.56-282(1H,br),3.01-332(3H,m),3.33-3.39(2H.m),3.52-3.61(1H,m),4.02-4.22(2H,m),4.57(1H,t,J=5.4Hz),4.75-4.85(2H,m),4.87-5.07(1H,m),6.51(1H,s),6.71-6.77(1H,m),6.87(1H,d,J=83Hz),7.01-7.08(2H,m),7.19-7.25(2H,m),8.43(1H,t,J=5.4Hz).\n \n \n \n140\n \n1.69(3H,t,J=19Hz),2.26-2.47(3H,m),2.62-2.83(1H,br)3.05-3.22(1H,br),3.25-3.44(2H,m),4.34(2H,t,J=12.4Hz),4.68-4.92(1H,br),6.48(1H,s),6.72-6.77(1H,m),6.83-6.95(2H,m),7.01-7.13(2H,m),7.19(1H,dd,J=29,8.8Hz),7.30(1H,d,J=2.9Hz),7.34-7.40(1H,br),8.50(1H,t,J=5.3Hz).\n \n \n \n \n \n\n\n \n \n \n \nIn the following, structures of other compounds of the invention are shown in Tables 20 to 36. These are synthesized or can be synthesized by using the aforementioned production methods or the methods described in Examples, or methods obvious to those skilled in the art or modified methods thereof.\n\n\n \n \n \n \nIn this connection, signs in the tables represent the following meanings.\n\n \n \n \nNo: compound number.\n \nR\n1A\n, -A\nA\n-B\nA\n, X, Y: substituent groups in respective general formulae, iPr: isopropyl, tBu: tert-butyl, cBu: cyclobutyl, nPen: normal pentyl, cPen: cyclopentyl, iAm: isoamyl, nHex: normal hexyl, pyrr: pyrrolidin-1-yl, pipe: piperidin-1-yl, pipa: piperazin-1-yl, mor: morpholin-4-yl, Ac: acetyl, Ms: methanesulfonyl, cyano: cyano.\n \n\n\n \n(Table 20)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \n-A\nA\n-B\nA\n \n \nNo\n \nR\n1A\n \n \nA\nA\n-B\nA\n \n \n \n \n \nAl\n \nGly\n \n-O-Me\n \nA30\n \nCar\n \n-O-(CH\n2\n)\n2\n-cyano\n \n \n \nA2\n \nGly\n \n-O-Et\n \nA31\n \nEtha\n \n-O-CH\n2\nCH(Me)OMe\n \n \n \nA3\n \nEtha\n \n-O-Et\n \nA32\n \nEtha\n \n-O-CH\n2\nCH(Me)OMe\n \n \n \nA4\n \nCar\n \n-O-Et\n \nA33\n \nCar\n \n-O-CH\n2\nCH(Me)OMe\n \n \n \nA5\n \nEtha\n \n-O-iPr\n \nA34\n \nEtha\n \n-O-CH\n2\nCF\n2\nCF\n3\n \n \n \n \nA6\n \nCar\n \n-O-nBu\n \nA35\n \nCar\n \n-O-CH\n2\nCF\n2\nCF\n3\n \n \n \n \nA7\n \nCar\n \n-O-iBu\n \nA36\n \nEtha\n \n-O-CH\n2\nCF\n2\nCF\n2\n \n \n \n \nA8\n \nGly\n \n-O-tBu\n \nA37\n \nCar\n \n-O-CH\n2\nCF\n2\nCF\n2\n \n \n \n \nA9\n \nGly\n \n-O-iAm\n \nA38\n \nGly\n \n-O-(CH\n2\n)\n2\nOH\n \n \n \nA10\n \nGly\n \n-O-nPen\n \nA39\n \nEtha\n \n-O-(CH\n2\n)\n2\nOH\n \n \n \nA11\n \nEtha\n \n-O-nHex\n \nA40\n \nCar\n \n-O-(CH\n2\n)\n2\nOH\n \n \n \nA12\n \nGly\n \n-O-cPen\n \nA41\n \nGly\n \n-O-CH\n2\nCO\n2\nH\n \n \n \nA13\n \nGly\n \n-O-Ph\n \nA42\n \nEtha\n \n-O-CH\n2\nCO\n2\nH\n \n \n \nA14\n \nCar\n \n-O-Ph\n \nA43\n \nCar\n \n-O-CH\n2\nCO\n2\nH\n \n \n \nA15\n \nGly\n \nO-CH\n2\nCF\n3\n \n \nA44\n \nEtha\n \n-N(Me)-iBu\n \n \n \nA16\n \nGly\n \nO-CH\n2\nCHF\n2\n \n \nA45\n \nCar\n \n-N(Me)-iBu\n \n \n \nA17\n \nGly\n \nO-CH\n2\nCH≡CH\n \nA46\n \nEtha\n \n-S-Et\n \n \n \nA18\n \nGly\n \nO-(CH\n2\n)\n2\nCH≡CH\n \nA47\n \nCar\n \n-S-Et\n \n \n \nA19\n \nGly\n \n-O(CH\n2\n)\n2\nOMe\n \nA48\n \nGly\n \n-S-iPr\n \n \n \nA20\n \nCar\n \n-O-CH\n2\ncPr\n \nA49\n \nEtha\n \n-S-iPr\n \n \n \nA21\n \nGly\n \n-O-CH\n2\ncBu\n \nA50\n \nCar\n \n-S-iPr\n \n \n \nA22\n \nCar\n \n-O-CH\n2\ncBu\n \nA51\n \nGly\n \n-N(Me)CH\n2\nCH\n2\nOMe\n \n \n \nA23\n \nGly\n \n-O-CH\n2\ntBu\n \nA52\n \nEtha\n \n-N(Me)-CH\n2\nCH\n2\nOMe\n \n \n \nA24\n \nEtha\n \nO-CH\n2\ntBu\n \nA53\n \nCar\n \n-N(Me)-CH\n2\nCH\n2\nOMe\n \n \n \nA25\n \nGly\n \n-O-CH\n2\nCONH\n2\n \n \nA55\n \nGly\n \n-N(Me)-nBu\n \n \n \nA27\n \nGly\n \n-O-CH\n2\nCONHMe\n \nA56\n \nEtha\n \n-N(Me)-nBu\n \n \n \nA28\n \nGly\n \n-O-(CH\n2\n)\n2\n-cyano\n \nA57\n \nCar\n \n-N(Me)-nBu\n \n \n \nA29\n \nEtha\n \n-O-(CH\n2\n)\n2\ncyano\n \nA58\n \nEtha\n \n-N(nPr)-nPr\n \n \n \n \n\n\n \n(Table 21)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \n-A\nA\n-B\nA\n \n \n \n \n \nA59\n \n-NHCH\n2\nCH(S-OH)CH\n2\nOH\n \n(S)-O-CH\n2\nCHFCH\n3\n \n \n \n \nA60\n \n-NHCH\n2\nCH(S-OH)CH\n2\nOH\n \n(R)O-CH\n2\nCHFCH\n3\n \n \n \n \n \n\n\n \n(Table 22)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \n-A\nA\n-B\nA\n \n \n \n \n \nA61\n \nGly\n \n-O-Et\n \n \n \nA62\n \nCar\n \n-O-nPr\n \n \n \nA63\n \nGly\n \n-O-iPr\n \n \n \nA64\n \nEtha\n \n-O-nBu\n \n \n \n \n\n\n \n(Table 23)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \n-X-\n \nY\n \n-A\nA\n-B\nA\n \n \n \n \n \nB1\n \nGly\n \n-N=C-\n \nN\n \n-O-nPr\n \n \n \nB2\n \nEtha\n \n-N=C-\n \nN\n \n-O-nPr\n \n \n \nB3\n \nCar\n \n-N=C-\n \nN\n \n-O-nPr\n \n \n \nB4\n \nGly\n \n-N=C-\n \nN\n \n-O-iBu\n \n \n \nB5\n \nEtha\n \n-N=C-\n \nN\n \n-O-iBu\n \n \n \nB6\n \nCar\n \n-N=C-\n \nN\n \n-O-iBu\n \n \n \nB7\n \nGly\n \n-N=C-\n \nN\n \n-S-nPr\n \n \n \nB8\n \nEtha\n \n-N=C-\n \nN\n \n-S-nPr\n \n \n \nB9\n \nCar\n \n-N=C-\n \nN\n \n-S-nPr\n \n \n \nB10\n \nGly\n \n-N=C-\n \nN\n \n-N(Me)-nPr\n \n \n \nB11\n \nEtha\n \n-N=C-\n \nN\n \n-N(Me)-nPr\n \n \n \nB12\n \nCar\n \n-N=C-\n \nN\n \n-N(Me)-nPr\n \n \n \nB13\n \nGly\n \n-N=N-\n \nCH\n \n-O-nPr\n \n \n \nB14\n \nEtha\n \n-N=N-\n \nCH\n \n-O-nPr\n \n \n \nB15\n \nCar\n \n-N=N-\n \nCH\n \n-O-nPr\n \n \n \nB16\n \nGly\n \n-N=N-\n \nCH\n \n-O-iBu\n \n \n \nB17\n \nEtha\n \n-N=N-\n \nCH\n \n-O-iBu\n \n \n \nB18\n \nCar\n \n-N=N-\n \nCH\n \n-O-iBu\n \n \n \nB19\n \nGly\n \n-N=N-\n \nCH\n \n-S-nPr\n \n \n \nB20\n \nEtha\n \n-N=N-\n \nCH\n \n-S-nPr\n \n \n \nB21\n \nCar\n \n-N=N-\n \nCH\n \n-S-nPr\n \n \n \nB22\n \nGly\n \n-N=N-\n \nCH\n \n-N(Me)-nPr\n \n \n \nB23\n \nEtha\n \n-N=N-\n \nCH\n \n-N(Me)-nPr\n \n \n \nB24\n \nCar\n \n-N=N-\n \nCH\n \n-N(Me)-nPr\n \n \n \nB25\n \nGly\n \n-S-\n \nN\n \n-O-nPr\n \n \n \nB26\n \nEtha\n \n-S-\n \nN\n \n-O-nPr\n \n \n \nB27\n \nCar\n \n-S-\n \nN\n \n-O-nPr\n \n \n \nB28\n \nGly\n \n-S-\n \nN\n \n-O-iBu\n \n \n \nB29\n \nEtha\n \n-S-\n \nN\n \n-O-iBu\n \n \n \nB30\n \nCar\n \n-S-\n \nN\n \n-O-iBu\n \n \n \nB31\n \nGly\n \n-S-\n \nN\n \n-S-nPr\n \n \n \nB32\n \nEtha\n \n-S-\n \nN\n \n-S-nPr\n \n \n \nB33\n \nCar\n \nS-\n \nN\n \n-S-nPr\n \n \n \nB34\n \nGly\n \n-S-\n \nN\n \n-N(Me)-nPr\n \n \n \nB35\n \nEtha\n \n-S-\n \nN\n \n-N(Me)-nPr\n \n \n \n \n\n\n \n(Table 24)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \n-X-\n \nY\n \n-A\nA\n-B\nA\n \n \n \n \n \nB36\n \nCar\n \n-S-\n \nN\n \n-N(Me)-nPr\n \n \n \nB37\n \nGly\n \n-N=C-\n \nCH\n \n-O-nPr\n \n \n \nB38\n \nEtha\n \n-N=C-\n \nCH\n \n-O-nPr\n \n \n \nB39\n \nCar\n \n-N=C-\n \nCH\n \n-O-nPr\n \n \n \nB40\n \nGly\n \n-N=C-\n \nCH\n \n-O-iBu\n \n \n \nB41\n \nEtha\n \n-N=C-\n \nCH\n \n-O-iBu\n \n \n \nB42\n \nCar\n \n-N=C-\n \nCH\n \n-O-iBu\n \n \n \nB43\n \nGly\n \n-N=C-\n \nCH\n \n-S-nPr\n \n \n \nB44\n \nEtha\n \n-N=C-\n \nCH\n \n-S-nPr\n \n \n \nB45\n \nCar\n \n-N=C-\n \nCH\n \n-S-nPr\n \n \n \nB46\n \nGly\n \n-N=C-\n \nCH\n \n-N(Me)-nPr\n \n \n \nB47\n \nEtha\n \n-N=C-\n \nCH\n \n-N(Me)-nPr\n \n \n \nB48\n \nCar\n \n-N=C-\n \nCH\n \n-N(Me)-nPr\n \n \n \n \n\n\n \n(Table 25)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \n-X-\n \nY\n \n-A\nA\n-B\nA\n \n \n \n \n \nB49\n \nEtha\n \n-C=C-\n \nN\n \n-O-nPr\n \n \n \nB50\n \nGly\n \n-C=C-\n \nN\n \n-O-iBu\n \n \n \nB51\n \nEtha\n \n-C=C-\n \nN\n \n-O-iBu\n \n \n \nB52\n \nCar\n \n-C=C-\n \nN\n \n-O-iBu\n \n \n \nB53\n \nGly\n \n-C=C-\n \nN\n \n-S-nPr\n \n \n \nB54\n \nEtha\n \n-C=C-\n \nN\n \n-S-nPr\n \n \n \nB55\n \nCar\n \n-C=C-\n \nN\n \n-S-nPr\n \n \n \nB56\n \nGly\n \n-C=C-\n \nN\n \n-N(Me)-nPr\n \n \n \nB57\n \nEtha\n \n-C=C-\n \nN\n \n-N(Me)-nPr\n \n \n \nB58\n \nCar\n \n-C=C-\n \nN\n \n-N(Me)-nPr\n \n \n \nB59\n \nGly\n \n-S-\n \nCH\n \n-O-nPr\n \n \n \nB60\n \nEtha\n \n-S-\n \nCH\n \n-O-nPr\n \n \n \nB61\n \nCar\n \n-S-\n \nCH\n \n-O-nPr\n \n \n \nB62\n \nGly\n \n-S-\n \nCH\n \n-O-iBu\n \n \n \nB63\n \nEtha\n \n-S-\n \nCH\n \n-O-iBu\n \n \n \nB64\n \nCar\n \n-S-\n \nCH\n \n-O-iBu\n \n \n \nB65\n \nGly\n \n-S-\n \nCH\n \n-S-nPr\n \n \n \nB66\n \nEtha\n \n-S-\n \nCH\n \n-S-nPr\n \n \n \nB67\n \nCar\n \n-S-\n \nCH\n \n-S-nPr\n \n \n \n \n\n\n \n(Table 26)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \nX\n \nY\n \n-A\nA\n-B\nA\n \n \n \n \n \nB68\n \nGly\n \nN\n \nS\n \n-N(Me)-nPr\n \n \n \nB69\n \nEtha\n \nN\n \nS\n \n-N(Me)-nPr\n \n \n \nB70\n \nCar\n \nN\n \nS\n \n-N(Me)-nPr\n \n \n \n \n\n\n \n(Table 27)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \n-A\nA\n-B\nA\n \n \nNo\n \nR\n1A\n \n \n-A\nA\n-B\nA\n \n \n \n \n \nC1\n \nGly\n \n-O-iBu\n \nC10\n \nGly\n \n-S-iPr\n \n \n \nC2\n \nEtha\n \n-O-iBu\n \nC11\n \nEtha\n \n-S-iPr\n \n \n \nC3\n \nCar\n \n-O-iBu\n \nC12\n \nCar\n \n-S-iPr\n \n \n \nC4\n \nGly\n \n-O-nBu\n \nC13\n \nGly\n \n-S-Et\n \n \n \nC5\n \nEtha\n \n-O-nBu\n \nC14\n \nEtha\n \n-S-Et\n \n \n \nC6\n \nCar\n \n-O-nBu\n \nC15\n \nCar\n \n-S-Et\n \n \n \nC7\n \nGly\n \n-S-nPr\n \nC16\n \nGly\n \n-N(Me)-nPr\n \n \n \nC8\n \nEtha\n \n-S-nPr\n \nC17\n \nEtha\n \n-N(Me)-nPr\n \n \n \nC9\n \nCar\n \n-S-nPr\n \nC18\n \nCar\n \n-N(Me)-nPr\n \n \n \n \n\n\n \n(Table 28)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \n-A\nA\n-B\nA\n \n \nNo\n \nR\n1A\n \n \nA\nA\n-B\nA\n \n \n \n \n \nC19\n \nGly\n \n-O-nPr\n \nC30\n \nCar\n \n-S-nPr\n \n \n \nC20\n \nEtha\n \n-O-nPr\n \nC31\n \nGly\n \n-S-iPr\n \n \n \nC21\n \nCar\n \n-O-nPr\n \nC32\n \nEtha\n \n-S-iPr\n \n \n \nC22\n \nGly\n \n-O-iBu\n \nC33\n \nCar\n \n-S-iPr\n \n \n \nC23\n \nEtha\n \n-O-iBu\n \nC34\n \nGly\n \n-S-Et\n \n \n \nC24\n \nCar\n \n-O-iBu\n \nC35\n \nEtha\n \n-S-Et\n \n \n \nC25\n \nGly\n \n-O-nBu\n \nC36\n \nCar\n \n-S-Et\n \n \n \nC26\n \nEtha\n \n-O-nBu\n \nC37\n \nGly\n \n-N(Me)-nPr\n \n \n \nC27\n \nCar\n \n-O-nBu\n \nC38\n \nEtha\n \n-N(Me)-nPr\n \n \n \nC28\n \nGly\n \n-S-nPr\n \nC39\n \nCar\n \n-N(Me)-nPr\n \n \n \nC29\n \nEtha\n \n-S-nPr\n \n \n \n \n \n \n\n\n \n(Table 29)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \n-A\nA\n-B\nA\n \n \nNo\n \nR\n1A\n \n \n-A\nA\n-B\nA\n \n \n \n \n \nC40\n \nGly\n \n-O-iBu\n \nC49\n \nGly\n \n-S-iPr\n \n \n \nC41\n \nEtha\n \n-O-iBu\n \nC50\n \nEtha\n \n-S-iPr\n \n \n \nC42\n \nCar\n \n-O-iBu\n \nC51\n \nCar\n \n-S-ipr\n \n \n \nC43\n \nGly\n \n-O-nBu\n \nC54\n \nGly\n \n-S-Et\n \n \n \nC44\n \nEtha\n \n-O-nBu\n \nC55\n \nEtha\n \n-S-Et\n \n \n \nC45\n \nCar\n \n-O-nBu\n \nC56\n \nCar\n \n-S-Et\n \n \n \nC46\n \nGly\n \n-S-nPr\n \nC57\n \nGly\n \n-N(Me)-nPr\n \n \n \nC47\n \nEtha\n \n-S-nPr\n \nC58\n \nEtha\n \n-N(Me)-nPr\n \n \n \nC48\n \nCar\n \n-S-nPt\n \nC59\n \nCar\n \n-N(Me)-nPr\n \n \n \n \n\n\n \n(Table 30)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \n-A\nA\n-B\nA\n \n \nNo\n \nR\n1A\n \n \n-A\nA\n-B\nA\n \n \n \n \n \nC60\n \nEtha\n \n-O-nPr\n \nC70\n \nGly\n \n-S-iPr\n \n \n \nC61\n \nGly\n \n-O-iBu\n \nC71\n \nEtha\n \n-S-iPr\n \n \n \nC62\n \nEtha\n \n-O-iBu\n \nC72\n \nCar\n \n-S-iPr\n \n \n \nC63.\n \nCar\n \n-O-iBu\n \nC73\n \nGly\n \n-S-Et\n \n \n \nC64\n \nGly\n \n-O-nBu\n \nC74\n \nEtha\n \n-S-Et\n \n \n \nC65\n \nEtha\n \n-O-nBu\n \nC75\n \nCar\n \n-S-Et\n \n \n \nC66\n \nCar\n \n-O-nBu\n \nC16\n \nGly\n \n-N(Me)-nPr\n \n \n \nC67\n \nGly\n \n-S-nPr\n \nC77\n \nEtha\n \n-N(Me)-nPr\n \n \n \nC68\n \nEtha\n \n-S-nPr\n \nC78\n \nCar\n \n-N(Me)-nPr\n \n \n \nC69\n \nCar\n \n-S-nPr\n \n \n \n \n \n \n\n\n \n(Table 31)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \nNo\n \nR\n1A\n \n \n \n \n \nD1\n \nNHCH\n2\n(2-Py)\n \nD33\n \n4-H\n2\nNO-pipe\n \n \n \nD2\n \nNHPh\n \nD34\n \nNHCH\n2\nCO-pyn\n \n \n \nD3\n \nNHCH\n2\nPh\n \nD35\n \nNHCH\n2\nCO-(3-H-pyn)\n \n \n \nD4\n \nNHCH\n2\n(2-HO-Ph)\n \nD36\n \nNHCH\n2\nCO-(3-HO-pipe)\n \n \n \nD5\n \nNHCH\n2\n-(3HO-ph)\n \nD37\n \nNHCH\n2\nCO-(4-HO-pipe)\n \n \n \nD6\n \nNHCH\n2\n-(4-HO-Ph)\n \nD38\n \nNH-(3-Ac-Ph)\n \n \n \nD7\n \nNHCH\n2\n-(2H\n2\nNOC-Ph)\n \nD39\n \nNH-(3-MeHNOC-Ph)\n \n \n \nD8\n \nNHCH\n2\n(3-H\n2\nNOC-Ph)\n \nD40\n \nNHCH\n2\n(4-H\n2\nNO\n2\nS-Ph)\n \n \n \nD9\n \nNHCH\n2\n-(4-H\n2\nNOC-Ph)\n \nD41\n \nNH-(3-Ms-Ph)\n \n \n \nD10\n \nNH-(\n2\n-HO-Ph)\n \nD42\n \nNRCH\n2\nCO-mor\n \n \n \nD11\n \nNH(3-HO-Ph)\n \nD43\n \nNHCH\n2\n-(6-HO-2Py)\n \n \n \nD12\n \nNH-(4-HO-Ph)\n \nD44\n \nNHCH\n2\n(6-MeO-2-Py)\n \n \n \nD13\n \nNH-(2-H\n2\nNOC-Ph)\n \nD45\n \nNHCH\n2\n-(6-H\n2\nNOC-2-Py)\n \n \n \nD14\n \nNH-(3-H\n2\nNOC-Ph)\n \nD46\n \nNHCH\n2\n-(6-cyano-2-Ph)\n \n \n \nD15\n \nNH-(4-H\n2\nNOC-Ph)\n \nD47\n \nNHCH\n2\n(6-Me\n2\nNOC-2-Py)\n \n \n \nD16\n \nNH-(CH\n2\n)\n2\nOMe\n \nD48\n \nNHCH\n2\n-(6-H\n2\nN-2-Py)\n \n \n \nD17\n \nNH-(CH\n2\n)\n3\nOH\n \nD49\n \nNHCH\n2\n-(6-Me\n2\nN-2-Py)\n \n \n \nD18\n \nN(CH\n2\nCHOH)\n2\n \n \nD50\n \nNHCH\n2\n-(6-F-2-PY)\n \n \n \nD19\n \nNHCH\n2\nCH(CH\n2\nOH)OH\n \nD51\n \nNHCH\n2\n-(6-Cl-2-PH)\n \n \n \nD20\n \nN(Me)CH\n2\nCH\n2\nOH\n \nD52\n \nNHCH\n2\n-(6-Me-2-Py)\n \n \n \nD21\n \n3-HO-pyrr\n \nD53\n \nNHCH\n2\n-(pyrazol-2-yl)\n \n \n \nD22\n \n3-HO-pipe\n \nD54\n \nNHCH\n2\n-(pyridazine-2-yl)\n \n \n \nD23\n \n4-HO-pipe\n \nD55\n \nNHCH\n2\n-(pyrimidine-yl)\n \n \n \nD24\n \nNHCH\n2\nCONHMe\n \nD56\n \nN(CH\n2\nCONH\n2\n)((CH\n2\n)\n2\nOH)\n \n \n \nD25\n \nNHCH\n2\nCONMe\n2\n \n \nD57\n \nNHCH(Me)CH\n2\nOH\n \n \n \nD26\n \nN(Me)CH\n2\nCH\n2\nCOH\n2\n \n \nD58\n \nNHCH\n2\n(Me)OH\n \n \n \nD27\n \nN(Me)CH\n2\nCONHMe\n \nD59\n \nNHC(Me)\n2\nCH\n2\nOH\n \n \n \nD28\n \nN(Me)CONMe\n2\n \n \nD60\n \nNHCH\n2\nCMe)\n2\nOH\n \n \n \nD29\n \nNH(CH\n2\n)\n2\nCONH\n2\n \n \nD61\n \n3-oxo-pipa\n \n \n \nD30\n \nN(CH\n2\nCONH\n2\n)\n2\n \n \nD62\n \nNHCH\n2\nCO-(3-H\n2\nNOC-pipe)\n \n \n \nD31\n \nNHCH(CONH\n2\n)CH\n2\n-OH\n \nD63\n \nNHCH\n2\nCO-(4-H\n2\nNOC-pipe)\n \n \n \nD32\n \n3-H\n2\nNOC-pipe\n \nD64\n \nNHCH(CH\n2\nOH)\n2\n \n \n \n \n \n\n\n \n(Table 32)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \nNo\n \nR\n1A\n \n \n \n \n \nE1\n \nNHCH\n2\nPh\n \nE20\n \nNHCH\n2\n-(6-H\n2\nNOC-2-Py)\n \n \n \nE2\n \nNHCH\n2\n-(2-HO-Ph)\n \nE21\n \nNHCH\n2\n-(6-cyano-2-Py)\n \n \n \nE3\n \nNHCH\n2\n(2-H\n2\nNOC-Ph)\n \nE22\n \nNHCH\n2\n-(6Me\n2\nNOC-2-Py)\n \n \n \nE4\n \nNHCH\n2\n(3-H\n2\nNOC-Ph)\n \nE23\n \nNHCH\n2\n-(6H\n2\nN-2-Py)\n \n \n \nE5\n \nNHCH\n2\n(4-H\n2\nNOC-Ph)\n \nE24\n \nNHCH\n2\n-(6-Me\n2\nN-2-Py)\n \n \n \nE6\n \nN(Me)CH\n2\nCH\n2\nOH\n \nE25\n \nNHCH\n2\n(6-F-2-Py)\n \n \n \nE7\n \n4-HO-pipe\n \nE26\n \nNHCH\n2\n-(6-Cl-2-Py)\n \n \n \nE8\n \nN(MeP)CH\n2\nCONH\n2\n \n \nE27\n \nNHCH\n2\n(6-Me-2-Py)\n \n \n \nE9\n \nN(Me)CH\n2\nCONHMe\n \nE28\n \nNHCH\n2\n-(pyrazaol-2-yl)\n \n \n \nE10\n \nN(Me)CH\n2\nCONMe\n2\n \n \nE29\n \nNHCH\n2\n-(pyridazine-2-yl)\n \n \n \nE11\n \nNHCH(CONH\n2\n)CH\n2\nOH\n \nE30\n \nNHCH\n2\n-(pyrimidine-2-yl)\n \n \n \nE12\n \nNHCH\n2\nCO-(3-HO-pipe)\n \nE31\n \nN(CH\n2\nCONH\n2\n)((CH\n2\n)\n2\nOH)\n \n \n \nE13\n \nNH-(3-Ac-Ph)\n \nE32\n \nNHCH(Me)CH\n2\nOH\n \n \n \nE14\n \nhH-(3-MeHNOC-Ph)\n \nE33\n \nNHCH\n2\nCH(Me)OH\n \n \n \nE15\n \nNHCH\n2\n-(4-HNO\n2\nS-Ph)\n \nE34\n \nNHCH\n2\nC(Me)\n2\nOH\n \n \n \nE16\n \nNH-(3-Ms-Ph)\n \nE35\n \nNHCH\n2\nCO-(3-H\n2\nNOC-pipe)\n \n \n \nE17\n \nNHCH\n2\nCO-mor\n \nE36\n \nNHCH\n2\nCO-(4-H\n2\nNOC-pipe)\n \n \n \nE18\n \nNRCH\n2\n-(6-HO-2-Py)\n \nE37\n \nNHCH(CH\n2\nOH)\n2\n \n \n \n \nE19\n \nNHCH\n2\n(6-MeO-2-Py)\n \n \n \n \n \n \n\n\n \n(Table 33)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \nNo\n \nR\n1A\n \n \n \n \n \nF1\n \nNHCH\n2\n(2-Py)\n \nF33\n \n4-H\n2\nNOC-pipe\n \n \n \nF2\n \nNHPh\n \nF34\n \nNHCH\n2\nCO-pyr\n \n \n \nF3\n \nNHCH\n2\nPh\n \nF35\n \nNHCH\n2\nCO-(3-HO-pyrr)\n \n \n \nF4\n \nNHCH\n2\n-(2-HO-Ph)\n \nF36\n \nNHCH\n2\nCO-(3-HO-pipe)\n \n \n \nF5\n \nNHCH\n2\n-(3-HO-Ph)\n \nF37\n \nNHCH\n2\nCO-(4-HO-pipe)\n \n \n \nF6\n \nNHCH\n2\n-(4-HO-Ph)\n \nF38\n \nNH-(3-Ac-Ph)\n \n \n \nF7\n \nNHCH\n2\n-(2-H\n2\nNOC-Ph)\n \nF39\n \nNN-(3-MeHNOC-Ph)\n \n \n \nF8\n \nNHCH\n2\n-(3-H\n2\nNOC-Ph)\n \nF40\n \nNHCH\n2\n-(4-H\n2\nNO\n2\nS-Ph)\n \n \n \nF9\n \nNHCH\n2\n-(4-H\n2\nNOC-Ph)\n \nF41\n \nNH-(3-Ms-Ph)\n \n \n \nF10\n \nNH-(2-HO-Ph)\n \nF42\n \nNHCH\n2\nCO-morr\n \n \n \nF11\n \nNH(3-HO-Ph)\n \nF43\n \nNHCH\n2\n-(6-HO-2-Py)\n \n \n \nF12\n \nNH-(4-HO-Ph)\n \nF44\n \nNHCH\n2\n-(6-MeO-2-Py)\n \n \n \nF13\n \nNH-(2-H\n2\nNOC-Ph)\n \nF45\n \nNHCH\n2\n-(6-H\n2\nNOC-Py)\n \n \n \nF14\n \nNH-(3-H\n2\nNOC-Ph)\n \nF46\n \nNHCH\n2\n-(6-cyano-2-Py)\n \n \n \nF15\n \nNH-(4-H\n2\nNOC-Ph)\n \nF47\n \nNHCH\n2\n-(6-Me\n2\nNOC2-Py)\n \n \n \nF16\n \nNH-(CH\n2\n)\n2\nOMe\n \nF48\n \nNHCH\n2\n-(6-H\n2\nN-2-Py)\n \n \n \nF17\n \nNH-(CH\n2\n)OH\n \nF49\n \nNHCH\n2\n-(6-Me\n2\nN-2-Py)\n \n \n \nF18\n \nN(CH\n2\nCH\n2\nOH)\n2\n \n \nF50\n \nNHCH\n2\n-(6-F-2-Py)\n \n \n \nF19\n \nNHCH\n2\nCH(Ch\n2\nOH)OH\n \nF51\n \nNHCH\n2\n-(6-Cl-2-Py)\n \n \n \nF20\n \nN(Me)CH\n2\n-CH\n2\nOH\n \nF52\n \nNHCH\n2\n-(6-Me-2-Py)\n \n \n \nF21\n \n3-HO-pyrr\n \nF53\n \nNHCH\n2\n-(pyrazol-2-yl)\n \n \n \nF22\n \n3-HC-pipe\n \nF54\n \nNHCH\n2\n-(pyridazine-2-yl)\n \n \n \nF23\n \n4-HO-pipe\n \nF55\n \nNHCH\n2\n-(pyrimidine-2-yl)\n \n \n \nF24\n \nNHCH\n2\nCONHMe\n \nF56\n \nN(CH\n2\nCONH\n2\n)((CH\n2\n)\n2\nOH)\n \n \n \nF25\n \nNHCH\n2\nCONMe\n2\n \n \nF57\n \nNHCH(Me)CH\n2\nOH\n \n \n \nF26\n \nN(Me)CH\n2\nONH\n2\n \n \nF58\n \nNHCH\n2\nCH(Me)OH\n \n \n \nF27\n \nN(Me)CH\n2\nCONHMe\n \nF59\n \nNHC(Me)\n2\nCH\n2\nOH\n \n \n \nF28\n \nN(Me)CH\n2\nCONMe\n2\n \n \nF60\n \nNHCH\n2\nC(Me)\n2\nOH\n \n \n \nF29\n \nNH(CH\n2\n)\n2\nCONNH\n2\n \n \nF61\n \n3-oxo-pipa\n \n \n \nF30\n \nN(CH\n2\nCONH\n2\n)\n2\n \n \nF62\n \nNHCH\n2\nCO-(3-H\n2\nNOC-pipe)\n \n \n \nF31\n \nNHCHCONH\n2\n)CH\n2\nOH\n \nF63\n \nNHCH\n2\nCO)-(4-H\n2\nNOC-pipe)\n \n \n \nF32\n \n3-H\n2\nNOC-pipe\n \nF64\n \nNHCH(CH\n2\nOH)\n2\n \n \n \n \n \n\n\n \n(Table 34)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \nNo\n \nR\n1A\n \n \n \n \n \nG1\n \nNHCH\n2\n-(2-Py)\n \nG32\n \nNHCH\n2\nCO-pyrr\n \n \n \nG2\n \nNHPh\n \nG33\n \nNHCH\n2\nCO-(3-HO-pyrr)\n \n \n \nG3\n \nNHCH\n2\nPh\n \nG34\n \nNHCH\n2\nCO-(3-HO-pipe)\n \n \n \nG4\n \nNHCH\n2\n-(2-HO-Ph)\n \nG35\n \nNHCH\n2\nCO-(4-HO-pipe)\n \n \n \nG5\n \nNHCH\n2\n-(3-HO-Ph)\n \nG36\n \nNH-(3-Ac-Ph)\n \n \n \nG6\n \nNHCH\n2\n-(4-HO-Ph)\n \nG37\n \nNH-(3-MeHNOC-Ph)\n \n \n \nG7\n \nNHCH\n2\n-(2-H\n2\nNOC-Ph)\n \nG38\n \nNHCH\n2\n(4-H\n2\nNO\n2\nS-Ph)\n \n \n \nG8\n \nNHCH\n2\n-(3-H\n2\nNOC-Ph)\n \nG39\n \nNH(3-Ms-Ph)\n \n \n \nG9\n \nNHCH\n2\n-(4-H\n2\nNOC-Ph)\n \nG40\n \nNHCH\n2\nCO-mor\n \n \n \nG10\n \nNH-(2-HO-Ph)\n \nG41\n \nNHCH\n2\n-(6HO-2-Py)\n \n \n \nG11\n \nNH-(3-HO-Ph)\n \nG42\n \nNHCH\n2\n-(6-MeO-2-Py)\n \n \n \nG12\n \nNH(4-HO-Ph)\n \nG43\n \nNHCH\n2\n-(6-H\n2\nNOC-2-Py)\n \n \n \nG13\n \nNH(2-H\n2\nNOC-Ph)\n \nG44\n \nNHCH\n2\n-(6-cyano-2-Py)\n \n \n \nG14\n \nNH(4-H\n2\nNOC-Ph)\n \nG45\n \nNHCH\n2\n-(6-Me\n2\nNOC-2-Py)\n \n \n \nG15\n \nNH-(CH\n2\n)\n2\nOMe\n \nG46\n \nNHCH\n2\n-(6H\n2\nN-2-Py)\n \n \n \nG16\n \nNH-(CH\n2\n)\n3\nOH\n \nG47\n \nNHCH\n2\n-(6-Me\n2\nN-2-Py)\n \n \n \nG17\n \nN(CH\n2\nCH\n2\nOH)\n2\n \n \nG48\n \nNHCH\n2\n-(6-F-2-Py)\n \n \n \nG18\n \nNHCH\n2\nCH(CH\n2\nOH)OH\n \nG49\n \nNHCH\n2\n-(6-Cl-2-Py)\n \n \n \nG19\n \nN(Me)CH\n2\nCH\n2\nOH\n \nG50\n \nNHCH\n2\n-(6-Me-2-Py)\n \n \n \nG20\n \n3-HO-pyrr\n \nG51\n \nNHCH\n2\n-(pyrazol-2-yl)\n \n \n \nG21\n \n3-HOpipe\n \nG52\n \nNHCH\n2\n-(pyridazine-2-yl\n \n \n \nG22\n \n4-HO-pipe\n \nG53\n \nNHCH\n2\n-(pyrimidine-2-yl)\n \n \n \nG23\n \nNHCH\n2\nCONHMe\n \nG54\n \nN(CH\n2\nCONH\n2\n)((CH\n2\n)\n2\nOH)\n \n \n \nG24\n \nNHCH\n2\nCONMe\n2\n \n \nG55\n \nNHCH(Me)CH\n2\nOH\n \n \n \nG25\n \nN(Me)CH\n2\nCONH\n2\n \n \nG56\n \nNHCH\n2\nCH(Me)OH\n \n \n \nG26\n \nN(Me)CH\n2\nCONHMe\n \nG57\n \nNHC(Me)\n2\nCH\n2\nOH\n \n \n \nG27\n \nN(Me)CH\n2\nCONMe\n2\n \n \nG58\n \nNHCH\n2\nC(Me)\n2\nOH\n \n \n \nG28\n \nN(CH\n2\nCONH\n2\n)\n2\n \n \nG59\n \n3-oxo-pipa\n \n \n \nG29\n \nNHCH(CONH\n2\n)CH\n2\nOH\n \nG60\n \nNHCH\n2\nCO-(3-H\n2\nNOC-pipe)\n \n \n \nG30\n \n3-H\n2\nNOC-pipe\n \nG61\n \nNHCH\n2\nCO)-(4-H\n2\nNOC-pipe)\n \n \n \nG31\n \n4-H\n2\nNOC-pipe\n \nG62\n \nNHCH(CH\n2\nOH)\n2\n \n \n \n \n \n\n\n \n(Table 35)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \nNo\n \nR\n1A\n \n \n \n \n \nH1\n \nNHCH\n2\n-(2-Py)\n \nH33\n \n4-H\n2\nNOC-pipe\n \n \n \nH2\n \nNHPh\n \nH34\n \nNHCH\n2\nCO-porr\n \n \n \nH3\n \nNHCH\n2\nPh\n \nH35\n \nNHCH\n2\nCO-(3-HO-pyrr)\n \n \n \nH4\n \nNHCH\n2\n-(2-HO-Ph)\n \nH36\n \nNHCH\n2\nCO-(3-HO-pipe)\n \n \n \nH5\n \nNHCH\n2\n-(3-HO-Ph)\n \nH37\n \nNHCH\n2\nCO4-HO-pipe)\n \n \n \nH6\n \nNHCH\n2\n-(4-HO-Ph)\n \nH38\n \nNH(3-Ac-Ph)\n \n \n \nH7\n \nNHCH\n2\n-(2H\n2\n-4NOC-Ph)\n \nH39\n \nNH(3-MeHNOC-Ph)\n \n \n \nH8\n \nNHCH\n2\n-(3-H\n2\nNOC-Ph)\n \nH40\n \nNHCH\n2\n-(4-H\n2\nNO\n2\nS-Ph)\n \n \n \nH9\n \nNHCH\n2\n-(4-H\n2\nNOC-Ph)\n \nH41\n \nNH-(3-Ms-Ph)\n \n \n \nH10\n \nNH-(2-HOPh)\n \nH42\n \nNHCH\n2\nCO-mor\n \n \n \nH11\n \nNH-(3-HO-Ph)\n \nH43\n \nNHCH\n2\n-(6-HO-2-Py)\n \n \n \nH12\n \nNH-(4-HOPh)\n \nH44\n \nNHCH\n2\n-(6-MeO-2-Py)\n \n \n \nH13\n \nNH-(2H\n2\nNOC-Ph)\n \nH45\n \nNHCH\n2\n-(6-H\n2\nNOC-2-Py)\n \n \n \nH14\n \nNH-(3-H\n2\nNOC-Ph)\n \nH46\n \nNHCH\n2\n-(6-cyano-2-Py)\n \n \n \nH15\n \nNH-(H4-H\n2\nNOC-Ph)\n \nH47\n \nNHCH\n2\n-(6-Me\n2\nNOC-2-Py)\n \n \n \nB16\n \nNH-(CH\n2\n)\n2\nOMe\n \nH48\n \nNHCH\n2\n-(6-H\n2\nN-2-Py)\n \n \n \nH17\n \nNH-(CH\n2\n)\n3\nOH\n \nH49\n \nNHCH\n2\n-(6Me\n2\nN-2-Py)\n \n \n \nH18\n \nN(CH\n2\nCH\n2\nOH)\n2\n \n \nH50\n \nNHCH\n2\n-(6-F-2-Py)\n \n \n \nH19\n \nNHCH\n2\nCH(CH\n2\nOH)OH\n \nH51\n \nNHCH\n2\n-(6-Cl-2-Py)\n \n \n \nH20\n \nN(Me)CH\n2\nCH\n2\nOH\n \nH52\n \nNHCH\n2\n-(6Me-2-Py)\n \n \n \nH21\n \n3-HO-pyrr\n \nH53\n \nNHCH\n2\n-(pyrazol-2-yl)\n \n \n \nH22\n \n3-HO-pipe\n \nH54\n \nNHCH\n2\n-(pyridazine-2-yl)\n \n \n \nH23\n \n4-HD-pjpe\n \nH55\n \nNHCH\n2\n-(pyrimidine-2-yl)\n \n \n \nH24\n \nNHCH\n2\nCONHMe\n \nH56\n \nN(CH\n2\nCONH\n2\n)((CH\n2\n)\n2\n(OH)\n \n \n \nH25\n \nNRCH\n2\nCONMe\n2\n \n \nH57\n \nNHCH(Me)CH\n2\nOH\n \n \n \nH26\n \nN(Me)CH\n2\nCONNH\n2\n \n \nH58\n \nNHCH\n2\nCH(Me)OH\n \n \n \nH27\n \nN(Me)CH\n2\nCONHMe\n \nH59\n \nNHC(Me)\n2\nCH\n2\nOH\n \n \n \nH28\n \nN(Me)CH\n2\nCONMe\n \nH60\n \nNHCH\n2\nC(Me)\n2\nOH\n \n \n \nH29\n \nNH(CH)\n2\nCONH\n2\n \n \nH61\n \n3-oxo-pipa\n \n \n \nH30\n \nN(CH\n2\nCONH\n2\n)\n2\n \n \nH62\n \nNHCH\n2\nCO-(3-H\n2\nNOC-pipe)\n \n \n \nH31\n \nNHCH(CONH\n2\n)CH\n2\nOH\n \nH63\n \nNHCH\n2\nCO-(4-H\n2\nNOC-pipe)\n \n \n \nH32\n \n3-H\n2\nNOC-pipe\n \nH64\n \nNHCH(CH\n2\nOH)\n2\n \n \n \n \n \n\n\n \n(Table 36)\n \n \n \n \n \n \n \n \n \n \n \n \nNo\n \nR\n1A\n \n \nNo\n \nR\n1A\n \n \n \n \n \n11\n \nNHCH\n2\n-(2-Py)\n \n133\n \n4-H\n2\nNOC-pipe\n \n \n \n12\n \nNHPh\n \n134\n \nNHCH\n2\nCO-pyrr\n \n \n \n13\n \nNHCH\n2\nPh\n \n135\n \nNHCH\n2\nCO-(3-HO-pyrr)\n \n \n \n14\n \nNHCH\n2\n-HO-Ph)\n \n136\n \nNHCH\n2\nCO-(-3-HP-pipe)\n \n \n \n15\n \nNHCH\n2\n-(3-HO-Ph)\n \nB7\n \nNHCH\n2\nCO-(4-HO-pipe)\n \n \n \n16\n \nNHCH\n2\n-(4-HO-Ph)\n \n138\n \nNH-(3-Ac-Ph)\n \n \n \n17\n \nNHCH\n2\n-(2-H\n2\nNOC-Ph)\n \n139\n \nNH(3-MeHNOC-Ph)\n \n \n \n18\n \nNHCH\n2\n-(3-H\n2\nNOC-Ph)\n \n140\n \nNHCH\n2\n-(4-H\n2\nNO\n2\n-S-Ph)\n \n \n \n19\n \nNHCH\n2\n-(4-H\n2\nNOC-Ph)\n \n141\n \nNH-(3-Ms-Ph)\n \n \n \n110\n \nNH(2-HO-Ph)\n \n142\n \nNHCH\n2\nCO-mor\n \n \n \n111\n \nNH-(3-HO-Ph)\n \n143\n \nNHCH\n2\n-(6-HO-2-Py)\n \n \n \n112\n \nNH-(4-HO-Ph)\n \n144\n \nNHCH\n2\n-(6-MeO-2-Py)\n \n \n \n113\n \nNH-(2-H\n2\nNOC-Ph)\n \n145\n \nNHC\n2\n-(6-H\n2\nNOC-2-Py)\n \n \n \n114\n \nNH-(3-H\n2\nNOC-Ph)\n \n146\n \nNHCH\n2\n-(6-cyano-2-Py)\n \n \n \n115\n \nNH-(4-H\n2\nNOC-Ph)\n \n147\n \nNHCH\n2\n-(6-Me\n2\nNOC-2-Py)\n \n \n \n116\n \nNH-(CH\n2\n)\n2\nOMe\n \n148\n \nNHCH\n2\n-(6-H\n2\nN-2-Py)\n \n \n \n117\n \nNH-(CH\n2\n)3OH\n \n149\n \nNHCH\n2\n-(6-MeN-2-Py)\n \n \n \n118\n \nN(CH\n2\nCHOH)\n2\n \n \n150\n \nNH\n2\n-(6-F-2-Py)\n \n \n \n119\n \nNHCH\n2\nCH(CH\n2\nOH)OH\n \n151\n \nNHCH\n2\n-(6-Cl-2-Py)\n \n \n \n120\n \nN(Me)CH\n2\nCH\n2\nOH\n \n152\n \nNHCH\n2\n-(6-Me-2-Py)\n \n \n \n121\n \n3-HO-pyrr\n \n153\n \nNHCH\n2\n-(pyrazol-2-yl)\n \n \n \n122\n \n3-HO-pipe\n \n154\n \nNHCH\n2\n-(pyridazine-2-yl\n \n \n \n123\n \n4-HO-pipe\n \n155\n \nNHCH\n2\n-(pyrimidine-2-yl)\n \n \n \n124\n \nNHOCH\n2\nCONHMe\n \n156\n \nN(CH\n2\nCONH\n2\n)((CH\n2\n)OH\n \n \n \n125\n \nNHCH\n2\nCONMe\n2\n \n \n157\n \nNHCH(Me)CH\n2\nOH\n \n \n \n126\n \nN(Me)CH\n2\nCONH\n2\n \n \n158\n \nNHCH\n2\nCH(Me)OH\n \n \n \n127\n \nN(Me)CH\n2\nCONHMe\n \n159\n \nNHC(Me)\n2\nCH\n2\nOH\n \n \n \n128\n \nNO(Me)CH\n2\nCONMe\n2\n \n \n160\n \nNHCH\n2\nC(Me)\n2\nOH\n \n \n \n129\n \nNH(CH\n2\n)\n2\nCONH\n2\n \n \n161\n \n3-oxo-pipa\n \n \n \n130\n \nN(CH\n2\nCONH\n2\n)\n2\n \n \n162\n \nNHCH\n2\nCHO-(3-H\n2\nNOC-pipe)\n \n \n \n131\n \nNHCH(CONH\n2\n)CH\n2\nOH\n \n163\n \nNHCH\n2\nCO-(4-H\n2\nNOC-pipe)\n \n \n \n132\n \n3-H\n2\nNOC-pipe\n \n164\n \nNHCH(CH\n2\nOH)\n2"
  }
]